US 20100130537A1 ( 19 ) United States ( 12 ) Patent Applicati0n Publicati0n mm Pub. N0. : US 2010 / 0130537 A1 Miyagawa ( 43 ) Pub. Date : May 27 , 2010 ( 54 ) CINNAMIDE COMPOUNDS FOR DEMENTIA Related U. S. Applicati0n Data. ( 75 ) . ( 73 ) . ( 21 ) ( 22 ) . ( 86 ) . 1nVent0r : Takehik0 MiyagaWa , 1bara1<i ( JP ) . C0rresp0ndence Address : . BIRCH STEWART KOLASCH & BIRCH P0 BOX 747. FALLS CHURCH , VA 22040 - 0747 ( US ) . Assignee : EISAI R&D MANAGEMENT C0. , LTD , TOKYO ( JP ) . App1. N0. : 12 / 594 , 172. PCT Fi1ed : Apr. 25 , 200s. PCT N0. : PCT / JP2008 / 058452. § 371 ( C ) ( 1 ) , . ( 2 ) , ( 4 ) Date : Sep. 30 , 2009. ( 60 ) . ( 51 ) . ( 52 ) ( 57 ) . Pr0Visi0na1 apphcation N0. 60 / 924 , 009 , ﬁ1ed 011 Apr. 26 , 2007. Publicati0n Classiﬁcati0n. Int. Cl. A61K 31 / 435 ( 2006.01 ) . A61K 3I / 454 ( 2006.01 ) . A6IP 25 / 00 ( 2006.01 ) . A61P 25 / 28 ( 2006.01 ) . U. S. Cl. . 514 / 295 ; 514 / 297 ; 514 / 326 ABSTRACT. The inVenti0n pr0Vides meth0ds f0r treating , preVenting , and de1aying the 0nset 0f dementia and mi1d c0gnitiVe impairments by administering t0 3 patient in need there0f at least 0ne cinnamide c0mp0und and 0ne 0r m0re sec0nd - line actiVe ingredients , such as ch01inesterase inhibit0rs ; AMPA recep - t0r antag0nists ; NMDA recept0r antag0nists ; and the like. The inVenti0n als0 pr0Vides pharmaceutical c0mp0siti0ns , c0mbinati0ns , and kits. US 2010 / 0130537 A1. CINNAMIDE COMPOUNDS FOR DEMENTIA. RELATED APPLlCATlON. [ 0001 ] This app1icati0n c1aims pri0rity under 35 U. S. C. §119 t0 U. S. Pr0Visi0na1App1icati0n N0. 60 / 924 , 009 ﬁ1ed Apr. 26 , 2007 , the disc10sures 0f Which are inc0rp0rated by reference herein in their entirety. FlELD OF THE 1NVENTlON. [ 0002 ] The inVenti0n pr0Vides pharmaceutical c0mp0si - ti0ns , c0mbinati0ns , and kits c0mprising cinnamide c0m - p0unds , and meth0ds f0r treating dementia using cinnamide c0mp0unds. BACKGROUND OF THE 1NVENTlON. [ 0003 ] Ch01inesterase inhibit0rs haVe c0nVenti0nal1y been used t0 treat dementia , such as A1Zheimers Disease and Seni1e Dementia 0f the A1zheimers Type. ln particu1ar , d0nepezil hydr0ch10ride that acts as an acety1ch01inesterase inhibit0r increases acetylch0line in the brain and is used eXtensiVe1y as a drug f0r treating Atheimers senile dementia. D0nepezi1 is described in U. S. Pat. N0. 4 , 895 , 84l. Other drugs inc1uding N - methy1 - D - aspartic acid ( NMDA ) recept0r antag0nists are als0 used. N0netheless , n0Ve1 drugs and treatment meth0ds are needed. [ 0004 ] Memantine hydr0chl0ride ( NAMENDA® , F0rest Pharmaceutica1s , lnc. ; AXURA® , Merz Pharmaceutica1s ) , Which is an NMDA recept0r antag0nist , is an amantadine deriVatiVe and is kn0Wn t0 pr0tect nerVe ce11s and impr0Ves the sympt0ms 0f Parkins0ns disease. Recent1y deVel0ped as a drug f0r treating m0derate t0 seVere A1Zheimers disease , memantine hydr0ch10ride is pr0Vided in a 1iquid f0rm 0r as ﬁ1m - c0ated tab1ets. [ 0005 ] 1 , 2 - dihydr0pyridine c0mp0unds are kn0Wn as a - amin0 - 3 - hydr0xy - 5 - methyl - 4 - is0Xaz0le pr0pi0nic acid ( AMPA ) recept0r antag0nists and are described in U. S. Pat. N0. 6 , 949 , 571. Meth0ds f0r treating diseases and administering these c0mp0unds in c0njuncti0n With a ch01inesterase inhibit0r are described in WO 2006 / 10785 9. [ 0006 ] Cinnamide c0mp0unds are kn0Wn as agents f0r inhibiting the pr0ducti0n 0f amy10id beta 40 and amy10id beta 42 fr0m amy10id precurs0r pr0teins. Cinnamide c0mp0unds are effectiVe f0r treating neur0degeneratiVe diseases caused by amy10id beta , such as A1Zheimers disease and DOWns syndr0me. Cinnamide c0mp0unds are described , f0r example in US Pub1icati0n N0. 2006 / 0004013 and PCT Publicati0n N0. WO 2006 / 046575. [ 0007 ] There is a need in the art f0r treating dementia using n0Ve1 pharmaceutica1 c0mp0siti0ns 0r c0mbinati0ns. The inVenti0n is directed t0 these , as Well as 0ther , imp0rtant g0a1s. SUMMARY OF THE lNVENTION. [ 0008 ] The inVenti0n pr0Vides meth0ds f0r treating dementia and / 0r mi1d c0gnitiVe impairments ; meth0ds f0r the pr0 - phy1aXis 0f dementia and / 0r mi1d c0gnitiVe impairments ; and meth0ds f0r de1aying the 0nset 0f dementia and / 0r mi1d c0g - nitiVe impairments in a patient in need there0f by admini stering at least 0ne cinnamide c0mp0und and 0ne 0r m0re sec - 0nd - 1ine actiVe ingredients se1ected fr0m the gr0up c0nsisting 0f ch01inesterase inhibit0rs ; AMPA recept0r antag0nists ; NMDA recept0r antag0ni sts ; pramiracetam ; aniracetam ; ace - ty1ch01ine re1easing stimu1ants ; ca1cium channe1 ag0nists ; . May 27 , 2010. free radica1 scaVengers ; plate1et actiVating fact0r antag0nists ; p1ate1et aggregati0n antag0nists ; insu1in sensitizers ; per0xisome pr01iferat0r - actiVated recept0r ag0nists ; per0Xis0me pr01iferat0r - actiVated recept0r gamma ag0nists ; m0n0amine 0Xidase B inhibit0rs ; carnitine acety1transferase stimu1ants ; NSAIDs ; nerVe gr0Wth fact0r ag0nists ; beta - amy10id inhibi - t0rs ; immun0m0du1at0rs ; NF - kappa B inhibit0rs ; thyr0tr0pin re1easing h0rm0ne ag0nists ; d0pamine D2 recept0r antag0 - nists ; ser0t0nin 2 recept0r antag0nists ; muscarinic M1 recep - t0r ag0nists ; a1pha 1 adren0cept0r ag0nists ; ser0t0nin 3 recept0r antag0nists ; d0pamine D2 recept0r ag0nists ; d0pamine D2 recept0r antag0nists ; ser0t0nin 1A recept0r ag0nists ; ser0t0nin 2A recept0r antag0nists ; g1uc0c0rtic0id antag0 - nists ; pr0gester0ne antag0nists ; HMG - COA reductase inhibi - t0rs ; aden0sine uptake inhibit0rs ; ph0sph0diesterase inhibi - t0rs ; acety1ch01ine recept0r ag0nists ; membrane permeability enhancers ; cannabin0id 1 recept0r antag0nists ; cannabin0id recept0r ag0nists ; angi0genesis inhibit0rs ; immun0suppressants ; tubu1in antag0nists ; thr0mb0Xane A2 synthase inhibi - t0rs ; anti0Xidants ; a1pha adren0recept0r antag0nists ; estr0 - gen ag0nists ; 3 - beta hydr0Xyster0id dehydr0genase inhibit0rs ; signa1transducti0n pathWay inhibit0rs ; me1at0nin recept0r ag0nists ; immun0stimu1ants ; HlV entry inhibit0rs ; s0dium channe1 antag0nists ; micr0tubu1e inhibit0rs ; glycine NMDA ag0nists ; aden0 sine Al recept0r antag0nists ; ATPase stimu1ants ; mit0ch0ndrial functi0n enhancers ; and gr0Wth h0rm0ne re1easing fact0r ag0nists. [ 0009 ] The inVenti0n pr0Vides pharmaceutical c0mbina - ti0ns , pharmaceutical c0mp0siti0ns , and kits c0mprising ( i ) at 1east 0ne cinnamide c0mp0und ; and ( ii ) 0ne 0r m0re c0m - p0unds se1ected fr0m the gr0up c0nsisting 0f the sec0nd - 1ine actiVe ingredients described herein. The pharmaceutica1 c0m - binati0ns may c0mprise tW0 0r m0re f0rmulati0r1s c0mprising actiVe ingredients that may be separately administered ( e. g. , simu1tane0us1y , sequentia11y ) t0 a patient. The pharmaceutica1 c0mp0siti0ns may c0mprise tW0 0r m0re actiVe ingredients. [ 0010 ] lt has been unexpected1y disc0Vered that the c0m - binati0n 0f the cinnamide c0mp0und and 0ne 0r m0re 0f the sec0nd - 1ine c0mp0unds pr0duces synergistic effects in the treatment and / 0r pr0phylaXis 0f dementia 0r mi1d c0gnitiVe impairments , and in delaying the 0nset 0f dementia 0r mild c0gnitiVe impairments. [ 0011 ] The present inVenti0n re1ates t0 the f0l10Wing. [ 0012 ] ( 1 ) A pharmaceutica1 c0mp0siti0n c0mprising : . ( A ) a c0mp0und 0f F0rmu1a ( l ) 0r a pharmaceutically accept - ab1e sa1t there0f : . [ 0013 ] Wherein R1 is : . [ 0014 ] ( a ) —Xl—Arl , Wherein X1 is a C1_6 a1ky1ene gr0up 0pti0na11y substituted With a Cl - 6 alky1 gr0up ; and Arl is a pheny1 gr0up 0pti0na11y substituted With 1 t0 3 substituents selected fr0m the gr0up c0nsisting 0f ( i ) a ha10gen at0m and. US 2010 / 0130537 A1. ( ii ) a C1_6 alky1 gr0up Which may 0pti0nal1y be substituted With 0ne t0 ﬁVe C1_6 a1ky1 gr0ups ; . [ 0015 ] ( b ) an indeny1 gr0up 0pti0na11y substituted With 1 t0 3 ha10gen at0ms ; . [ 0016 ] ( c ) a tetrahydr0naphthy1 gr0up 0pti0na11y sub stituted With 1 t0 3 ha10gen at0ms ; 0r. [ 0017 ] ( d ) a chr0many1 gr0up 0pti0na11y substituted With 1 t0 3 ha10gen at0ms ; . ( B ) a ch01inesterase inhibit0r ; an AMPA recept0r antag0nist ; an NMDA recept0r antag0nist ; 0r a miXture 0r c0mbinati0n 0f tW0 0r m0re there0f ; and. ( C ) 0ne 0r m0re pharmaceutica11y acceptab1e carriers. [ 0018 ] ( 2 ) The pharmaceutical c0mp0siti0n 0f ( 1 ) , Wherein R1 is 7X17Ar1 ; Wherein X1 is a C1_6 a1ky1ene gr0up 0pti0n - a1ly substituted With a C1_6 a1ky1 gr0up ; and Arl is a pheny1 gr0up 0pti0na11y substituted With 1 t0 3 substituents se1ected fr0m the gr0up c0nsisting 0f ( i ) a ha10gen at0m and ( ii ) a C M alky1 gr0up Which may 0pti0nal1y be substituted With 0ne t0 ﬁVe Cl - 6 a1ky1 gr0ups ; . [ 0019 ] ( 3 ) The pharmaceutical c0mp0siti0n 0f ( 1 ) , Wherein R1 is an indeny1 gr0up 0pti0na11y substituted With 1 t0 3 ha10 gen at0ms ; a tetrahydr0naphthy1 gr0up 0pti0na11y substituted With 1 t0 3 ha10gen at0ms ; 0r 3 chr0manyl gr0up 0pti0n - ally substituted With 1 t0 3 hal0gen at0ms. [ 0020 ] ( 4 ) The pharmaceutical c0mp0siti0n 0f ( 1 ) , Wherein ( A ) is at 1east 0ne c0mp0und se1ected fr0m : ( E ) - 1 - ( 3 , 4 - dif - 1u0r0benzy1 ) - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzylidene ] piperidir1 - 2 - 0ne 0r a pharmaceutically acceptable salt there0f ; . [ 0021 ] ( E ) - 1 - indan - 2 - yl - 3 - [ 3 - meth0xy - 4 - ( 4 - methyl - 1H - imidaz01 - 1 - y1 ) benZy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; . [ 0022 ] ( E ) - 1 - [ ( 4R ) - chr0man - 4 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methyl - 1H - imidaZ0l - 1 - yl ) benzylidene ] piperidin - 2 - 0r1e 0r a pharmaceutically acceptable salt there0f ; ( E ) - 1 - [ ( 4S ) - chr0man - 4 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; . [ 0023 ] ( E ) - 1 - [ ( 1S ) - 1 - ( 4 - ﬂu0r0pheny1 ) ethy1 ] - 3 - [ 3 - meth - 0xy - 4 - ( 4 - methyl - 1H - imidaz0l - 1 - yl ) benzylidene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; . [ 0024 ] ( E ) - 1 - ( 4 - tert - buty1benzy1 ) - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; . [ 0025 ] ( E ) - 1 - [ ( 2S ) - 5 - ﬂu0r0indan - 2 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methyl - 1 H - imidaz0l - 1 - yl ) benZy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; ( E ) - 1 - [ ( 2R ) - 5 - ﬂu0r0indan - 2 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benZy1idene ] piperidin - 2 - 0ne 0r a pharmaceuti - ca11y acceptab1e salt there0f ; . [ 0026 ] ( E ) - 1 - [ ( 4R ) - 7 - ﬂu0r0chr0man - 4 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutical1y acceptab1e sa1t there0f ; 0r ( E ) - 1 - [ ( 4S ) - 7 - flu0r0chr0man - 4 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; . [ 0027 ] ( E ) - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] - 1 - [ ( 2R ) - 1 , 2 , 3 , 4 - tetrahydr0naphtha1en - 2 - y1 ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; ( E ) - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benZy1idene ] - 1 - [ ( 2S ) - 1 , 2 , 3 , 4 - tetrahydr0naphtha1en - 2 - y1 ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; and. May 27 , 2010. [ 0028 ] ( E ) - 1 - [ ( 1R ) - 1 - ( 2 , 4 - diﬂu0r0phenyl ) ethyl ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benZy1idene ] pi - peridin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; 0r ( E ) - 1 - [ ( 1S ) - 1 - ( 2 , 4 - diﬂu0r0pheny1 ) ethy1 ] - 3 - [ 3 - meth0xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] pi - peridin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f. [ 0029 ] ( 5 ) The pharmaceutica1 c0mp0siti0n 0f ( 1 ) , Wherein ( B ) is 0ne 0r m0re c0mp0unds se1ected fr0m the gr0up c0n - sisting 0f d0nepezi1 0r a pharmaceutica11y acceptab1e sa1t there0f , huperzine A 0r a pharmaceutical1y acceptab1e sa1t there0f , tacrine 0r a pharmaceutica11y acceptable sa1t there0f , riVastigmine 0r a pharmaceutica11y acceptab1e sa1t there0f , ga1antamine 0r a pharmaceutica11y acceptab1e sa1t there0f , pramiracetam 0r a pharmaceutica11y acceptab1e sa1t there0f , aniracetam 0r a pharmaceutically acceptab1e salt there0f , neﬁracetam 0r a pharmaceutica11y acceptab1e sa1t there0f , EGb 761 0r a pharmaceutica11y acceptab1e sa1t there0f , r0sig1itaz0ne 0r a pharmaceutica11y acceptab1e sa1t there0f , rasagi1ine 0r a pharmaceutica11y acceptab1e sa1t there0f , leVacecamine 0r a pharmaceutically acceptable salt there0f , ce1ec0xib 0r a pharmaceutica11y acceptable sa1t there0f , 3 - ( 2 - cyan0pheny1 ) - 5 - ( 2 - pyridy1 ) - 1 - pheny1 - 1 , 2 - dihydr0pyridin - 2 - 0ne , a pharmaceutica11y acceptab1e sa1t there0f 0r a hydrate there0f , talampanel 0r a pharmaceutically acceptab1e sa1t there0f , becampanel 0r a pharmaceutically acceptable sa1t there0f , memantine 0r a pharmaceutica11y acceptab1e sa1t there0f , neramexane 0r a pharmaceutica11y acceptab1e sa1t there0f , xa1ipr0den 0r a pharmaceutica11y acceptab1e sa1t there0f , tarenﬂurbil 0r a pharmaceutica11y acceptab1e sa1t there0f , tramipr0sate 0r 3 pharmaceutica11y acceptable sa1t there0f , and 1eupr0re1in - D 0r a pharmaceutica11y acceptab1e sa1t there0f. [ 003 0 ] ( 6 ) The pharmaceutica1 c0mp0siti0n 0f ( 1 ) , Wherein ( B ) is 011e 0r m0re c0mp0u11ds selected fr0m the gr0up 0011 - sisting 0f d0nepezil 0r a pharmaceutically acceptable sa1t there0f , 3 - ( 2 - cyan0pheny1 ) - 5 - ( 2 - pyridy1 ) - 1 - pheny1 - 1 , 2 - dihydr0pyridin - 2 - 0ne , a pharmaceutica11y acceptab1e sa1t there0f 0r a hydrate there0f and memantine 0r a pharmaceutical1y acceptable sa1t there0f. [ 0031 ] ( 7 ) The pharmaceutical c0mp0siti0n 0f ( 1 ) , Wherein. ( B ) is d0nepezi1 0r a pharmaceutica11y acceptab1e sa1t there0f. [ 0032 ] ( 8 ) The pharmaceutica1 c0mp0siti0n 0f ( 1 ) , Wherein. the c0mp0siti0n is used f0r : treating dementia 0r 0ne 0r m0re. mild c0gnitiVe impairments ; the pr0phylaXis 0f dementia 0r. 0ne 0r m0re mi1d c0gnitiVe impairments ; 0r de1aying the. 0nset 0f dementia 0r 0ne 0r m0re mi1d c0gnitiVe impairments. [ 0033 ] ( 9 ) A c0mbinati0n c0mprising : . ( A ) a c0mp0und 0f F0rmu1a ( I ) 0r a pharmaceutica11y accept - . ab1e salt there0f : . [ 0034 ] Wherein R1 is : [ 0035 ] ( a ) 7X17Ar1 , Wherein X1 is a C1_6 a1ky1ene gr0up 0pti0na11y substituted With a C1_6 alky1 gr0up ; and Arl is a. US 2010 / 0130537 A1. pheny1 gr0up 0pti0na11y substituted With 1 t0 3 substituents se1ected fr0m the gr0up c0nsisting 0f ( i ) a ha10gen at0m and ( ii ) a C1_6 a1ky1 gr0up Which may 0pti0na1ly be substituted With 0ne t0 ﬁVe C1_6 alky1 gr0ups ; . [ 003 6 ] ( b ) an indeny1 gr0up 0pti0na11y substituted With 1 t0 3 ha10gen at0ms ; . [ 0037 ] ( c ) a tetrahydr0naphthy1 gr0up 0pti0na11y substituted With 1 t0 3 ha10gen at0ms ; 0r. [ 0038 ] ( d ) a chr0many1 gr0up 0pti0na11y substituted With 1 t0 3 ha10gen at0ms ; and. ( B ) a ch01inesterase inhibit0r ; an AMPA recept0r antag0nist ; an NMDA recept0r antag0nist ; 0r a miXture 0r c0mbinati0n 0f tW0 0r m0re there0f. [ 0039 ] ( 10 ) The c0mbinati0n 0f ( 9 ) , Wherein R1 is —X 1— Ar1 ; Wherein X1 is a C1_6 a1ky1ene gr0up 0pti0na11y substituted With a C1 - 5 a1ky1 gr0up ; and Arl is a pheny1 gr0up 0pti0na11y substituted With 1 t0 3 substituents se1ected fr0m the gr0up c0nsisting 0f ( i ) a ha10gen at0m and ( ii ) a C1_6 a1ky1 gr0up Which may 0pti0na11y be substituted With 0ne t0 ﬁVe Cl - 6 a1ky1 gr0ups ; . [ 0040 ] ( 11 ) The c0mbinati0n 0f ( 9 ) , Wherein R1 is an indenyl grOup 0pti0nally substituted With 1 t0 3 hal0gen at0ms ; a tetrahydr0naphthy1 gr0up 0pti0na11y substituted With 1 t0 3 ha10gen at0ms ; 0r a chr0many1 gr0up 0pti0na11y substituted With 1 t0 3 hal0gen at0ms. [ 0041 ] ( 12 ) The c0mbinati0n 0f ( 9 ) , Wherein ( A ) is at 1east 0ne c0mp0und selected fr0m : . [ 0042 ] ( E ) - 1 - ( 3 , 4 - diﬂu0r0benzy1 ) - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutical1y acceptable salt there0f ; . [ 0043 ] ( E ) - 1 - indan - 2 - y1 - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz0l - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r 3 pharmaceutica1ly acceptable salt there0f ; . [ 0044 ] ( E ) - 1 - [ ( 4R ) - chr0man - 4 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methyl - 1H - imidaZ0l - 1 - yl ) benzylidene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; ( E ) - 1 - [ ( 4S ) - chr0man - 4 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a phannaceutica11y acceptab1e salt there0f ; . [ 0045 ] ( E ) - 1 - [ ( 1S ) - 1 - ( 4 - ﬂu0r0pheny1 ) ethy1 ] - 3 - [ 3 - meth - 0xy - 4 - ( 4 - methyl - 1H - imidaz0l - 1 - yl ) benzylidene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; . [ 0046 ] ( E ) - 1 - ( 4 - tert - buty1benzy1 ) - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; . [ 0047 ] ( E ) - 1 - [ ( 2S ) - 5 - flu0r0indan - 2 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methyl - 1 H - imidaz0l - 1 - yl ) benZy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; ( E ) - 1 - [ ( 2R ) - 5 - ﬂu0r0indan - 2 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutical1y acceptab1e sa1t there0f ; . [ 0048 ] ( E ) - 1 - [ ( 4R ) - 7 - flu0r0chr0man - 4 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; 0r ( E ) - 1 - [ ( 4S ) - 7 - ﬂu0r0chr0man - 4 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; . [ 0049 ] ( E ) - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] - 1 - [ ( 2R ) - 1 , 2 , 3 , 4 - tetrahydr0naphtha1en - 2 - y1 ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t. May 27 , 2010. there0f ; ( E ) - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] - 1 - [ ( 2S ) - 1 , 2 , 3 , 4 - tetrahydr0naphthalen - 2 - y1 ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; and. [ 0050 ] ( E ) - 1 - [ ( lR ) - 1 - ( 2 , 4 - diflu0r0pheny1 ) ethy1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] pi - peridin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; 0r ( E ) - 1 - [ ( 1S ) - 1 - ( 2 , 4 - diﬂu0r0pheny1 ) ethy1 ] - 3 - [ 3 - meth0xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] pi - peridin - 2 - 0ne 0r a pharmaceutically acceptable sa1t there0f. [ 0051 ] ( 13 ) The c0mbinati0n 0f ( 9 ) , Wherein ( B ) is 0ne 0r m0re c0mp0unds se1ected fr0m the gr0up c0nsisting 0f d0nepezi1 0r a pharmaceutical1y acceptab1e salt there0f , huperzine A 0r a pharmaceutica11y acceptab1e sa1t there0f , tacrine 0r a pharmaceutica11y acceptab1e sa1t there0f , riVastigmine 0r a pharmaceutica11y acceptab1e sa1t there0f , ga1antamine 0r a pharmaceutica11y acceptab1e sa1t there0f , pramiracetam 0r a pharmaceutically acceptab1e sa1t there0f , aniracetam 0r a pharmaceutically acceptable salt there0f , neﬁracetam 0r a pharmaceutica11y acceptable sa1t there0f , EGb 761 0r a pharmaceutica11y acceptab1e sa1t there0f , r0sig1itaZ0ne 0r 3 pharmaceutica11y acceptab1e sa1t there0f , rasagi1ine 0r a pha1maceutica11y acceptab1e sa1t there0f , 1eVacecamine 0r a pharmaceutica11y acceptab1e sa1t there0f , ce1ec0xib 0r a pharmaceutica11y acceptab1e sa1t there0f , 3 - ( 2 - cyan0pheny1 ) - 5 - ( 2 - pyridy1 ) - 1 - phenyl - 1 , 2 - dihydr0pyridin - 2 - 0ne , a pharmaceutica11y acceptab1e sa1t there0f 0r a hydrate there0f , ta1ampane1 0r a pharmaceutica11y acceptab1e sa1t there0f , becampanel 0r a pharmaceutically acceptable salt there0f , memantine 0r a pharmaceutica11y acceptab1e sa1t there0f , nerameXane 0r a pharmaceutically acceptab1e salt there0f , xalip - r0der1 0r a pharmaceutically acceptable salt there0f , tarenﬂur - bi1 0r a pharmaceutica11y acceptab1e sa1t there0f , tramipr0sate 0r a pharmaceutica11y acceptab1e sa1t there0f , and 1eupr0re - 11n - D 0r a phannaceuticaHy acceptable salt there0f. [ 0052 ] ( 14 ) The c0mbinati0n 0f ( 9 ) , Wherein ( B ) is 0ne 0r m0re c0mp0unds selected fr0m the gr0up c0nsisting 0f d0nepezi1 0r a pharmaceutica11y acceptab1e sa1t there0f , 3 - ( 2 - cy - an0pheny1 ) - 5 - ( 2 - pyridy1 ) - 1 - pheny1 - 1 , 2 - dihydr0pyridin - 2 - 011e , a pharmaceutically acceptab1e salt there0f 0r a hydrate there0f and memantine 0r a pharmaceutica11y acceptab1e sa1t there0f. [ 0053 ] ( 15 ) The 00mbinati0n 0f ( 9 ) , Wherein ( B ) is d0nepezi1 0r a pharmaceutica11y acceptab1e sa1t there0f. [ 0054 ] ( 16 ) The c0mbinati0n 0f ( 9 ) , Wherein ( A ) and ( B ) are administered separate1y t0 a patient 0r are administered t0 a patient in the f0rm 0f a pharmaceutica1 c0mp0siti0n. [ 0055 ] ( 17 ) The c0mbinati0n 0f ( 9 ) , Wherein the c0mbina - ti0n is used f0r treating dementia 0r 0ne 0r m0re mi1d c0gnitiVe impairments ; f0r the pr0phy1aXis 0f dementia 0r 0ne 0r m0re mi1d c0gnitiVe impairments ; 0r de1aying the 0nset 0f dementia 0r 0ne 0r m0re mi1d c0gnitiVe impairments. [ 0056 ] ( l 8 ) Use 0f c0mp0unds ( A ) and ( B ) f0r pr0ducing a pharmaceutica1 c0mp0siti0n in the treatment 0f dementia 0r 0ne 0r m0re mild c0gnitiVe impairments ; f0r the pr0phy1axis 0f dementia 0r 0ne 0r m0re mi1d c0gnitiVe impairments ; 0r de1aying the 0nset 0f dementia 0r 0ne 0r m0re mi1d c0gnitiVe impairments , Wherein ( A ) and ( B ) are : . US 2010 / 0130537 A1. ( A ) a c0mp0und 0f F0rmula ( l ) 0r a pharmaceutica1ly accept - ab1e sa1t there0f : . [ 0057 ] Wherein R1 is : . [ 0058 ] ( a ) 7X17Ar1 , Wherein X 1 is a C1_6 a1ky1ene gr0up. 0pti0na11y substituted With a Cl - 6 a1ky1 gr0up ; and Arl is a. pheny1 gr0up 0pti0nal1y substituted With 1 t0 3 substituents. selected fr0m the gr0up c0nsisting 0f ( i ) a hal0gen at0m and. ( ii ) a C1_6 a1ky1 gr0up Which may 0pti0na1ly be substituted. With 0ne t0 ﬁVe C1_6 a1ky1 gr0ups ; . [ 0059 ] ( b ) an indenyl gr0up 0pti0nally substituted With 1 t0. 3 ha10gen at0ms ; . [ 0060 ] ( c ) a tetrahydr0naphthyl gr0up 0pti0nally substi - . tuted With 1 t0 3 hal0gen at0ms ; 0r. [ 0061 ] ( d ) a chr0many1 gr0up 0pti0na11y substituted With 1. t0 3 ha10gen at0ms ; and. ( B ) a ch01inesterase inhibit0r ; an AMPA recept0r antag0nist ; . an NMDA recept0r antag0nist ; 0r a miXture 0r c0mbinati0n. 0f tW0 0r m0re there0f. [ 0062 ] ( 19 ) The use 0f ( 18 ) , Wherein R1 is 7Xl7Ar1 ; . Wherein X1 is a C1_6 a1ky1ene gr0up 0pti0na11y substituted. With a C1_6 a1ky1 gr0up ; and Arl is a pheny1 gr0up 0pti0na11y. substituted With 1 t0 3 substituents selected fr0m the gr0up. c0nsisting 0f ( i ) a hal0gen at0m and ( ii ) a Cl - 6 alkyl gr0up. Which may 0pti0na1ly be substituted With 0ne t0 ﬁVe C1_6. a1ky1 gr0ups ; . [ 0063 ] ( 20 ) The use 0f ( 1 8 ) , Wherein R1 is an indeny1 gr0up. 0pti0na1ly substituted With 1 t0 3 ha10gen at0ms ; a tetrahy - . dr0naphthy1 gr0up 0pti0nally substituted With 1 t0 3 hal0gen at0ms ; 0r a chr0many1 gr0up 0pti0nal1y substituted With 1 t0. 3 ha10gen at0ms. [ 0064 ] ( 21 ) The use 0f ( 18 ) , Wherein ( A ) is at 1east 0ne. c0mp0und se1ected fr0m : ( E ) - 1 - ( 3 , 4 - diﬂu0r0benzy1 ) - 3 - [ 3 - . meth0xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a phannaceuticaHy acceptable salt there0f ; . [ 0065 ] ( E ) - 1 - indan - 2 - y1 - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; . [ 0066 ] ( E ) - 1 - [ ( 4R ) - chr0man - 4 - y1 ] - 3 - [ 3 - meth0xy - 4 - ( 4 - methyl - 1H - imidaz0l - 1 - yl ) benzylidene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; ( E ) - 1 - [ ( 4S ) - chr0man - 4 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; . [ 0067 ] ( E ) - 1 - [ ( 1S ) - 1 - ( 4 - ﬂu0r0phenyl ) ethy1 ] - 3 - [ 3 - meth - 0xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; . [ 0068 ] ( E ) - 1 - ( 4 - tert - buty1benzy1 ) - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzylidene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; . [ 0069 ] ( E ) - 1 - [ ( 2S ) - 5 - flu0r0indan - 2 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - l H - imidaz0l - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; ( E ) - 1 - [ ( 2R ) - . May 27 , 2010. 5 - ﬂu0r0indan - 2 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - l - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r a pharmaceuti - ca11y acceptab1e sa1t there0f ; . [ 0070 ] ( E ) - 1 - [ ( 4R ) - 7 - flu0r0chr0man - 4 - y1 ] - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benZy1idene ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; 0r ( E ) - 1 - [ ( 4 S ) - 7 - ﬂu0r0chr0man - 4 - y1 ] - 3 - [ 3 - meth0xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] piperidin - 2 - 0ne 0r 3 pharmaceutical1y acceptab1e sa1t there0f ; . [ 0071 ] ( E ) - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] - 1 - [ ( 2R ) - 1 , 2 , 3 , 4 - tetrahydr0naphthalen - 2 - y1 ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; ( E ) - 3 - [ 3 - meth0Xy - 4 - ( 4 - methy1 - lH - imidaz01 - 1 - y1 ) benzy1idene ] - 1 - [ ( 2S ) - 1 , 2 , 3 , 4 - tetrahydr0naphtha1en - 2 - y1 ] piperidin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f ; and. [ 0072 ] ( E ) - 1 - [ ( 1R ) - 1 - ( 2 , 4 - diﬂu0r0pheny1 ) ethy1 ] - 3 - [ 3 - meth0xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] pi - peridin - 2 - 0ne 0r a pharmaceutically acceptable sa1t there0f ; 0r ( E ) - 1 - [ ( 1S ) - l - ( 2 , 4 - diﬂu0r0pheny1 ) ethy1 ] - 3 - [ 3 - meth0xy - 4 - ( 4 - methy1 - 1H - imidaz01 - 1 - y1 ) benzy1idene ] pi - peridin - 2 - 0ne 0r a pharmaceutica11y acceptab1e sa1t there0f. [ 0073 ] ( 22 ) The use 0f ( 18 ) , Wherein ( B ) is 0ne 0r m0re c0mp0unds selected fr0m the gr0up c0nsisting 0f d0nepezi1 0r 3 pharmaceutica1ly acceptab1e sa1t there0f , huperzineA 0r a pharmaceutical1y acceptable salt there0f , tacrine 0r a pharmaceutica11y acceptab1e sa1t there0f , riVastigmine 0r a pharmaceutica11y acceptab1e sa1t there0f , ga1antamine 0r a pharmaceutica11y acceptable sa1t there0f , pramiracetam 0r a pharmaceutically acceptab1e sa1t there0f , aniracetam 0r a pharmaceutically acceptable salt there0f , neﬁracetam 0r a pharmaceutica11y acceptab1e sa1t there0f , EGb 761 0r a pharmaceutica11y acceptab1e sa1t there0f , r0sig1itaz0ne 0r a pharmaceutical1y acceptab1e sa1t there0f , rasagi1ine 0r a pharmaceutica1ly acceptable salt there0f , leVacecarnine 0r a pharmaceutically acceptable salt there0f , celec0xib 0r a pharmaceutica11y acceptab1e sa1t there0f , 3 - ( 2 - cyan0pheny1 ) - 5 - ( 2 - pyridy1 ) - 1 - pheny1 - 1 , 2 - dihydr0pyridin - 2 - 0ne , a pha1maceutica1ly acceptab1e salt there0f 0r a hydrate there0f , talampanel 0r a pharmaceutically acceptab1e salt there0f , becampane1 0r a pharmaceutica11y acceptab1e sa1t there0f , memantine 0r a pharmaceutica11y acceptab1e sa1t there0f , nerameXane 0r a pharmaceutica11y acceptab1e sa1t there0f , Xa1ip - r0den 0r a pharmaceutica11y acceptab1e sa1t there0f , tarenflur - bi1 0r a pharmaceutically acceptable sa1t there0f , tramipr0sate 0r a pharmaceutica11y acceptab1e sa1t there0f , and 1eupr0re - 1in - D 0r a pharmaceutica11y acceptab1e sa1t there0f. [ 0074 ] ( 23 ) The use 0f ( 18 ) , Wherein ( B ) is 0ne 0r m0re. c0mp0unds selected fr0m the gr0up c0nsisting 0f d0nepezi1. 0r 3 pharmaceutical1y acceptab1e salt there0f , 3 - ( 2 - cyan0phe - . ny1 ) - 5 - ( 2 - pyridy1 ) - 1 - pheny1 - 1 , 2 - dihydr0pyridin - 2 - 0ne , a. pharmaceutica11y acceptable sa1t there0f 0r a hydrate there0f. and memantine 0r a pharmaceutica11y acceptab1e sa1t there0f. [ 0075 ] ( 24 ) The use 0f ( 18 ) , Wherein ( B ) is d0nepezi1 0r a. pharmaceutica11y acceptab1e salt there0f. [ 0076 ] ( 25 ) The use 0f ( 1 8 ) , Wherein ( A ) and ( B ) are admin - . istered separate1y t0 a patient 0r are administered t0 a patient. in the f0rm 0f a pharmaceutical c0mp0siti0n. [ 0077 ] ( 26 ) C0mp0unds ( A ) and ( B ) f0r use in the treatment. 0f dementia 0r 0ne 0r m0re mi1d c0gnitiVe impairments ; f0r. the pr0phy1aXis 0f dementia 0r 0ne 0r m0re mi1d c0gnitiVe impairments ; 0r de1aying the 0nset 0f dementia 0r 0ne 0r m0re mi1d c0gnitiVe impairments , Wherein ( A ) and ( B ) are : . US 20l0 / 0l30537 Al. ( A ) a c0mp0und 0f F0rmula ( l ) 0r a pharmaceutically acceptable salt there0f : . [ 0078 ] Wherein R1 is : . [ 0079 ] ( a ) —Xl—Arl , Wherein X 1 is a C M alkylene gr0up 0pti0nally substituted With a Cl - 6 alkyl gr0up ; and Ar1 is a phenyl gr0up 0pti0nally substituted With 1 t0 3 substituents selected fr0m the gr0up c0nsisting 0f ( i ) a hal0gen at0m and ( ii ) a C1_6 alkyl gr0up Which may 0pti0nally be substituted With 0ne t0 ﬁVe C1_6 alkyl gr0ups ; . [ 0080 ] ( b ) an indenyl gr0up 0pti0nally substituted With 1 t0 3 hal0gen at0ms ; . [ 0081 ] ( c ) a tetrahydr0naphthyl gr0up 0pti0nally substituted With 1 t0 3 hal0gen at0ms ; 0r. [ 0082 ] ( d ) a chr0manyl gr0up 0pti0nal1y substituted With 1 t0 3 hal0gen at0ms ; and. ( B ) a ch0linesterase inhibit0r ; an AMPA recept0r antag0nist ; an NMDA recept0r antag0nist ; 0r a mixture 0r c0mbinati0n 0f tW0 0r m0re there0f. [ 0083 ] ( 27 ) A kit c0mprising the pharmaceutical c0mp0si - ti0n 0f any 0ne 0f ( 1 ) t0 ( 8 ) 0r the c0mbinati0n 0f any 0ne 0f ( 9 ) t0 ( 17 ) . [ 0084 ] ( 28 ) A meth0d f0r treating dementia 0r 0ne 0r m0re mi1d c0gnitiVe impairments ; f0r the pr0phylaxis 0f dementia 0r 0ne 0r m0re mild c0gnitiVe impairments ; 0r de1aying the 0nset 0f dementia 0r 011e 0r m0re mild c0gnitiVe impairments c0mprising administering t0 3 patient in need there0f a therapeutica1ly effectiVe am0unt 0f the pharmaceutical c0mp0si - ti0n 0f any 0ne 0f ( 1 ) t0 ( 8 ) 0r a therapeutically effectiVe am0unt 0f the c0mbinati0n 0f any 0ne 0f ( 9 ) t0 ( 17 ) . [ 0085 ] These and 0ther aspects 0f the inVenti0n are described in m0re detail herein. DETAlLED DESCRlPTlON OF THE lNVENTlON. [ 0086 ] “Patient” refers t0 animals , preferably mammals , m0re preferably humans. The term “patient” includes men and W0men ; and includes adults , children and ne0nates. [ 0087 ] “Active ingredient” refers t0 and includes c0m - p0unds useful f0r treating dementia , delaying the 0nset 0f dementia , 0r the pr0phy1axis 0f dementia. The actiVe ingredients may haVe mechanisms 0f acti0n that are kn0Wn 0r unkn0Wn , and the actiVe ingredients may haVe 0ne 0r m0re mechanisms 0f acti0n. The actiVe ingredient may have an asymmetric carb0n depending 0n the type 0f substituent and may haVe a stere0is0mer ( e. g. , a ge0metric is0mer , an enan - ti0mer , a diastere0mer 0r the like ) . The actiVe ingredient 0r a stere0is0mer there0f may f0rm a pharmaceutically acceptable salt. The actiVe ingredient , a pharmaceutically acceptable salt there0f , a stere0is0mer there0f 0r a pharmaceutica11y acceptable salt 0f a stere0is0mer there0f may be an anhydride , and may f0rm a solVate. The actiVe ingredient , a pharmaceutically acceptable salt there0f , a stere0is0mer there0f , a pharmaceutically acceptable salt 0f a stere0is0mer there0f 0r. May 27 , 2010. a s0lVate there0f may be a crystal 0r an am0rph0us. Crystal p0lym0rph may exist in the actiVe ingredient , a pharmaceutically acceptable salt there0f , a stere0is0mer there0f , a pharmaceutically acceptable salt 0f a stere0is0mer there0f 0r a s0lVate there0f , alth0ugh n0t limited theret0 and any f0rm 0f crystal may exist al0ne 0r in c0mbinati0n , Which are Within the sc0pe 0f the present inVenti0n. Exemplary actiVe ingredients include cinnamide c0mp0unds and the sec0nd - line c0m - p0unds described herein. [ 0088 ] “Treatment” and “treating” refer t0 the acquisiti0n 0f a desired pharmac0l0gical effect and / 0r physi0l0gic effect. These effects are pr0phylactic in teens 0f c0mpletely 0r partially preVenting a disease and / 0r sympt0m ( s ) , and therapeutic in terms 0f partially 0r c0mpletely curing a disease and / 0r an adVerse eVent caused by a disease. “Treatment” and “treating” include any treatment 0f a disease in a patient inc1uding , f0r example : ( a ) t0 preVent a disease 0r sympt0m ( s ) in a patient Wh0 is suspected 0f being predisp0sed t0 the disease 0r sympt0m ( s ) but n0t yet diagn0sed t0 be so ; ( b ) t0 inhibit a sympt0m ( s ) 0f a disease , i. e. , t0 inhibit 0r delay the pr0gres - si0n 0f the sympt0m ( s ) ; and ( c ) t0 alleViate a sympt0m ( s ) 0f a disease , i. e. , t0 reVerse 0r eliminate the sympt0m ( s ) 0f the disease ; 0r t0 reVerse the pr0gress 0f the sympt0m ( s ) . [ 0089 ] “Administered separately” With reference t0 the admini strati0n 0f tW0 0r m0re actiVe ingredients t0 treat and / 0r preVent and / 0r delay the 0nset 0f the diseases described herein includes , f0r example , the sequential administrati0n 0f the actiVe ingredients in any 0rder 0r the simultane0us administrati0n 0f the actiVe ingredients. Simultane0us administra - ti0n 0f the actiVe ingredients means that the actiVe ingredients are administered t0 the patient at substantially the same time 0r at exactly the same time , depending 0n the m0de 0f administrati0n. The sequential administrati0r1 0f the actiVe ingredients may 0ccur in any 0rder and may 0ccur With any am0unt 0f time elapsing betWeen administrati0n 0f the actiVe ingredients. Sequential administrati0n may be based 0n fact0rs that W0uld inﬂuence Which 0f the actiVe ingredients sh0uld be administered ﬁrst and Which sh0uld be administered sec0nd , and h0W much time sh0uld elapse betWeen administrati0n 0f the actiVe ingredients. F0r example , When tW0 0r m0re actiVe ingredients are administered separately and sequentially , fac - t0rs that effect When the actiVe ingredients are administered t0 the patient include , f0r examp1e , ( a ) the time ( s ) that pr0Vides the best efﬁcacy f0r the actiVe ingredient being administered , ( b ) the time ( s ) that pr0Vides the feWest side effects f0r the actiVe ingredient being administered , ( c ) the d0sage 0f the actiVe ingredient , ( d ) the r0ute 0f administrati0n 0f the actiVe ingredient , ( e ) the disease being treated , ( f ) the patient being treated , ( g ) the in ViV0 relati0nship 0f the actiVe ingredients being administered , and 0ther such fact0rs kn0Wn in the art. The time interVals f0r sequential administrati0n are generally ch0sen s0 that the effect 0n the disease being treated in the c0mbined use 0f the actiVe ingredients is greater than additiVe When c0mpared t0 the effect Which W0uld be 0btained by use 0f 0nly 0ne 0f the actiVe ingredients. [ 0090 ] “C0mbinati0n” refers t0 tW0 0r m0re actiVe ingredients being administered separately as distinct pharmaceutical f0rmulati0ns ( e. g. , a ﬁrst pharmaceutica1 f0rmulati0n c0mprising a cinnamide c0mp0und and a sec0nd pharmaceutical f0rmulati0n c0mprising a sec0nd - line actiVe ingredient ) . The pharmaceutical f0rmulati0ns can haVe the same 0r different m0des 0f administrati0n. US 20l0 / 0l30537 Al. [ 0091 ] “M0n0therapy” is a therapy Which uses 0nly 0ne actiVe ingredient f0r treatment and / 0r pr0phylaxis and / 0r delaying the 0nset 0f a disease. [ 0092 ] “C0mbinati0n therapy” is a therapy Where tW0 0r m0re actiVe ingredients are administered separately 0r are administered in the f0rm 0f a pharmaceutical c0mp0siti0n f0r the treatment and / 0r pr0phylaxis and / 0r delayed 0nset 0f a disease. [ 0093 ] “Therapeutically effectiVe am0unt” refers t0 the am0unt 0f the actiVe ingredient that is necessary f0r the treatment and / 0r pr0phylaxis and / 0r delayed 0nset 0f a disease. When tW0 0r m0re actiVe ingredients are administered as a pharmaceutical c0mp0siti0n 0r f0r c0mbinati0n therapy , the term “therapeutically effectiVe am0unt” refers t0 the am0unt 0f actiVe ingredients that are necessary f0r treatment and / 0r pr0phylaxis and / 0r de1ayed 0nset 0f a disease and includes , f0r example : ( a ) a therapeutically effectiVe am0unt 0f a ﬁrst actiVe ingredient and a therapeutically effectiVe am0unt 0f a sec0nd actiVe ingredient ( i. e. , the am0unt 0f each actiVe ingredient that W0uld be used f0r m0n0therapy f0r the treatment and / 0r pr0phylaxis 0f a disease is used f0r the pharmaceutical c0mp0siti0n 0r c0mbinati0n therapy ) ; ( b ) a therapeutically effectiVe am0unt 0f a ﬁrst actiVe ingredient and a sub - therapeutic am0unt 0f a sec0nd actiVe ingredient , Which in c0m - binati0n effectiVely pr0Vide f0r treatment and / 0r pr0phylaxis 0f a disease ( e. g. , the sub - therapeutic am0unt 0f the sec0nd actiVe ingredient can be used in a pharmaceutical c0mp0si - ti0n 0r c0mbinati0n therapy t0 achieVe a result that W0uld be equal t0 0r greater than the result that the sec0nd actiVe ingredient W0uld achieVe if it Was used f0r m0n0therapy ) ; ( c ) a sub - therapeutic am0unt 0f a ﬁrst actiVe ingredient and a therapeutically effectiVe am0unt 0f a sec0nd actiVe ingredient , Which in c0mbinati0n effectiVely pr0Vide f0r treatment and / 0r pr0phy1axis 0f a disease ( e. g. , the sub - therapeutic am0unt 0f the ﬁrst actiVe ingredient can be used in a pharmaceutical c0mp0siti0n 0r c0mbinati0n therapy t0 achieVe a result that W0uld be equal t0 0r greater than the result that the ﬁrst active ingredient W0uld achieVe if it Was used f0r m0n0 - therapy ) ; and ( d ) a sub - therapeutic am0unt 0f a ﬁrst actiVe ingredient and a sub - therapeutic am0unt 0f a sec0nd actiVe ingredient , Which ln c0mbinati0n therapy pr0Vide f0r treatment and / 0r pr0phylaxis 0f a disease 0r dis0rder ( e. g. , the sub - therapeutic am0unt 0f the ﬁrst actiVe ingredient can be used in a pharmaceutical c0mp0siti0n 0r c0mbinati0n therapy t0 achieVe a result that W0uld be equa1 t0 0r greater than the result that the ﬁrst actiVe ingredient W0u1d achieVe if it Was used f0r m0n0therapy ; and the sub - therapeutic am0unt 0f the sec0nd active ingredient can be used in pharmaceutical c0m - p0siti0n 0r c0mbinati0n therapy t0 achieVe a result that W0uld be equa1 t0 0r greater than the result that the sec0nd actiVe ingredient W0uld achieVe if it Was used f0r m0n0therapy ) . [ 0094 ] “Kits” can include a c0mbinati0n 0f ( i ) a ﬁrst pharmaceutical c0mp0siti0n 0r f0rmulati0n c0mprising the cinnamide c0mp0und ; ( ii ) 0ne 0r m0re sec0nd - line actiVe ingredients ; ( iii ) instructi0ns f0r using the pharmaceutical c0mp0siti0ns 0r f0rmulati0ns f0r treating 0r preVenting 0r delaying the 0nset 0f the disease ; and ( iV ) 0pti0nally 0ther materials t0 administer the pharmaceutical c0mp0siti0ns 0r f0rmulati0ns ( e. g. , syringes , diluents , medical gl0Ves , hand sanitizers , and the like ) ; t0 m0nit0r drug leVels in the b0dy ; t0 supp0rt patient c0mpliance With medicati0n d0sing ; 0r t0 m0nit0r the status 0f the disease. The kit can supply en0ugh medicati0n and materials f0r days , Weeks 0r m0nths. ln an0ther emb0diment , “kits” can include ( i ) pharmaceutical. May 27 , 2010. c0mp0siti0ns 0r f0rmulati0ns c0mpri sing b0th the cinnamide c0mp0und and 0ne 0r m0re sec0nd - line actiVe ingredients ; ( ii ) instructi0ns f0r using the pharmaceutical c0mp0siti0ns 0r f0rmulati0ns f0r treating 0r preVenting 0r delaying the 0nset 0f the disease ; and ( iii ) 0pti0nally 0ther materia1s t0 administer the pharmaceutical c0mp0siti0ns 0r f0rmulati0ns ( e. g. , syringes , diluents , medical gl0Ves , hand sanitizers , and the like ) ; t0 m0nit0r drug leVels in the b0dy ; t0 supp0rt patient c0mpliance With medicati0n d0sing ; 0r t0 m0nit0r the status 0f the disease. The kit can supply en0ugh medicati0n and materials f0r days , Weeks 0r m0nths. [ 0095 ] “S0lVate” is Well kn0Wn in the art. The sOlVate is preferably a pharmaceutically acceptable s0lVate. The pharmaceutically acceptable s0lVate may be either a hydrate 0r a n0nhydrate , but preferab1y a hydrate. The s0lVent such as Water , alc0h0l ( e. g. , methan0l , ethan0l , n - pr0par10l ) , dimethylf0rmamide , dimethyl sulf0xide ( DMSO ) 0r the like may be used. [ 0096 ] “Hydrate” refers t0 an actiVe ingredient 0r c0m - p0und c0ntaining a m0lecule 0f Water 0f crystallizati0n. The m0lecule 0f Water 0f crystallizati0n can be an integer 0f 1 0r m0re , such as 1 t0 10 ; 0r can be any fracti0n greater than 0 0r a fracti0n 0f an integer fr0m 1 t0 10. F0r example , the hydrate may be represented as ( actiVe ingredient ) .1 / 4H2O ; ( actiVe ingredient ) .1 / 2H2O ; ( actiVe ingredient ) .1A1H2O ; ( actiVe ingredient ) .2H2O ; ( actiVe ingredient ) .5 1 / 2H2O ; ( actiVe ingredient ) . 6H2O ; and the like. [ 0097 ] “Pharmaceutically acceptable salts” are Well kn0Wn in the art and include th0se 0f in0rganic acids , such as hydr0 - chl0ride , sulfate , hydr0br0mide and ph0 sphate ; and th0se 0f 0rganic acids , such as f0rmate , acetate , triflu0r0acetate , methanesulf0nate , benzenesulf0nate and t0luenesulf0nate. When certain substituents are selected , the actiVe ingredients can f0rm , f0r examp1e , alkali metal salts , such as s0dium 0r p0tassium salts ; alkaline earth meta1 sa1ts , such as calcium 0r magnesium salts ; 0rgar1ic amine salts , such as a salt With trimethylamine , triethylamine , pyridine , pic0line , dicycl0 - hexylamine 0r N , N ' - dibenzylethylenediamine. One ski1led in the art Wil1 rec0gnize that the actiVe ingredients can be made in the f0rm 0f any 0ther pharmaceutically acceptable salt. One skilled in the art Will als0 rec0gnize that any actiVe ingredient described herein can be in the f0rm 0f a pharmaceutically acceptable salt. [ 0098 ] “Dementia” refers t0 a deteri0rati0n 0f intellectual functi0ning , and is characterized by 0ne 0r m0re sympt0ms 0f c0gnitiVe impairments , dis0rientati0n , impaired mem0ry , impaired judgment , impaired intellect , and the 1ike. “Dementia” may als0 inc1ude behaVi0ral disturbances. Exemp1ary behaVi0ral disturbances include sexual disinhibiti0n , changes in actiVity , changes in interpers0nal relati0nships , physical aggressiVeness , physical n0n - aggressiVeness ( e. g. , Wandering ) , Verbal aggressiVeness , and Verbal n0n - aggressiVeness ( e. g. , repetitiVe V0calizati0n ) . With respect t0 dementia , the meth0ds 0f the inVenti0n may be used t0 treat , preVent , 0r delay the 0nset 0f ( i ) intellectual functi0ning ass0ciated With dementia ; ( ii ) behaVi0ral disturbances ass0ciated With dementia ; 0r ( iii ) inte1lectual functi0ning and behaVi0ral disturbances ass0ciated With dementia. ln 0ne emb0diment , the inVenti0n pr0Vides meth0ds that are used t0 treat , preVent , 0r delay the 0nset 0f intellectual functi0ning ass0ciated With. dementia. The cause ( s ) 0f dementia may be kn0Wn 0r unkn0Wn. [ 0099 ] “Mild c0gnitiVe impairments” are a transiti0n , stage betWeen the c0gnitiVe changes 0f n0rmal aging and the m0re. US 20l0 / 0l30537 Al. serious problems caused by dementia. While mild cognitiVe impairments can affect many areas of cognition7language , attention , reasoning , judgment , reading and Writing—most research has focused on its effects on memory. The disorder can be diVided into tWo broad subtypes. Amnestic mi1d cognitiVe impairments signiﬁcantly affect memory , While nonamnestic mild cognitiVe impairments do not. Other functions , such as language and attention span , may be impaired in either subtype. [ 0100 ] Exemplary causes of dementia and / or mild cognitiVe impairments include neurodegeneratiVe diseases , Alzheimers disease , Parkinsons disease , Huntingtons disease , Picks disease , LeWy body disease , Vascular disease ( e. g. , cerebroVascular disease ) , HlV / AlDS , epilepsy , brain tumors , brain lesions , multiple sclerosis , DoWns syndrome , Retts syndrome , progressiVe supranuclear palsy , frontal lobe syndrome , schjzophrenia , traumatic brain injuries ( e. g. , closed head injuries ) , post coronary artery by - pass graft surgery , electroconVulsiVe shock therapy , chemotherapy , radiation therapy , radiation exposure , encephalitis , meningitis , fetal alcohol syndrome , Korsakoffs syndrome , anoxic brain injury , cardiopulmonary resuscitation , diabetes , menopause , strokes , high cholesterol leVels , or spinal cord disorders. For additional descriptions of dementia and mild cognitiVe impairments , the disclosures of U. S. Pat. No. 6 , 458 , 807 , US Publication No. 2006 / 00l8839 , and WO 2005 / 074535 are incorporated by reference herein in their entirety. [ 0101 ] “NeurodegeneratiVe disease” refers to any neurodegeneratiVe disease knoWn in the art. Exemplary neurodegeneratiVe diseases include Alzheimers disease , Parkinsons disease , Huntingtons disease , amyotrophic lateral sclerosis , multiple sclerosis , Picks disease , LeWy body disease , prion diseases ( e. g. , Creutzfeldt - Jakob disease ) , epilepsy , strokes , and the like. [ 0102 ] “Alzheimers disease” refers to and includes one or more of mild Alzheimers disease ; mild - to - moderate Alzheimers disease ; moderate Alzheimers disease ; moderate - toseVere A1zheimers disease ; and seVere Alzheimers disease. Clinica1 symptoms of Alzheimers disease include progressiVe disorientation , amnesia , and aphasia , Which eVentually cause incompetence , speech loss , and akinesia. Examples of pathological signs of Alzheimers disease include neuroﬁbrillary tangle , senile p1aque , and amyloid Vascular disorder. “To preVent progression of Alzheimers disease” refers to preVenting the onset or further progression of a clinical symptom ( s ) and / or a pathological sign ( s ) of Alzheimers disease. For example , progression of a clinical symptom or a pathological sign can be preVented for patients Who do not exhjbit the clinical symptom ( s ) or patho1ogical sign ( s ) of Alzheimers disease. ln addition , patients With a milder form of Alzheimers disease can be preVented from progressing to a more seVere of Alzheimers disease. “To delay the progression of Alzheimers disease” refers to delaying the onset of a symptom ( s ) and / or patho1ogical sign ( s ) of Alzheimers disease ; or to sloW doWn the rate at Which Alzheimers disease progresses , as determined by a clinical symptom ( s ) and / or a pathological sign ( s ) . “To reVerse the progression of Alzheimers disease” refers to alleViating the seVerity of a symptom ( s ) of Alzheimers disease , i. e. , to alter the patients symptom ( s ) from a more seVere to a more mild condition , as determined by a reduction of the clinical symptom ( s ) and / or the pathological sign ( s ) . [ 0103 ] AnAlzheimers disease diagnosis can be carried out using Various knoWn methods. Typically , clinical and patho - . May 27 , 2010. logical assessments are combined to diagnose a patient With Alzheimers disease. For example , progression or seVerity of Alzheimers disease can be assessed using the Mini Mental State Examination ( MMSE ) ( Mohs et al , ( 1996 ) Int. Psych0 - geriatr 8 : 195 - 203 ) ; the Alzheimers Disease Assessment Scale - CognitiVe Subscale ( ADAS - cog ) ( Galasko et al , ( l 997 ) Alzheimer Dis. Ass0c. Dis0rd. , 11 Suppl. 2 : S33 - 39 ) ; the Alzheimers Disease CooperatiVe Study - ActiVities of Daily LiVing scale ( ADCS - ADL ) ( McKhann et al , ( 1984 ) Neuml - 0gy 34 : 939 - 944 ) ; and the National lnstitute of Neurologic CommunicatiVe Disorders and the Stroke - Alzheimers Disease and Related Disorders Association ( N lNCDS - ADRDA ) criteria ( Folstein et al , ( 1975 ) J Psychiatn Res. l2 : 189 - l98 ; McKhann et a1 , ( l 984 ) Neumlogy 34 : 939 - 944 ) . Additionally , methods capable of assessing Various areas in the brain to estimate frequency of senile plaque or neuroﬁbrillary tangle may be used ( Braak et al ( 1991 ) Acta Neumpathol 82 : 239 - 259 ; Khachaturian ( l985 ) Arc / 7 Neum 42 : 1097 - l lO5 ; Mirra et al , ( l 99l ) Neum / ogy , 4l : 479 - 486 ; Mirra et al , ( l 993 ) Arc / 7 Pat / 2d Lab Med 117 : l32 - 144 ) . [ 0104 ] The inVention proVides methods for treating dementia and / or mild cognitiVe impairments ; methods for the prophylaxis of dementia and / or mild cognitiVe impairments ; and methods for delaying the onset of dementia and / or mild co g - nitiVe impairments in a patient in need thereof by administering at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of cholinesterase inhibitors ( e. g. , donepezil , huperzine A , tacrine , riVastigmine , galantamine ) ; AMPA receptor antagonists ( e. g. , l , 2 - dihydropyridine compounds such as 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - phenyl - 1 , 2 - dihydropyridin - 2 - . one ) ; and NMDA receptor antagonists ( e. g. , memantine ) . [ 0105 ] The inVention proVides methods for treating dementia and / or mild cognitiVe impairments ; methods for the prophy1axis of dementia and / or mild cognitiVe impairments ; and methods for delaying the onset of dementia and / or mild co g - nitiVe impairments in a patient in need thereof by administering at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of cholinesterase inhibitors ( e. g. , donepezil , huperzine A , tacrine , riVastigmine , galantamine ) ; AMPA receptor antagonists ( e. g. , 1 , 2 - dihydropyridine compounds such as 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - phenyl - 1 , 2 - dihydropyridin - 2 - . one ) ; and NMDA receptor antagonists ( e. g. , memantine ) ; pramiracetam ; aniracetam ; acetylcholine releasing stimu - 1ants ( e. g. , neﬁracetam ) ; calcium channe1 agonists ( e. g. , neﬁracetam ) ; free radical scaVengers ( e. g. , EGb 761 ) ; platelet actiVating factor antagonists ( e. g. , EGb 761 ) ; platelet aggregation antagonists ( e. g. , EGb 761 , triﬂusal ) ; insulin sensitizers ( e. g. , rosiglitazone ) ; peroxisome proliferator - actiVated receptor agonists ( e. g. , rosiglitazone ) ; peroxisome proliferator - actiVated receptor gamma agonists ( e. g. , rosiglitazone ) ; monoamine oxidase B inhibitors ( e. g. , rasagiline , selegiline , procaine ) ; camitine acetyltransferase stimulants ( e. g. , leVacecarnine ) ; NSAle ( e. g. , triﬂusal , cyclooxygenase - 2 inhibitors , such as celecoxib ) ; nerVe grthh factor agonists ( e. g. , xaliproden , FPF lO70 ) ; beta - amyloid inhibitors ( e. g. , taren - ﬂurbil , tramiprosate , leuprorelin - D ) ; immunomodulators. ( e. g. , tarenﬂurbil , immune globulin , icosapentethyl ester ) ; and NF - kappa B inhibitors ( e. g. , tarenﬂurbil ) . [ 0106 ] The inVention proVides methods for treating dementia and / or mild cognitiVe impairments ; methods for the prophylaxis of dementia and / or mild cognitiVe impairments ; and methods for delaying the onset of dementia and / or mild co g - . US 20l0 / 0l30537 Al. nitiVe impairments in a patient in need thereof by admini stering at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of cholinesterase inhibitors ( e. g. , donepezil , huperzine A , tacrine , riVastigmine , galantamine ) ; AMPA receptor antagonists ( e. g. , 1 , 2 - dihydropyridine compounds such as 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - phenyl - 1 , 2 - dihydropyridin - 2 - one ) ; and NMDA receptor antagonists ( e. g. , memantine ) ; pramiracetam ; aniracetam ; acetylcholine releasing stimulants ( e. g. , neﬁracetam ) ; calcium channel agonists ( e. g. , neﬁracetam ) ; free radical scaVengers ( e. g. , EGb 761 ) ; p1atelet actiVating factor antagonists ( e. g. , EGb 761 ) ; p1atelet aggregation antagonists ( e. g. , EGb 761 , triﬂusal ) ; insulin sensitizers ( e. g. , rosiglitazone ) ; peroxisome proliferator - actiVated receptor agonists ( e. g. , rosiglitazone ) ; peroxisome proliferator - actiVated receptor gamma agonists ( e. g. , rosiglitazone ) ; monoamine oxidase B inhibitors ( e. g. , rasagiline , selegiline , procaine ) ; camitine acetyltransferase stimulants ( e. g. , leVacecarnine ) ; NSAIDs ( e. g. , triﬂusal , cyclooxygenase - 2 inhibitors , such as celecoxib ) ; nerVe grthh factor agonists ( e. g. , xaliproden , FPF lO70 ) ; beta - amyloid inhibitors ( e. g. , tarenflurbil , tramiprosate , leuprorelin - D ) ; immunomodulators ( e. g. , tarenﬂurbil , immune globulin , icosapentethyl ester ) ; NF - kappa B inhibitors ( e. g. , tarenﬂurbil ) ; thyrotropin releasing hormone agonists ( e. g. , taltire1in ) ; dopamine D2 receptor antagonists ( e. g. , risperidone ) ; serotonin 2 receptor antagonists ( e. g. , risperidone ) ; muscarinic M1 receptor agonists ( e. g. , ceVimeline ) ; alpha 1 adrenoceptor agonists ( e. g. , modaﬁnil ) ; serotonin 3 receptor antagonists ( e. g. , alosetron ) ; dopamine D2 receptor agonists ( e. g. , aripiprazole ) ; dopamine D2 receptor antagonists ( e. g. , aripiprazole ) ; serotonin 1A receptor agonists ( e. g. , aripiprazole ) ; serotonin 2A receptor antagonists ( e. g. , aripiprazole ) ; glucocorticoid antagonists ( e. g. , mifepristone ) ; progesterone antagonists ( e. g. , mifepristone ) ; HMG - CoA reductase inhibitors ( e. g. , atorVastatin , simVastatin ) ; adenosine uptake inhibitors ( e. g. , propentofylline ) ; phosphodiesterase inhibitors ( e. g. , propentofylline ) ; acetylcholine receptor agonists ( e. g. , choline alfoscerate ) ; membrane permeability enhancers ( e. g. , choline alfo scerate ) ; cannabinoid 1 receptor antagonists ( e. g. , rimonabant ) ; cannabinoid receptor agonists ( e. g. , dronabinol ) ; angiogenesis inhibitors ( e. g. , paclitaxel ) ; immunosuppressants ( e. g. , paclitaxel ) ; tubulin antagonists ( e. g. , paclitaxel ) ; thromboxane A2 synthase inhibitors ( e. g. , triﬂusal ) ; antioxidants ( e. g. , idebenone ) ; alpha adrenoreceptor antagonists ( e. g. , nicergoline ) ; estrogen agonists ( e. g. , conjugated estrogens , trilostane ) ; 3 - beta hydroxysteroid dehydrogenase inhibitors ( e. g. , trilostane ) ; signal transduction pathWay inhibitors ( e. g. , tri1ostane ) ; melatonin receptor agonists ( e. g. , ramelteon ) ; immunostimulants ( e. g. , immune globulin , icosapentethyl ester , procaine ) ; HlV entry inhibitors ( e. g. , procaine ) ; sodium channel antagonists ( e. g. , procaine ) ; microtubule inhibitor ( e. g. , CPH 82 ) ; glycine NMDA agonists ( e. g. , cycloserine ) ; adenosine A1 receptor antagonists ( e. g. , KW 3902 ) ; ATPase stimulants ( e. g. , triacety1uridine ) ; mitochondrial function enhancers ( e. g , triacetyluridine ) ; and grthh hormone releasing factor agonists ( e. g. , tesamorelin ) . [ 0107 ] The inVention proVides methods for treating dementia and / or mild cognitiVe impairments ; methods for the prophylaxis of dementia and / or mild co gnitiVe impairments ; and methods for delaying the onset of dementia and / or mild co g - nitiVe impairments in a patient in need thereof by admini stering at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting. May 27 , 2010. of donepezil , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - phenyl - 1 , 2 - dihydropyridin - 2 - one , and memantine. [ 0108 ] The inVention proVides methods for treating dementia and / or mild cognitiVe impairments ; methods for the prophylaxis of dementia and / or mild cognitiVe impairments ; and methods for delaying the onset of dementia and / or mild co g - nitiVe impairments in a patient in need thereof by administering at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of donepezil , huperzine A , tacrine , riVastigmine , galantamine , pramiracetam , aniracetam , neﬁracetam , EGb 761 , rosiglitazone , rasagiline , leVacecamine , ce1ecoxib , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - phenyl - 1 , 2 - dihydropyridin - 2 - one , talampanel , becampanel , memantine , neramexane , xaliproden , tarenﬂurbil , tramiprosate , and leuprorelin - D. [ 0109 ] The inVention proVides pharmaceutical compositions comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of cholinesterase inhibitors ; AMPA receptor antagonists ; and NMDA receptor antagonists. The pharmaceutical compositions may comprise one or more pharmaceutically acceptable carriers. [ 0110 ] The inVention proVides pharmaceutical compositions comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of cholinesterase inhibitors ; AMPA receptor antagonists ; NMDA receptor antagonists ; pramiracetam ; aniracetam ; acetylcholine releasing stimulants ; calcium channel agonists ; free radical scaVengers ; platelet actiVating factor antagonists ; platelet aggregation antagonists ; insulin sensitizers ; peroxisome proliferator - actiVated receptor agonists ; peroxisome proliferator - actiVated receptor gamma agonists ; monoamine oxidase B inhibitors ; carnitine acetyltransferase stimulants ; NSAle ; nerVe grthh factor agonists ; beta - amyloid inhibitors ; immunomodulators ; and NF - kappa B inhibitors. The pharmaceutical compositions may comprise one or more pharmaceutically acceptable carriers. [ 0111 ] The inVention proVides pharmaceutical compositions comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of cholinesterase inhibitors ; AMPA receptor antagonists ; NMDA receptor antagonists ; pramiracetam ; aniracetam ; acetylcholine releasing stimulants ; calcium channel agonists ; free radical scaVengers ; platelet actiVating factor antagonists ; p1atelet aggregation antagonists ; insulin sensitizers ; peroxisome proliferator - actiVated receptor agonists ; peroxisome proliferator - actiVated receptor gamma agonists ; monoamine oxidase B inhibitors ; carnitine acetyltransferase stimulants ; NSAle ; nerVe grthh factor agonists ; beta - amyloid inhibitors ; immunomodulators ; NF - kappa B inhibitors ; thyrotropin releasing hormone agonists ; dopamine D2 receptor antagonists ; serotonin 2 receptor antagonists ; muscarinic M1 receptor agonists ; alpha 1 adrenoceptor agonists ; serotonin 3 receptor antagonists ; dopamine D2 receptor agonists ; dopamine D2 receptor antagonists ; serotonin 1A receptor agonists ; serotonin 2A receptor antagonists ; glucocorticoid antagonists ; progesterone antagonists ; HMG - CoA reductase inhibitors ; adenosine uptake inhibitors ; phosphodiesterase inhibitors ; acetylcholine receptor agonists ; membrane permeability enhancers ; cannabinoid 1 receptor antagonists ; cannabinoid receptor agonists ; angiogenesis inhibitors ; immunosuppressants ; tubulin antagonists ; thromboxane A2 synthase inhibi - . US 20l0 / 0l30537 Al. tors ; antioxidants ; alpha adrenoreceptor antagonists ; estrogen agonists ; 3 - beta hydroxysteroid dehydrogenase inhibitors ; signal transduction pathWay inhibitors ; melatonin receptor agonists ; immunostimulants ; HlV entry inhibitors ; sodium channel antagonists ; microtubule inhibitors ; glycine NMDA agoni sts ; adenosine A1 receptor antagonists ; ATPase stimulants ; mitochondrial function enhancers ; and grthh hormone releasing factor agonists. The pharmaceutical compositions may comprise one or more pharmaceutica1ly acceptable carriers. [ 0112 ] The inVention proVides pharmaceutica1 compositions comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of donepezi1 , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one , and memantine. The pharmaceutica1 compositions may comprise one or more pharmaceutically acceptable car - r1ers. [ 0113 ] The inVention proVides pharmaceutical compositions comprising a therapeutically effectiVe amount of at 1east one cinnamide compound and one or more second - 1ine actiVe ingredients selected from the group consisting of donepezil , huperzine A , tacrine , riVastigmine , galantamine , pramiracetam , aniracetam , neﬁracetam , EGb 761 , rosiglitazone , rasagiline , leVacecarnine , celecoxib , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - 1 , 2 - dihydropyridin - 2 - one , talampane1 , becampanel , memantine , neramexane , xaliproden , tarenﬂurbil , tramiprosate , and leuprorelin - D. The pharmaceutical compositions may comprise one or more pharmaceutically acceptable carriers. [ 0114 ] The inVention proVides pharmaceutical compositions comprising a therapeutically effectiVe amount of at 1east one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of donepezil , huperzine A , tacrine , riVastigmine , galantamine , pramiracetam , aniracetam , neﬁracetam , EGb 761 , rosiglitazone , rasagiline , leVacecarnine , celecoxib , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - phenyl - 1 , 2 - dihydropyridin - 2 - one , talampanel , becampanel , memantine , xaliproden , tarenﬂurbil , tramiprosate , leuprorelin - D , taltirelin , risperidone , ceVimeline , modaﬁnil , alosetron , aripiprazole , mifepristone , atorVastatin , propentofylline , cho1ine alfoscerate , FPF 1070 ( CAS Number 143637 - 01 - 8 ) , rimonabant , dronabinol , docosahexaenoic acid , paclitaxel , triﬂusal , idebenone , nicergoline , conjugated estrogens , trilostane , simVastatin , selegi1ine , ramelteon , immune g1obulin , icosapentethyl ester , procaine , CPH 82 , cycloserine , KW 3902 ( CAS Number l361 99 - 02 - 5 ) , triacetyluridine , estrogen dementia therapeutics ( e. g. , MlGENlX , VancouVer , Canada ) , and tesamorelin. ln other embodiments , the second - line actiVe ingredients can be one or more compounds selected from the group consisting of leVprorelin , prasterone , peptide T ( CAS Number 53 - 43 - 0 ) , besipiridine , lexipafant , stacofylline , SGS 742 ( CAS Number 123690 - 78 - 8 ) , T 588 ( CAS Number 142935 - 03 - 3 ) , nerispiridine , dexanabinol , sabcomeline , GTS 21 ( CAS Number 156223 - 05 - 1 ) , CX 516 ( CAS Number lS4235 - 83 - 3 ) , ABT 089 ( CAS Number l61417 - 03 - 4 ) , anapsos , tesofensine , SlB lS53A ( i. e. , 4 - [ [ 2 - ( 1 - methyl - yl - 2 - pyrrolidinyl ) ethyl ] thia ] phenol ) , ladostigil , radequinil , GPI 1485 , ispronicline , arundic acid , MEM 1003 ( i. e. , 3 - lsopropyl 5 - ( 2 - methoxyethyl ) 4 - ( 2 - chloro - 3 - cyanophenyl ) - 2 , 6 - dimethylpyridine - 3 , 5 - dicar - . boxylate ) , V 338l ( i. e. , 2 - ( 2 , 3 - Dihydro - lH - inden - 3 - ylamino ) acetamide hydrochloride ) , farampator , paliroden , prasterone - paladin , urocortin , DP b99 ( i. e. , 2 , 2 ' - ( Ethylene - . May 27 , 2010. dioxy ) bis ( 2 , 1 - phenylene ) bis [ N - [ 2 - [ 2 - ( octyloxy ) ethoxy ] - 2 - oxoethyl ] imino ] bis ( acetic acid ) ) , capserod , DU 125530 , bapineuzumab , AL 108 ( i. e. , L - Asparaginyl - L - alanyl - L - prolyl - L - Valyl - L - seryl - L - isoleucyl - L - proly1 - L - glutamine ) , DAS 43l , DEBlO 9902 , DAR 100 , mitoquinone , lPL 455903 ( i. e. , 5 ( S ) - [ 3 - ( Cyclopentyloxy ) - 4 - methoxyphenyl ] - 3 ( S ) - ( 3 - methylbenzyl ) piperidin - 2 - one ) , E2CDS , PYM 50028 , PBT 2 , lecozotan , SB 742457 , CX 717 , AVE l625 ( i. e. , 1 - ( bis ( 4 - chlorophenyl ) methyl ) - 3 - ( ( 3 , 5 - difluorophenyl ) ( methylsulfonyl ) methylene ) azetidine ) , LY 450139 ( i. e. , N2 - [ 2 ( s ) - Hydroxy - 3 - methylbutyryl ] - Nl - [ 3 - methyl - 2 - oxo - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzazepin - 1 ( 5 ) - yl ] - L - alaninamide ) , EM 1421 ( i. e. , 4 , 4 ' - [ ( 2R , 3S ) - 2 , 3 - Dimethylbutane - 1 , 4 - diyl ] bis ( 1 , 2 - dimethoxybenzene ) , SRN 001 , TTP 488 , PRX 03140 , dimebolin , glycine - proline - glutamate , C105 , AL 208 , MEM 3454 , AC l202 , L 830982 , LY 451395 ( i. e. , ( R ) —N - [ 2 - [ 4 ' - ( methylsulfonamidomethyl ) biphenyl - 4 - yl ] propyl ] propane - 2 - sulfonamide ) , MK 0249 , LY 2062430 , diethylnorspermine , neboglamine , S 18986 , SA 4503 ( CAS Number 165377 - 44 - 6 ) , GRl 1 , S 17092 ( i. e. , ( 2S , 3aS , 7aS ) - 1 { [ ( R , R ) - 2 - Phenylcyclopropyl ] carbonyl } - 2 - [ ( thiazolidin - 3 - yl ) carbonyl ] octahydro - 1H - indole ) , SL 251l88 , EUK lS9 , R 1450 , 6 , 6 - dimethy1 - 3 - ( 2 - hydroxyethyl ) thio - 1 - ( thiazol - 2 - yl ) - 6 , 7 - dihydro - 2 - benzothiophen - 4 ( 5H ) - one , CERE 110 , dexefaroxan , CAD lO6 , HF 0220 , HF 0420 , EHT 0202 , VP 025 , MEM l4l4 , BGC 201259 ( i. e. , N , N - Dimethylcarbamic acid , 4 - [ 1 ( S ) - ( methylamino ) - 3 - ( 4 - nitrophenoxy ) propyl ] phenyl ester ) , EN 100 , ABT 834 , ABT 239 ( i. e. , 4 - [ 2 - [ 2 - [ ( 2R ) - 2 - Methylpyrrolidinyl ] ethyl ] - benzofuran - 5 - yl ] benzonitrile ) , SGS 518 , R lS00 , C 9l38 , SSR l807ll , a1fatradiol , R lS77 , T 817MA ( i . e. , l - [ 3 - [ 2 - ( l - Benzothien - 5 - yl ) ethoxy ] propyl ] azetidin - 3 - olma1eate ) , CNP 1061 ( i. e. , 4 - Methyl - 5 - ( 2 - nitrooxyethyl ) thiazole ) , KTX 0101 ( i. e. , sodium beta - hydroxybutyrate ) , GSK 189254 ( i. e. , 6 - [ 3 - Cyclobutyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - benzo [ d ] azepin - 7 - y1oxy ] - N - methylnicotinamide ) , AZD lO80 , ACC 001 , PRX 07034 , midazolam , R - phenserine , AZD 103 ( CAS Number488 - 59 - 5 ) , SN 522 , NGX 267 ( CAS Number 503431 - 81 - 0 ) , N - PEP - 12 , RN 1219 , FGLL , AVE 8112 , EVT 101 , NP 031112 , MK 0752 , MK 0952 , LX 6171 , PAZ 4l7 , AV 965 , PP 3084014 , SYN 114 , GSl 953 , SAM 3l5 , SAM 531 , D - serine , leteprinim potassium , BR l6A ( CAS Number 149175 - 77 - 9 ) , RPR 107393 ( CAS Number 190841 - 57 - 7 ) , NXD 2858 , REN 1654 , CDD 0102 , NC 190O ( CAS Number 132925 - 74 - 7 ) , ciclosporin , NCX 2216 ( i. e. , ( E ) - 4 - ( Nitrooxy ) butyl 3 - [ 4 - [ 2 - ( 2 - ﬂuorobipheny1 - 4 - yl ) propanoyloxy ] - 3 - methoxyphenyl ] acrylate ) , NXD 3l09 , NXD 1191 , ZSET 845 ( i. e. , 3 , 3 - diphenylimidazo [ 1 , 2 - a ] pyridin - 2 - ( 3H ) - one ) , ET 002 , NT 13 , RO 638695 ( i. e. , [ 1 , 6 - ( 1 , 6 - dioxohexyl ) ] dipyrrolidine - ( 2R ) - carboxylic acid ) , bisnorcymserine , BA lO16 , XD 4241 , EUK 207 ( i. e. , ( SP - 5 - l3 ) - ( acetato - KO ) [ l3 , l6 , l9 , 22 - tetraoxa - 3 , 6 - diazatricyclo [ 21 .3.18.12 ] octacosa - 1 ( 27 ) , 2 , 6 , 8 , 10 , l2 ( 28 ) , 23 , 25 - octaene - 27 , 28 - diolato ( 2 - ) - KN3 , KN6 , KO27 , KO28 ] manganese ) , LG 617 inhibitors , ZSET l446 , PAN 811 , F 14413 ( i. e. , 2 - [ 5 - fluoro - 2 ( S ) - methoxy - 2 , 3 - dihydro - 1 , 4 - benzodioxin - 2 - yl ] - 4 , 5 - dihydro - 1H - imidazole ) , PP 7832 ( i. e. , N - [ 2 - ( 5 - methoxy - l - nitroso - lH - indol - 3 - yl ) ethyl ] acetamide ) , ARA 014418 ( i. e. , N - ( 4 - methoxybenzyl ) - N ' - ( 5 - nitro - 1 , 3 - thiazol - 2 - yl ) urea ) , AZD 3102 , KP 544 ( i. e. , 2 - amino - 5 - ( 4 - chlorophenylethynyl ) - 4 - ( 4 - trans - hydroxycyc10hexylamino ) pyrimidine ) , DP 155 , 5 - chloro - N - [ 3 - [ 2 - ( dimethylamino ) ethyl ] - 1H - indol - 5 - y1 ] naphthalene - 2 - sulfonamide , TAK 070 , huperzine , N - [ 2 - ( 3 , 5 - dimethyladamant - 1 - yl ) ethyl ] acetamidine hydrochloride , 6 - [ 4 - [ ( dimethylamino ) methyl ] - 5 - ethyl - 2 - methoxyphenyl ] . US 20l0 / 0l30537 Al. pyridin - 2 - amine , 4 , 6 - diphenyl - 3 - ( 4 - ( pyrimidin - 2 - yl ) piperazin - l - y1 ) pyridazine , N - [ ( l S , 2R ) - 3 - ( 3 , 5 - difluorophenyl ) - l - hydroxy - 1 - [ ( 5 S , 6R ) - 5 - methyl - 6 - ( neopentyloxy ) morpholin - 3 - yl ] propan - 2 - yl ] acetamide hydrochloride , N - [ ( l R , 25 ) - 3 - ( 3 , 5 - diﬂuorophenyl ) - l - hydroxy - l - [ ( 2R , 4R ) - 4 - phenoxypyrrolidin - 2 - yl ] propan - 2 - yl ] - 3 - [ ( R ) - 2 - ( methoxymethyl ) pyrrolidine - l - carbonyl ] - 5 - methylbenzamide , R 1589 , midafotel , phenserine , coluracetam , physostigmine , cipralisant , nitroflurbiprofen , PPl 1019 ( i. e. , ( 30. , 5 [ 3 , 7o. , 12o. ) - trihydroxycholan - 24 - oyl - L - leucy1 - L - Valyl - L - phenylalanyl - L - phenylalanyl - L - alanine ) , dapsone , MDL 100453 ( CAS Number l29938 - 34 - 7 ) , NS 377 , midaxifylline , propofol phosphate , metrifonate , ceronapril , tenilsetam , sufoxazine , seglitide , ebiratide , nebracetam , milacemide , iododoxorubicin , SM 10888 ( CAS Number 129297 - 2l - 8 ) , U 808l6 ( CAS Number l38554 - ll - 7 ) , YM 954 ( CAS Number l3204l - 85 - l ) , SUT 870l ( CAS Number l23577 - 73 - l ) , apoVincamine , FR 121196 ( CAS Number l33920 - 65 - 7 ) , LY 274614 ( CAS Number l36l09 - 04 - l ) , CL 275838 ( CAS Number 11593 1 - 65 - 2 ) , igmesine , K 7259 ( CAS Number l33667 - 88 - 6 ) , Vinconate , itasetron , CL 287663 ( CAS Number l25l09 - 98 - 0 ) , WAY 100289 ( CAS Number l36013 - 69 - 9 ) , SR 46559A ( CAS Number l37733 - 33 - 6 ) , GYKl 46903 ( CAS Number l42999 - 59 - 5 ) , L 670548 ( CAS Number l2l564 - 89 - 4 ) , Y 29794 ( CAS Number l29l84 - 48 - l ) , AF 125 ( CAS Number 7631 - 86 - 9 ) , KFM 19 ( CAS Number l33058 - 72 - 7 ) , ST 796 ( i. e. , ( S ) - 3 - [ 3 - ( trifluoromethyl ) benzoyl ) amino ] hexahydroazepin - 2 - one ) , RU 33965 ( CAS Number l2232l - 05 - 5 ) , SDZ 210086 ( i. e. , ( — ) - l ' , 2 ( S ) - Dimethylspiro [ l , 3 - dioxolan - 4 , 4 ' - piperidine ] ) , L 689660 ( CAS Number l44860 - 79 - 7 ) , L 689560 ( CAS Number 13905l - 78 - 8 ) , ST 618 ( i. e. , 1 - ( 6 , 7 - Dimethoxy - l , 2 , 3 , 4 - tetrahydro - 2 - naphthyl ) - 4 - hydroxy pyrrolidin - 2 - one ) , U 74500A ( CAS Number 110101 - 65 - 0 ) , GEA 857 ( CAS Number l20493 - 42 - 7 ) , BlBN 99 ( CAS Number l4530l - 48 - 0 ) , DX 9366 , ONO 1603 ( CAS Number ll4668 - 76 - 7 ) , MDL 102234 ( CAS Number 137766 - 8l - 5 ) , P 9939 ( CAS Number lS797l - 37 - 4 ) , PD 140532 ( CAS Number 15797l - 39 - 6 ) , azetirelin , MR 16728 ( CAS Number l476l4 - 2l - 9 ) , dabelotine , MDL 102503 ( i. e. , 8 - [ l ( R ) - methyl - 2 - pheny1ethyl ] - l , 3 - dipropyl - 7H - xanthine ) , PD 141606 ( i. e. , ( : ) - ( Z ) - 3 - ( 3 - Phenyl - 2 - propynyloxyimino ) - l - azabicyclo [ 2.2. l ] heptane ) , SNK 882 ( CAS Number 15222l - l2 - 0 ) , L 696986 ( CAS Number 14l553 - 45 - 9 ) , tazomeline , LY 235959 ( CAS Number l37433 - 06 - 8 ) , 2 - ( 2 - thiooxopyrrolidin - l - yl ) acetamide , AK 30 NGF , ABT 4l8 ( CAS Number l47402 - 53 - 7 ) , itameline , HUP l3 , sibopirdine , KST 5452 ( CAS Number lS7998 - 88 - 4 ) , TJ 54 , U 92798 ( i. e. , 7 - [ 4 - [ Bis ( 4 - fluorophenyl ) methyl ] perhydro - l , 4 - diazepin - l - ylmethyl ] - 4 - isopropyl - 2 - methoxy - 2 , 4 , 6 - cycloheptatrien - l - one ) , U 92032 ( CAS Number l42223 - 92 - 5 ) , 3 - ( su1famoyloxy ) estra - l , 3 , 5 ( l0 ) - trien - l7 - one , P llOl2 ( CAS Number l64723 - 36 - 8 ) , A 82695 ( CAS Number l47388 - 86 - l ) , FR 76659 ( CAS Number ll6904 - 25 - 7 ) , apaxifylline , CX 417 , 7 MEOTA ( CAS Number 5778 - 80 - 3 ) , BU 45l4N ( CAS Number lSl0l3 - 39 - 7 ) , pregnenolone , mexidol , ST 857 ( CAS Number lS4755 - 63 - 2 ) , RU 4904l ( CAS Number lZ3828 - 80 - 8 ) , RU 35929 ( CAS Number lll71 l - 47 - 8 ) , P 878l84 , P 128 ( CAS Number 157716 - 52 - 4 ) , eurystatin A , eurystatin B , LK 12 , NBl lO8 , NBl 107 , NBl ll7 , L 705l06 , bacoside A + B , clausenamide , SM 2l ( CAS Number lS5l56 - 22 - 2 ) , alaptide , RS l70l7 ( i. e. , l - ( 4 - Amino - 5 - chloro - 2 - methoxyphenyl ) - 5 - ( l - piperidinyl ) - l - pentanone hydrochloride ) , AF 150 ( S ) ( i. e. , ( S ) - [ 1 - Methyl - piperidine - 4 - spiro - ( 2 ' - methylthiazoline ) ] ) , RO 153505 ( CAS Number. lO. May 27 , 2010. 7877l - l3 - 8 ) , PV ll3 ( i. e. , l , 2 , 3 , 4 - Tetrahydropyrrolo - [ l , 2 - a ] - pyrazine ) , arisugacin , A 98284 ( i. e. , 2 ( R ) - ( 3 - Methylisoxazol - 5 - yl ) quinuclidine ) , AP 5 ( CAS Number 13694l - 85 - 0 ) , BD lO54 , SDZ NDD 094 ( i. e. , bis - ( 2 - ( 2 - methylimidazol - l - yl ] methyl ) - pyridine - tris ( hydrogen - fumarate ) , AZ 3604l ( CAS Number l73324 - 76 - 0 ) , quilostigmine , A 84543 ( i. e. , 3 - [ l - Methylpyrrolidin - 2 - ( S ) - ylmethoxy ] pyridine fumarate ) , BTG 4247 ( i. e. , ( 2 - [ 2 - Chloroethoxy [ 4 - ( dimethylamino ) phenyl ] phosphoryl ] - acetohydrazide ) , CGP 50068 ( CAS Number lS8647 - 49 - 5 ) , cerebrocrast , desferri - nordanoxamine , isolichenan , MHP l33 ( i. e. , 3 - ( N , N - dimethylcarbamoyloxy ) - l - methyl - 2 - ( 4 - phenyl - semicarbazonomethyppyridinium chloride ) , FR lS2558 ( CAS Number lSlO98 - O8 - 7 ) , GVS 111 ( CAS Number 1571l5 - 85 - 0 ) , P 11149 ( CAS Number l64724 - 79 - 2 ) , PDC 008004 , KST 2818 ( CAS Number lS8623 - 26 - 8 ) , KST 54l0 ( CAS Number lS8623 - 27 - 9 ) , RU 52583 ( CAS Number l23829 - 33 - 4 ) , PD lS lS32 ( CAS Number 149929 - 39 - 5 ) , UCL 1199 ( i. e. , 4 - [ 2 - [ ( 5 - Nitropyridin - 2 - ylsulfanyl ) ethyl ] - 1H - imidazole ) , isoVanihuperzine A , SlB l765F ( CAS Number l79l20 - 52 - 6 ) , JWS USC 751X ( i. e. , 3 - [ [ [ 2 - [ [ ( 5 - dimethy1aminomethyl ) - 2 - furanyl ] methyl ] thio ] ethyl ] amino ] - 4 - nitropyridazine ) , GR l75737 ( i. e. , 3 - ( 4 - Chlorobenzyl ) - 5 - [ 2 - ( 1H - imidazol - 4 - yl ) ethyl ] - 1 , 2 , 4 - oxadiazole ) , KS 505A ( CAS Number 13l774 - 53 - 3 ) , ZTTA 1 ( i. e. , N - benzyloxycarbonyl - thioprolyl - thioprolynal - dimethylaceta l ) , AGN 190837 ( CAS Number l36527 - 40 - 7 ) , P lO358 ( l88240 - 59 - 7 ) , WAY 13l256 ( CAS Number 17400l - 71 - 9 ) , DBO 83 ( i. e. , 3 - ( 6 - chloropyridazin - 3 - yl ) - diazabicyclo [ 3.2. l ] octane dihydrochloride monohydrate ) , FUB l8l ( CAS Number lS2029 - 80 - 6 ) , RJR 2557 , WSU 2088 , LVV - haemorphin - 7 , M 40 ( i. e. , galanin [ l - l2 ] - Pro3 - ( Ala - Leu ) 2 - Ala - NH2 ) , SlB l757 , SKF 74652 ( i. e. , [ 5 - chloro - 2 - ( 4 - methoxy phenyl ) - 3 - benzofuranyl ] [ 4 - [ 3 - ( diethylamino ) - propoxy ] phenyl ] methanone ) , CGP 7l982 , SCH 57790 ( i. e. , 4 - cyclohexyl - alpha - [ 4 - [ [ 4 - methoxyphenyl ] sulﬁnyl ] phenyl ] - l - piperazineacetonitrile ) , Putrescine - D - YiAbetall , DU l4 ( i. e. , p - O - ( sulfamoyl ) - N - tetradecanoyl tyramine ) , CLZ 4 , SL 340026 , PPRT 424 , ciproxifan , UR l827 ( i. e. , 2 - ( 1 - benzylpiperidin - 4 - yl ) - l - [ 4 - ( 5 - methylpyrimidin - 4 - ylamino ) phenyl ] - l - ethanone ) , caproctamine , TGS 20 ( i. e. , L - pyroglutamil - D - alanine amide ) , PG 9 ( i. e. , a1pha - tropanyl 2 - [ ( 4 - bromo ) phenyl ] propionate ) , TEl 3356 ( i. e. , ( l6S ) - l5 - Deoxy - l6 - hydroxy - l 6 - methyl - 9 - ( O ) - methano - DELTA6 ( 9alpha ) - prostaglandin 11 ) , LY 392098 ( i. e. , Thiophene , 3 - [ ( 2 - methylethyl - 2 ) sulphonylaminopropyl - 2 ] phenyl - 4 - yl - ) , PG lO00 , DM 232 , NEPP ll ( i. e. , lZ - iso - l5 - Deoxy - l8 - ( 4 - methyl ) phenyl - l 3 , l 4 - dihydro - delta7 - prostaglandinAl methyl ester ) , VA 100 ( i. e. , ( 2 , 3 - Dihydro - 2 - [ [ ( 4 - ﬂuorobenzoyl ) amino ] ethyl ] - l - methyl - 5 - phenyl - 1H - 1 , 4 - benzodiazepine ) , VA lOl ( i. e. , ( 2 , 3 - dihydro - 2 - [ [ ( 2 - thienylcarbonyl ) amino ] ethy1 ] - l - methyl - 5 - phenyl - l H - l , 4 - benzodiazepine ) , NC lllS85 ( i. e. , ( 3S ) - l , 3 - Bis - [ 3 - [ ( 3 - azabicylo [ 2.2.2 ] octanyl ) - l , 2 , 5 - thiadiazol - 4 - yloxy ] - l - propyn - 1 - yl ] benzene , 2L - ( + ) - tartate ) , lN 201 , imoproxifan , kanokodiol , picro side l , picroside ll , DM 235 ( i. e. , l - ( 4 - Benzoylpiperazin - l - yl ) propan - l - one ) , monoclonal antibody lOD5 , J LK2 , JLK 6 , JLK 7 , DAPT ( i. e. , N - [ N - ( 3 , 5 - diﬂuorophenacetyl ) - L - alanyl ] - S - phenylglycine t - butyl ester ) , huperine X , SGS 111 ( i. e. , ( S ) - ethyl 2 - [ l - ( 2 - phenylacetyl ) pyrrolidine - 2 - carboxamido ] acetate ) , NP 7557 , C 9l36 , C 76l7 , R l485 , rofecoxib , Velnacrine , montirelin , lazabemide , ORG 2766 ( CAS Number 509l3 - 82 - l ) , sabeluzole , adafenoxate , CAS Number 906l - 6l - 4 , ipidacrine , bemesetron , idazoxan , linopirdine , selfotel , suritozole , milameline , xanomeline , TJ 960 , fasoracetam , eptastigmine , . US 20l0 / 0l30537 Al. ensaculin , zanapezil , posatirelin , zacopride , RS 86 ( CAS Number 3576 - 73 - 6 ) , ORG 5667 ( CAS Number 37552 - 33 - 3 ) , RX 77368 ( CAS Number 76820 - 40 - l ) , BMS l8l l68 ( CAS Number lZ3259 - 9l - 6 ) , BY l949 ( CAS Number 90l58 - 59 - l ) , AWD 5239 ( CAS Number lO9002 - 93 - 9 ) , YM 796 ( 171252 - 79 - 2 ) , aloracetam , Cl - 933 ( CAS Number 91829 - 95 - 7 ) , ST 793 ( CAS Number 99306 - 37 - 3 ) , cebaracetam , zifrosilone , talsaclidine , alVameline , JTP 2942 ( l48l52 - 77 - 6 ) , OPC l41 l7 ( CAS Number 103233 - 65 - 4 ) , elziVerine , AP 52l ( i. e. , N - ( 1 , 3 - Benzodioxol - 5 - ylmethyl ) - 1 , 2 , 3 , 4 - tetrahydro [ l ] benzothieno [ 2 , 3 - c ] pyridine - 3 ( R ) - carboxamide hydrochloride ) , S 85l0 ( CAS Number lSl466 - 23 - 8 ) , JTP 48l9 ( CAS Number l62203 - 65 - 8 ) , icopezil , SC 1 lO , FK 960 ( CAS Number l33920 - 70 - 4 ) , DMP 543 ( CAS Number l60588 - 45 - 4 ) , ganstigmine , Cl 1017 ( i. e. , ( R ) - ( — ) - ( Z ) - 1 - Azabicyclo [ 2.2. l ] heptan - 3 - one , 0 - ( 3 - ( 3 ' - methoxyphenyl ) - 2 - propynyl ) - oxime maleate ) , T 82 ( i. e. , 2 - [ 2 - ( l - Benzy1piperidin - 4 - yl ) ethyl ] - 2 , 3 - dihydro - 9 - methoxy - l H - pyrrolo [ 3 , 4 - b ] quinolin - l - one hemifumarate ) , NGD 971 , Vaccine of Aspartyl - alanyl - g1utamyl - phenylalanyl - arginyl - histidyl - aspartyl - serylglycy1 - tyrosyl - glutamyl - Valyl - histidyl - histidyl - glutaminyllysy1 - leucyl - Valyl - phenylalanyl - phenylalanyl - alany1 - glutamyl - aspartyl - Valyl - glycyl - seryl - asparaginyl - lysylglycyl - alanyl - isoleucyl - isoleucyl - glycyl - leucyl - methionylValyl - glycy1 - glycyl - Valyl - Valyl - isoleucyl - alanine , PBT 1 ( CAS Number l30 - 26 - 7 ) , TCH 346 , FK 962 ( i. e. , N - ( 1 - acetylpiperidin - 4 - yl ) - 4 - fluorobenzamide ) , Voxergolide , KW 6055 ( CAS Number 63233 - 46 - 5 ) , thiopilocarpine , ZK 93426 ( CAS Number 89592 - 45 - 0 ) , SDZ NW 085 ( CAS Number lO4195 - l7 - 7 ) , Cl lO02 ( CAS Number l49028 - 28 - 4 ) , Z 32l ( CAS Number l30849 - 58 - 0 ) , mirisetron , CHF 2060 ( i. e. , N - Heptylcarbamic acid 2 , 4a , 9 - trimethyl - 2 , 3 , 4 , 4a , 9 , 9a - hexahydro - 1 , 2 - oxazino [ 6 , 5 - b ] indol - 6 - yl ester - L - tartrate ) , gedocarnil , terbequinil , HOE 065 ( CAS Number 123060 - 44 - 6 ) , SL 650l02 , GR 253035 , ALE 260l5 , SB 27l046 ( i. e. , 5 - Chloro - N - ( 4 - methoxy - 3 - piperazin - l - yl - phenyl ) - 3 - methyl - 2 - benzothiophenesulfonamide ) , iAbeta5 , SCH 2ll803 ( i. e. , Piperidine , 1 - [ l - ( 3 - methyl - 2 - aminophenyl ) carbonylpiperidin - 4 - yl ] - 4 - [ ( 3 - chlorophenypsulphonylphenyl - 4 ] methyl - ) , EVT 30l , alpha - Linolenic acid / 1inoleic acid , Kamikihi - To , siagoside , FG 7l42 ( CAS Number 78538 - 74 - 6 ) , RU 47067 ( CAS Number lll7ll - 92 - 3 ) , RU 35963 ( CAS Number l39886 - 03 - 6 ) , FG 7080 ( CAS Number lO0332 - l8 - l ) , E 2030 ( CAS Number l42007 - 70 - 3 ) , transforming grthh factor beta - l , A 72055 ( i. e. , 2 ' , l - Dimethylspiro [ piperidine - 4 , 5 ' oxazolidine ] - 3 ' - carboxa1dehyde ) , NS 626 , dimiracetam , GT 300l , GT 250l , GT 2342 , GT 20l6 ( CAS Number lS224l - 24 - 2 ) , ORG 2009l ( CAS Number l4l545 - 50 - 8 ) , BCE 001 ( CAS Number 95678 - 8l - 2 ) , CGP 35348 ( CAS Number l23690 - 79 - 9 ) , WAY 100635 ( CAS Number l467l4 - 97 - 8 ) , E 4804 ( CAS Number l62559 - 34 - 4 ) , LlGA 20 ( CAS Number lZ6586 - 85 - 4 ) , NG lZl ( i. e. , 2 - [ 4 , 8 - Dimethyl - 3 ( E ) , 7 ( E ) - nonadienyl ] - 3 , 5 - dihydroxy - 2 - methyl - 3 , 4 , 7 , 9 - tetrahydro - 2H - furo [ 3 , 4 - 13 ] - 1 - benzopyran - 7 - one ) , MF 247 ( i. e. , N - [ l0 - ( Diethylamino ) decyl ] carbamic acid ( 3aS , 8aR ) - l , 3a , 8 - trimethy1 - l , 2 , 3 , 3a , 8 , 8a - hexahydropyrrolo [ 2 , 3 - b ] indol - 5 - yl ester ) , JTP 3399 ( i. e. , N - Benzyl - 2 ( S ) - [ 2 ( S ) - ( phenoxyacetyl ) pyrrolidin - 1 - ylcarbonyl ] pyrrolidine - l - carboxamide ) , KF 17329 , thioperamide , F 3796 ( i. e. , 1 - [ 2 - ( l - Benzy1piperidin - 4 - yl ) ethyl ] - 3 - [ 3 , 4 - ( methylene - dioxy ) benzoyl ] thiourea ) , GT 400l , GT 4002 , FPL l4995 ( CAS Number l233 l 9 - 03 - 9 ) , RU 34332 ( CAS Number l37l57 - 58 - 5 ) , SR 96777A ( CAS Number llS767 - 94 - 7 ) , SlB Tl 980 , NS 649 ( CAS Number l46828 - 02 - 6 ) , PD l42505 ( CAS Number. May 27 , 2010. l49929 - 08 - 8 ) , GYKl 52466 ( CAS Number lO277l - 26 - 6 ) , RO 246l73 ( CAS Number lS9723 - 57 - 6 ) , SCH 509ll ( CAS Number l604l5 - 07 - 6 ) , Z 4105 ( CAS Number 1 l9737 - 52 - 9 ) , RS 67333 ( CAS Number l68986 - 60 - 5 ) , NS lS46 , ZM 24l385 ( CAS Number l39l80 - 30 - 6 ) , RO 249975 ( i. e. , [ lS , 3S ( 2 ' S ) , 5R ] - 3 - ( l - Benzyl - 5 - oxopyrrolidin - 2 - ylmethyl ) - 5 - . ( l H - imidazol - 5 - ylmethyl ) cyclohexane - l - acetamide ) , AF lS5 ( i. e. , 8 - Methyl - 3 - ( 2 - propynyl ) - l , 3 , 8 - triazaspiro [ 4 , 5 ] decane - 2 , 4 - dione ) , CEP 427 , CX 423 , CX 438 , CX 480 , CDPethanolamine , GT 4003 , GT 401 l , GT 50l1 , MS 430 ( CAS Number l22ll3 - 44 - 4 ) , MBF 379 ( i. e. , [ 3 , 3 - Bis ( hydroxymethyl ) - 8 - hydroxy - 3 , 4 - dihydro - 2H - 1 , 4 - benzoxazin - 5 - yl ] [ 3 ' , 5 ' - dihydroxy - 4 ' - ( 2 - oxo - 2 - phenylethoxy ) phenyl ] methanone ) , NGD l87 ( CAS Number l63565 - 48 - 8 ) , DUP 856 , MR 3066 , MF 8615 ( i. e. , 5 - Amino - 6 - chloro - 4 - hydroxy - 3 , 4 - dihydro - lH - thiopyrano - [ 3 , 4 - b ] quinoline ) , himbacine , ABS 300 , RJR 2403 ( CAS Number 538 - 79 - 4 ) , MF 268 ( CAS Number l7472l - 00 - 7 ) , RO 465 934 ( i. e. , N , N - Dimethylcarbamic acid 3 - ( 2 - cyclohexylethyl ) - 2 , 3 , 3a , 4 , 5 , 9b - hexahydro - 1H - benz [ e ] indol - 6 - yl ester ) , NS 393 , RGH 27l 6 ( CAS Number l34069 - 68 - 4 ) , WlN 678702 ( l2 , 12 - Bis ( 3 - furyl ) - 6 , ll - dihydro - 6 , 1l - ethanobenzo [ b ] quinolizinium chloride ) , RS 66252 ( i. e. , l - Butyl - 2 - [ ( 2 ' - ( 2H - tetrazol - 5 - yl ) - biphenyl - 4 - yl ) methyl ] - lH - indole - 3 - carboxylic acid ) , AlT 034 ( CAS Number l38ll7 - 48 - 3 ) , NG 012 ( CAS Number l3l774 - 53 - 3 ) , PD l420l2 ( CAS Number 5778 - 84 - 7 ) , GT 4054 , GT 4077 , GT 4035 , P 26 ( CAS Number 152l9l - 74 - 7 ) , RGH 5279 ( i. e. , ( — ) - ( 13aR , 13bS ) - 13a - Ethyl - 2 , 3 , 5 , 6 , 13a , 13b - hexahydro - 1H - indolo [ 3 , 2 , l - de ] pyrido [ 3 , 2 , l - ij ] [ l , 5 ] naphthyridine - l 2 - carboxylic acid 2 - acetoxyethyl ester ) , AlT 083 , CeNeS , estradiol ( i. e. , 1 , 3 , 5 ( 10 ) - Estratriene - 3 , l7beta - diol ) , WAY 132983 ( ( 3 R , 4R ) - 3 - ( 3 - hexy1sulfanylpyrazin - 2 - yloxy ) - l - azabicyclo [ 2.2.1 ] heptane hydrochloride ) , ABS 205 , ABS 401 , SX 3507 ( i. e. , 3 - ( 3 - Propyl - 1 , 2 , 4 - oxadiazol - 5 - yl ) quinoxaline - 2 ( 1H ) - one ) , ARR l7779 ( i. e. , ( — ) - Spiro [ l - azabicyclo [ 2.2.2 ] octane - 3 , 5 - oxazolidine ] - 2 - one ) , XE 99l ( i. e. , lO , l0 - bis ( 4 - Pyridylmethyl ) anthracen - l0 ( 9H ) - one ) , phenethylnorcymserine , RO 657l99 , RJR l78l ( i. e. , R ( + ) - 2 - ( 3 - pyridyl ) - l - azabicyclo [ 2. 2.2. ] octane ) , RJR 1782 ( i. e. , SH - 2 - ( 3 - pyridyl ) - l - azabicyclo [ 2.2.2doctane ) , gilatide , tolserine , TC 2559 ( i. e. , ( E ) - N - Methyl - 443 - ( 5 - ethoxypyridin ) yl ] - 3 - buten - l - amine ) , ER l27528 ( i. e. , 1 - ( 3 - Fluorobenzyl ) - 4 - [ ( 2 - ﬂuoro - 5 , 6 - dimethoxy - l - indanone - 2 - yl ) methyl ] piperidine hydrochloride ) , thiato1serine , targacept , axonyx , cymserine , thiacymserine , monoclonal antibody 266 , Apan - CH , DP lO3 , SPl 339 ( i. e. , 4 - [ 3 - ( 4 - Oxo - 4 , 5 , 6 , 7 - tetrahydroindol - l - yl ) propiony - 1amino ] benzoic acid ethy1 ester ) , S 37245 ( i. e. , 4 - ( l , 4 - Benzodioxan - 5 - yl ) - 1 - [ 3 ( S ) - hydroxy - 5 - nitro - indan - 2 - yl ] - piperazine ) , LLG 88 , AZD 2858 , trometamol , AN 240 , NG 002 ( i. e. , 5 - Hydroxy - 5 - ( 2 - hydroxy - 1 - methylethyl ) - 4 - methoxyfuran - 2 ( 5H ) - one ) , UCB 29427 ( i. e. , 2 - Cyclopropyl - 4 - ( cyclopropylamino ) - 6 - ( morpholino ) - l , 3 , 5 - triazine ) , TRH - SR , RO 40l64l ( CAS Number l22l99 - 02 - 4 ) , MPV l743AHl ( CAS Number lS0586 - 64 - 4 ) , lDRA 2l ( CAS Number 22503 - 72 - 6 ) , CEP 431 , ACPD ( CAS Number 67684 - 64 - 4 ) , CT 3577 ( i . e. , 3 , 7 - Dimethyl - 1 - [ 1 1 - ( 3 , 4 , 5 - trimethoxybenzylamino ) - ll - oxoundecy1 ] xanthine ) , CT 2583 , and NXD 9062. The pharmaceutical compositions may comprise one or more pharmaceutically acceptable carriers. [ 0115 ] The inVention proVides pharmaceutical combinations comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - line actiVe. US 20l0 / 0l30537 Al. ingredients selected from the group consisting of cholinesterase inhibitors ; AMPA receptor antagonists ; and NMDA receptor antagonists. [ 0116 ] The inVention proVides pharmaceutical combinations comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of cho1inesterase inhibitors ; AMPA receptor antagonists ; NMDA receptor antagonists ; pramiracetam ; aniracetam ; acetylcholine releasing stimulants ; calcium channel agonists ; free radical scaVengers ; platelet actiVating factor antagonists ; platelet aggregation antagonists ; insulin sensitizers ; peroxisome proliferator - actiVated receptor agonists ; peroxisome proliferator - actiVated receptor gamma agonists ; monoamine oxidase B inhibitors ; camitine acetyltransferase stimulants ; NSAle ; nerVe grthh factor agonists ; beta - amyloid inhibitors ; immunomodu1ators ; and NF - kappa B inhibitors. [ 0117 ] The inVention proVides pharmaceutical combinations comprising a therapeutically effectiVe amount of at 1east one cinnamide compound and one or more second - 1ine actiVe ingredients selected from the group consisting of cho1inesterase inhibitors ; AMPA receptor antagonists ; NMDA receptor antagonists ; pramiracetam ; aniracetam ; acetylcholine releasing stimu1ants ; calcium channel agonists ; free radical scaVengers ; p1atelet actiVating factor antagonists ; p1atelet aggregation antagonists ; insulin sensitizers ; peroxisome proliferator - actiVated receptor agonists ; peroxisome proliferator - actiVated receptor gamma agonists ; monoamine oxidase B inhibitors ; camitine acetyltransferase stimulants ; NSAle ; nerVe grthh factor agonists ; beta - amy1oid inhibitors ; immunomodulators ; NF - kappa B inhibitors ; thyrotropin releasing hormone agonists ; dopamine D2 receptor antagonists ; serotonin 2 receptor antagonists ; muscarinic Ml receptor agonists ; alpha 1 adrenoceptor agonists ; serotonin 3 receptor antagonists ; dopamine D2 receptor agonists ; dopamine D2 receptor antagonists ; serotonin lA receptor agonists ; serotonin 2A receptor antagonists ; glucocorticoid antagonists ; progesterone antagonists ; HMG - CoA reductase inhibitors ; adenosine uptake inhibitors ; phosphodiesterase inhibitors ; acetylcholine receptor agonists ; membrane permeability enhancers ; cannabinoid 1 receptor antagonists ; cannabinoid receptor agonists ; angiogenesis inhibitors ; immunosuppressants ; tubulin antagonists ; thromboxane A2 synthase inhibitors ; antioxidants ; alpha adrenoreceptor antagonists ; estrogen agonists ; 3 - beta hydroxysteroid dehydrogenase inhibitors ; signal transduction pathWay inhibitors ; melatonin receptor agonists ; immunostimulants ; HlV entry inhibitors ; sodium channel antagonists ; microtubule inhibitors ; glycine NMDA agoni sts ; adenosine Al receptor antagonists ; ATPase stimulants ; mitochondrial function enhancers ; and grthh hormone releasing factor agonists. [ 0118 ] The inVention proVides pharmaceutical combinations comprising a therapeutical1y effectiVe amount of at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of donepezil , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - 1 , 2 - dihydropyridin - 2 - one , and memantine. [ 0119 ] The inVention proVides pharmaceutical combinations comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - 1ine actiVe ingredients selected from the group consisting of donepezi1 , huperzine A , tacrine , riVastigmine , galantamine , pramiracetam , aniracetam , neﬁracetam , EGb 761 , rosiglitazone , rasagiline , leVacecamine , celecoxib , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - py - . May 27 , 2010. ridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one , talampanel , becampanel , memantine , neramexane , xaliproden , tarenﬂurbil , tramiprosate , and leuprorelin - D. [ 0120 ] The inVention proVides pharmaceutical combinations comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of donepezil , huperzine A , tacrine , riVastigmine , galantamine , pramiracetam , aniracetam , neﬁracetam , EGb 761 , rosiglitazone , rasagiline , leVacecamine , celecoxib , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one , talampanel , becampanel , memantine , xaliproden , tarenﬂurbil , tramiprosate , leuprorelin - D , taltirelin , risperidone , ceVimeline , modaﬁnil , alosetron , aripiprazole , mifepristone , atorVastatin , propentofylline , choline alfoscerate , FPF 1070 ( CAS Number 443 637 - 0l - 8 ) , rimonabant , dronabinol , docosahexaenoic acid , pac1itaxel , triﬂusal , idebenone , nicergoline , conjugated estrogens , trilostane , simVastatin , selegiline , ramelteon , immune globulin , icosapentethyl ester , procaine , CPH 82 , cycloserine , KW 3902 ( CAS Number l3 6 l 99 - 02 - 5 ) , triacetyluridine , estrogen dementia therapeutics ( e. g. , MlGENlX , VancouVer , Canada ) , and tesamorelin. ln other embodiments , the second - line actiVe ingredients can be one or more compounds selected from the group consisting of leVprorelin , prasterone , peptide T ( CAS Number 53 - 43 - 0 ) , besipiridine , lexipafant , stacofy1line , SGS 742 ( CAS Number l23690 - 78 - 8 ) , T 588 ( CAS Number 142935 - 03 - 3 ) , nerispiridine ; dexanabinol , sabcomeline , GTS 21 ( CAS Number lS6223 - 05 - l ) , CX 516 ( CAS Number 154235 - 83 - 3 ) , ABT 089 ( CAS Number l6l4l7 - 03 - 4 ) , anapsos , tesofensine , SlB lS53A ( i. e. , 4 - [ [ 2 - ( l - methyl - y1 - 2 - pyrrolidinyl ) ethyl ] thia ] phenol ) , ladostigil , radequinil , GPl 1485 , ispronicline ; arundic acid , MEM lO03 ( i. e. , 3 - lsopropyl 5 - ( 2 - methoxyethyl ) 4 - ( 2 - chloro - 3 - cyanophenyl ) - 2 , 6 - dimethylpyridine - 3 , 5 - dicarboxy1ate ) , V 338l ( i. e. , 2 - ( 2 , 3 - Dihydro - lH - inden - 3 - ylamino ) acetamide hydrochloride ) , farampator , paliroden , prasterone - paladin , urocortin , DP b99 ( i. e. , 2 , 2‘ - ( Ethylenedioxy ) bis ( 2 - ( l - phenylene ) bis [ N - [ 2 - [ 2 - ( octyloxy ) ethoxy ] - 2 - oxoethyl ] imino ] bis ( acetic acid ) ) , capserod , DU l25530 , bapineuzumab , AL lO8 ( i. e. , L - Asparaginyl - L - alanyl - L - pro1yl - L - Valyl - L - seryl - L - isoleucyl - L - proly1 - L - glutamine ) , DAS 431 , DEBlO 9902 , DAR 1 - 00 ; mitoquinone , lPL 455903 ( i. e. , 5 ( S ) - [ 3 - ( Cyclopentyloxy ) - 4 - methoxyphenyl ] - 3 ( S ) - ( 3 - methylbenzyl ) piperidin - 2 - one ) , E2CDS , PYM 50028 , PBT 2 , lecozotan , SB 742457 , CX 7l7 , AVE l625 ( i. e. , l - ( bis ( 4 - chlorophenyl ) methyl ) - 3 - ( ( 3 , 5 - diﬂuorophenyl ) ( methylsu1fonyl ) methylene ) azetidine ) , LY 450l39 ( i. e. , N2 - [ 2 ( s ) - Hydroxy - 3 - methylbutyryl ] - Nl - [ 3 - methyl - 2 - oxo - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzazepin - l ( S ) - yl ] - L - alaninamide ) , EM l42l ( i. e. , 4 , 4 ' - [ ( 2R , 3S ) - 2 , 3 - Dimethylbutane - l , 4 - diyl ] bis ( l , 2 - dimethoxybenzene ) , SRN 001 , TTP 488 , PRX 03l40 , dimebolin , glycine - proline - glutamate , Cl05 , AL 208 , MEM 3454 , AC l202 , L 830982 , LY 45l395 ( i. e. , ( R ) 7N - [ 2 - [ 4 ' - ( methylsulfonamidomethyl ) biphenyl - 4 - yl ] propyl ] propane - 2 - sulfonamide ) , MK 0249 , LY 2062430 , diethylnorspermine , neboglamine , Sl8986 , SA 4503 ( CAS Number l65377 - 44 - 6 ) , GRl l , Sl7092 ( i. e. , ( 2S , 3aS , 7aS ) - l { [ ( R , R ) - 2 - Phenylcyclopropyl ] carbonyl } - 2 - [ ( thiazolidin - 3 - yl ) carbonyl ] octahydro - lH - indole ) , SL 251l88 , EUK 189 , R l450 , 6 , 6 - dimethyl - 3 - ( 2 - hydroxyethyl ) thio - l - ( thiazol - 2 - yl ) - 6 , 7 - dihydro - 2 - benzothiophen - 4 ( 5H ) - one , CERE llO , dexefaroxan , CAD lO6 , HF 0220 , HF 0420 , EHT 0202 , VP 025 , MEM l4l4 , BGC 201259 ( i. e. , N , N - Dimethylcarbamic acid , 4 - [ 1 ( S ) - ( methylamino ) - 3 - ( 4 - nitrophenoxy ) propyl ] phenyl ester ) , EN. US 20l0 / 0l30537 Al. lO0 , ABT 834 , ABT 239 ( i. e. , 4 - [ 2 - [ 2 - [ ( 2R ) - 2 - Methylpyrrolidinyl ] ethyl ] - benzofuran - 5 - yl ] benzonitri1e ) , SGS 518 , R lS00 , C 9l38 , SSR l807ll , alfatradiol , R lS77 , T 8l7MA ( i. e. , l - [ 3 - [ 2 - ( l - Benzothien - 5 - yl ) ethoxy ] propyl ] azetidin - 3 - olmaleate ) , CNP lO6l ( i. e. , 4 - Methy1 - 5 - ( 2 - nitrooxyethyl ) thiazole ) , KTX 0101 ( i. e. , sodium beta - hydroxybutyrate ) , GSK l89254 ( i. e. , 6 - [ 3 - Cyclobutyl - 2 , 3 , 4 , 5 - tetrahydro - lHbenzo [ d ] azepin - 7 - yloxy ] - N - methylnicotinamide ) , AZD lO80 , ACC 001 , PRX 07034 , midazolam , R - phenserine , AZD lO3 ( CAS Number488 - 59 - 5 ) , SN 522 , NGX 267 ( CAS Number 50343l - 8l - 0 ) , N - PEP - l2 , RN l2l9 , FGLL , AVE 81l2 , EVT lOl , NP 03lll2 , MK 0752 , MK 0952 , LX 6l7l , PAZ 4l7 , AV 965 , PF 30840l4 , SYN ll4 , GSl 953 , SAM 3l5 , SAM 531 , D - serine , leteprinim potassium , BR l6A ( CAS Number l49l75 - 77 - 9 ) , RPR lO7393 ( CAS Number l9084l - 57 - 7 ) , NXD 2858 , REN l654 , CDD 0102 , NC l900 ( CAS Number l32925 - 74 - 7 ) , ciclosporin , NCX 22l6 ( i. e. , ( E ) - 4 - ( Nitrooxy ) butyl 3 - [ 4 - [ 2 - ( 2 - fluorobiphenyl - 4 - yl ) propanoyloxy ] - 3 - methoxyphenyl ] acrylate ) , NXD 3109 , NXD 119l , ZSET 845 ( i. e. , 3 , 3 - diphenylimidazo [ l , 2 - a ] pyridin - 2 - ( 3H ) - one ) , ET 002 , NT l3 , RO 638695 ( i. e. , [ l , 6 - ( l , 6 - dioxohexyl ) ] dipyrrolidine - ( 2R ) - carboxy1ic acid ) , bisnorcymserine , BA lOl6 , XD 424l , EUK 207 ( i. e. , ( SP - 5 - l3 ) - ( acetato - KO ) [ l3 , l 6 , l 9 , 22 - tetraoxa - 3 , 6 - diazatricyclo [ 21 .3. 18.12 ] octacosa - 1 ( 27 ) , 2 , 6 , 8 , l0 , l2 ( 28 ) , 23 , 25 - octaene - 27 , 28 - dio1ato ( 2 - ) - KN3 , KN6 , KO27 , KO28 ] manganese ) , LG 6l7 inhibitors , ZSET l446 , PAN 81 1 , F 144l3 ( i. e. , 2 - [ 5 - Fluoro - 2 ( S ) - methoxy - 2 , 3 - dihydro - l , 4 - benzodioxin - 2 - yl ] - 4 , 5 - dihydro - 1H - imidazole ) , FP 7832 ( i. e. , N - [ 2 - ( 5 - Methoxy - l - nitroso - lH - indol - 3 - y1 ) ethyl ] acetamide ) , ARA 0144l8 ( i. e. , N - ( 4 - methoxybenzyl ) - N ' - ( 5 - nitro - l , 3 - thiazo1 - 2 - yl ) urea ) , AZD 3 l 02 , KP 544 ( i. e. , 2 - amino - 5 - ( 4 - chlorophenylethynyl ) - 4 - ( 4 - trans - hydroxycyclohexylamino ) pyrimidine ) , DP 1 55 , 5 - Chloro - N - [ 3 - [ 2 - ( dimethylamino ) ethyl ] - 1H - indol - 5 - yl ] naphthalene - 2 - su1fonamide , TAK 070 , huperzine , N - [ 2 - ( 3 , 5 - Dimethyladamant - l - yl ) ethyl ] acetamidine hydrochloride , 6 - [ 4 - [ ( Dimethylamino ) methyl ] - 5 - ethyl - 2 - methoxyphenyl ] pyridin - 2 - amine , 4 , 6 - diphenyl - 3 - ( 4 - ( pyrimidin - 2 - yl ) piperazin - 1 - yl ) pyridazine , N - [ ( l S , 2R ) - 3 - ( 3 , 5 - Difluorophenyl ) - 1 - hydroxy - l - [ ( 5 S , 6R ) - 5 - methyl - 6 - ( neopentyloxy ) morpholin - 3 - yl ] propan - 2 - yl ] acetamide hydrochloride , N - [ ( l R , 2S ) - 3 - ( 3 , 5 - Difluorophenyl ) - l - hydroxy - l - [ ( 2R , 4R ) - 4 - phenoxypyrrolidin - 2 - yl ] propan - 2 - yl ] - 3 - [ ( R ) - 2 - ( methoxymethyl ) pyrrolidine - 1 - carbonyl ] - 5 - methylbenzamide , R lS89 , midafotel , phenserine , coluracetam , physostigmine , cipralisant , nitroﬂurbiprofen , PPl lOl9 ( i. e. , ( 3alpha , 5beta , 7alpha , lZalpha ) - trihydroxycholan - 24 - oyl - L - leucyl - L - Valyl - L - phenylalanyl - L - phenylalanyl - L - alanine ) , dapsone , MDL lO0453 ( CAS Number l29938 - 34 - 7 ) , NS 377 , midaxifylline , propofol phosphate , metrifonate , ceronapril , tenilsetam , sufoxazine , seglitide , ebiratide , nebracetam , milacemide , iododoxorubicin , SM lO888 ( CAS Number l29297 - 2l - 8 ) , U 808l6 ( CAS Number 138554 - ll - 7 ) , YM 954 ( CAS Number l3204l - 85 - l ) , SUT 870l ( CAS Number l23577 - 73 - l ) , apoVincamine , FR l2ll96 ( CAS Number l33920 - 65 - 7 ) , LY 2746l4 ( CAS Number l36l09 - 04 - l ) , CL 275838 ( CAS Number llS93l - 65 - 2 ) , igmesine , K 7259 ( CAS Number l33667 - 88 - 6 ) , Vinconate , itasetron , CL 287663 ( CAS Number 125109 - 98 - 0 ) , WAY lO0289 ( CAS Number l360l3 - 69 - 9 ) , SR 46559A ( CAS Number l37733 - 33 - 6 ) , GYKl 46903 ( CAS Number l42999 - 59 - 5 ) , L 670548 ( CAS Number l2l564 - 89 - 4 ) , Y 29794 ( CAS Number l29l84 - 48 - l ) , AF l25 ( CAS Number 763l - 86 - 9 ) , KFM l9 ( CAS Number l33058 - 72 - 7 ) , ST 796. May 27 , 2010. ( i. e. , ( S ) - 3 - [ 3 - ( triﬂuoromethyl ) benzoyl ) amino ] hexahydroazepin - 2 - one ) , RU 33965 ( CAS Number l2232l - 05 - 5 ) , SDZ 2 lO086 ( i. e. , ( — ) - 1 ' , 2 ( S ) - Dimethylspiro [ l , 3 - dioxolan - 4 , 4 ' - piperidine ] ) , L 689660 ( CAS Number l44860 - 79 - 7 ) , L 689560 ( CAS Number l3905l - 78 - 8 ) , ST 6l8 ( i. e. , l - ( 6 , 7 - Dimethoxy - 1 , 2 , 3 , 4 - tetrahydro - 2 - naphthyl ) - 4 - hydroxy pyrrolidin - 2 - one ) , U 74500A ( CAS Number llOl0l - 65 - 0 ) , GEA 857 ( CAS Number l20493 - 42 - 7 ) , BlBN 99 ( CAS Number l4530l - 48 - 0 ) , DX 9366 , ONO l603 ( CAS Number ll4668 - 76 - 7 ) , MDL lO2234 ( CAS Number l37766 - 8l - 5 ) , P 9939 ( CAS Number lS797l - 37 - 4 ) , PD l40532 ( CAS Number 15797l - 39 - 6 ) , azetirelin , MR 16728 ( CAS Number l476l4 - 2l - 9 ) , dabelotine , MDL lO2503 ( i. e. , 8 - [ l ( R ) - methyl - 2 - phenylethyl ] - 1 , 3 - dipropyl - 7H - xanthine ) , PD 14l606 ( i . e. , ( : ) - ( Z ) - 3 - ( 3 - Phenyl - 2 - propynyloxyimino ) - l - azabicyclo [ 2.2. l ] heptane ) , SNK 882 ( CAS Number lS222l - l2 - 0 ) , L 696986 ( CAS Number l4l553 - 45 - 9 ) , tazomeline , LY 235959 ( CAS Number 137433 - 06 - 8 ) , 2 - ( 2 - thiooxopyrrolidin - 1 - yl ) acetamide , AK 30 NGF , ABT 4l8 ( CAS Number l47402 - 53 - 7 ) , itameline , HUP l3 , sibopirdine , KST 5452 ( CAS Number lS7998 - 88 - 4 ) , TJ 54 , U 92798 ( i. e. , 7 - [ 4 - [ Bis ( 4 - fluorophenyl ) methyl ] perhydro - l , 4 - diazepin - l - ylmethyl ] - 4 - isopropyl - 2 - methoxy - 2 , 4 , 6 - cycloheptatrien - 1 - one ) , U 92032 ( CAS Number l42223 - 92 - 5 ) , 3 - ( sulfamoyloxy ) estra - l , 3 , 5 ( l0 ) - trien - l7 - one , P llOl2 ( CAS Number l64723 - 36 - 8 ) , A 82695 ( CAS Number l47388 - 86 - l ) , FR 76659 ( CAS Number 116904 - 25 - 7 ) , apaxifylline , CX 417 , 7 MEOTA ( CAS Number 5778 - 80 - 3 ) , BU 45l4N ( CAS Number 15l013 - 39 - 7 ) , pregnenolone , mexidol , ST 857 ( CAS Number lS4755 - 63 - 2 ) , RU 49041 ( CAS Number l23828 - 80 - 8 ) , RU 35929 ( CAS Number lll7ll - 47 - 8 ) , P 878l84 , P l28 ( CAS Number lS77l 6 - 52 - 4 ) , eurystatin A , eurystatin B , LK l2 , NBl lO8 , NBl lO7 , NBl ll7 , L 705l06 , bacoside A + B , clausenamide , SM 2l ( CAS Number 155156 - 22 - 2 ) , alaptide , RS l70l7 ( i. e. , l - ( 4 - Amino - 5 - chloro - 2 - methoxyphenyl ) - 5 - ( l - piperidinyl ) - l - pentanone hydrochloride ) , AF lS0 ( S ) ( i. e. , ( S ) - [ l - Methyl - piperidine - 4 - spiro - ( 2 ' - methylthiazoline ) ] ) , RO lS3505 ( CAS Number 7877l - l3 - 8 ) , PV ll3 ( i. e. , l , 2 , 3 , 4 - Tetrahydropyrrolo - [ l , 2 - a ] - pyrazine ) , arisugacin , A 98284 ( i. e. , 2 ( R ) - ( 3 - Methylisoxazol - 5 - yl ) quinuclidine ) , AP 5 ( CAS Number l3694l - 85 - 0 ) , BD lO54 , SDZ NDD 094 ( i. e. , bis - ( 2 - ( 2 - methylimidazol - l - yl ] methyl ) - pyridine - tris ( hydrogenfumarate ) , AZ 36041 ( CAS Number 173324 - 76 - 0 ) , quilostigmine , A 84543 ( i. e. , 3 - [ 1 - Methylpyrrolidin - 2 - ( S ) - ylmethoxy ] pyridine fumarate ) , BTG 4247 ( i. e. , ( 2 - [ 2 - Chloroethoxy [ 4 - ( dimethylamino ) phenyl ] phosphory1 ] - acetohydrazide ) , CGP 50068 ( CAS Number lS8647 - 49 - 5 ) , cerebrocrast , desferri - nordanoxamine , isolichenan , MHP l33 ( i. e. , 3 - ( N , N - dimethylcarbamoyloxy ) - 1 - methyl - 2 - ( 4 - phenyl - semicarbazonomethyl ) pyridinium chloride ) , FR lS2558 ( CAS Number lSl098 - 08 - 7 ) , GVS lll ( CAS Number lS7ll5 - 85 - 0 ) , P lll49 ( CAS Number l64724 - 79 - 2 ) , PDC 008004 , KST 28l8 ( CAS Number lS8623 - 26 - 8 ) , KST 54l0 ( CAS Number lS8623 - 27 - 9 ) , RU 52583 ( CAS Number l23829 - 33 - 4 ) , PD lSl832 ( CAS Number l49929 - 39 - 5 ) , UCL ll99 ( i. e. , 442 - [ ( 5 - nitropyridin - 2 - ylsulfanyl ) ethyl ] - lH - imidazole ) , isoVanihuperzine A , SlB l765F ( CAS Number l79l20 - 52 - 6 ) , JWS USC 75 lX ( i. e. , 3 - [ [ [ 2 - [ [ ( 5 - dimethylaminomethyl ) - 2 - furanyl ] methyl ] thio ] ethyl ] amino ] - 4 - nitropyridazine ) , GR l75737 ( i. e. , 3 - ( 4 - Chlorobenzyl ) - 5 - [ 2 - ( l H - imidazol - 4 - yl ) ethyl ] - l , 2 , 4 - oxadiazole ) , KS 505A ( CAS Number l3l774 - 53 - 3 ) , ZTTA l ( i. e. , N - benzyloxycarbonylthioprolyl - thioprolynal - dimethylaceta 1 ) , AGN 190837 ( CAS Number l36527 - 40 - 7 ) , P lO358 ( l88240 - 59 - 7 ) , WAY. US 20l0 / 0l30537 Al. l3l256 ( CAS Number l7400l - 7l - 9 ) , DBO 83 ( i. e. , 3 - ( 6 - chloropyridazin - 3 - yl ) - diazabicyclo [ 3 .2. l ] octane dihydrochloride monohydrate ) , FUB 181 ( CAS Number 152029 - 80 - 6 ) , RJR 2557 , WSU 2088 , LVV - haemorphin - 7 , M 40 ( i. e. , galanin [ l - l2 ] - Pro3 - ( Ala - Leu ) - 2 - A1a - NH2 ) , SlB l757 , SKF 74652 ( i. e. , [ 5 - chloro - 2 - ( 4 - methoxy phenyl ) - 3 - benzofuranyl ] [ 4 - [ 3 - ( diethylamino ) - propoxy ] phenyl ] methanone ) , CGP 7l982 , SCH 57790 ( i. e. , 4 - cyclohexyl - alpha - [ 4 - [ [ 4 - methoxyphenyl ] sulﬁnyl ] phenyl ] - 1 - piperazineacetonitrile ) , Putrescine - D - YiAbetall , DU 14 ( i. e. , p - O - ( sulfamoyl ) - N - tetradecanoyl tyramine ) , CLZ 4 , SL 340026 , PPRT 424 , ciproxifan , UR l827 ( i. e. , 2 - ( l - benzylpiperidin - 4 - yl ) - 1 - [ 4 - ( 5 - methylpyrimidin - 4 - ylamino ) phenyl ] - 1 - ethanone ) , caproctamine , TGS 20 ( i. e. , L - pyroglutamil - D - alanine amide ) , PG 9 ( i. e. , alpha - tropanyl 2 - [ ( 4 - bromo ) phenyl ] propionate ) , TEl 3356 ( i. e. , ( l6S ) - l5 - Deoxy - l6 - hydroxy - l6 - methyl - 9 - ( O ) - methano - DELTA6 ( 9alpha ) - pro staglandin ll ) , LY 392098 ( i. e. , Thiophene , 3 - [ ( 2 - methylethyl - 2 ) sulphonylaminopropyl - 2 ] phenyl - 4 - yl - ) , PG 1000 , DM 232 , NEPP 11 ( i. e. , l2 - iso - l 5 - Deoxy - l 8 - ( 4 - methyl ) phenyl - l 3 , l4 - dihydrodelta7 - prostaglandinAl methy1 ester ) , VA lO0 ( i. e. , ( 2 , 3 - Dihydro - 2 - [ [ ( 4 - ﬂuorobenzoyl ) amino ] ethyl ] - l - methyl - 5 - phenyl - lH - 1 , 4 - benzodiazepine ) , VA lOl ( i. e. , ( 2 , 3 - dihydro - 2 - [ [ ( 2 - thienylcarbonyl ) amino ] ethyl ] - 1 - methyl - 5 - phenyl - 1H - l , 4 - benzodiazepine ) , NC lllS85 ( i. e. , ( 3S ) - l , 3 - Bis - [ 3 - [ ( 3 - azabicylo [ 2 .2.2 ] octanyl ) - l , 2 , 5 - thiadiazol - 4 - yloxy ] - l - propyn - 1 - yl ] benzene , 2L - ( + ) - tartate ) , lN 201 , imoproxifan , kanokodiol , picroside l , picroside ll , DM 235 ( i. e. , l - ( 4 - Benzoylpiperazin - 1 - yl ) propan - 1 - one ) , monoclonal antibody lOD5 , JLK2 , JLK 6 , JLK 7 , DAPT ( i. e. , N - [ N - ( 3 , 5 - difluorophenacetyl ) - L - alanyl ] - S - phenylglycine t - butyl ester ) , huperine X , SGS lll ( i. e. , ( S ) - ethyl 2 - [ l - ( 2 - phenylacetyl ) pyrrolidine - 2 - carboxamido ] acetate ) , NP 7557 , C 9l36 , C 76 l7 , R 1485 , rofecoxib , Velnacrine , montirelin , lazabemide , ORG 2766 ( CAS Number 509l3 - 82 - l ) , sabeluzole , adafenoxate , CAS Number 906l - 6l - 4 , ipidacrine , bemesetron , idazoxan , linopirdine , selfotel , suritozole , milameline , xanomeline , TJ 960 , fasoracetam , eptastigmine , ensaculin , zanapezil , posatirelin , zacopride , RS 86 ( CAS Number 3576 - 73 - 6 ) , ORG 5667 ( CAS Number 37552 - 33 - 3 ) , RX 77368 ( CAS Number 76820 - 40 - l ) , BMS lSl l68 ( CAS Number l23259 - 9l - 6 ) , BY l949 ( CAS Number 90l58 - 59 - l ) , AWD 5239 ( CAS Number lO9002 - 93 - 9 ) , YM 796 ( 171252 - 79 - 2 ) , aloracetam , Cl - 933 ( CAS Number 91829 - 95 - 7 ) , ST 793 ( CAS Number 99306 - 37 - 3 ) , cebaracetam , zifrosilone , talsaclidine , alVameline , JTP 2942 ( l48l52 - 77 - 6 ) , OPC l4l l7 ( CAS Number lO3233 - 65 - 4 ) , elziVerine , AP 52l ( i. e. , N - ( 1 , 3 - Benzodioxol - 5 - ylmethyl ) - 1 , 2 , 3 , 4 - tetrahydro [ 1 ] benzothieno [ 2 , 3 - c ] pyridine - 3 ( R ) - carboxamide hydrochloride ) , S 85l0 ( CAS Number lSl466 - 23 - 8 ) , JTP 48l9 ( CAS Number l62203 - 65 - 8 ) , icopezil , SC 1 lO , FK 960 ( CAS Number l33920 - 70 - 4 ) , DMP 543 ( CAS Number l60588 - 45 - 4 ) , ganstigmine , Cl 1017 ( i. e. , ( R ) - ( — ) - ( Z ) - 1 - Azabicyclo [ 2.2. l ] heptan - 3 - one , O - ( 3 - ( 3 ' - methoxyphenyl ) - 2 - propynyl ) - oxime maleate ) , T 82 ( i. e. , 2 - [ 2 - ( l - Benzylpiperidin - 4 - yl ) ethy1 ] - 2 , 3 - dihydro - 9 - methoxy - l H - pyrrolo [ 3 , 4 - b ] quinolin - l - one hemifumarate ) , NGD 97l , Vaccine of Aspartyl - alanylglutamyl - phenylalanyl - arginyl - histidyl - aspartyl - serylglycyl - tyrosyl - glutamyl - Valyl - histidyl - histidyl - glutaminyllysy1 - leucyl - Valyl - phenylalanyl - phenylalanyl - alany1 - glutamyl - asparty1 - Valyl - glycyl - seryl - asparaginyl - lysylglycyl - alanyl - isoleucyl - isoleucyl - glycyl - leucyl - methionylValyl - glycyl - glycyl - Valyl - Valyl - isoleucyl - alanine , PBT 1 ( CAS Number l30 - 26 - 7 ) , TCH 346 , FK 962 ( i. e. , N - ( l - . May 27 , 2010. acetylpiperidin - 4 - yl ) - 4 - ﬂuorobenzamide ) , Voxergolide , KW 6055 ( CAS Number 63233 - 46 - 5 ) , thiopilocarpine , ZK 93426 ( CAS Number 89592 - 45 - 0 ) , SDZ NVl 085 ( CAS Number lO4l95 - l7 - 7 ) , Cl lO02 ( CAS Number l49028 - 28 - 4 ) , Z 32l ( CAS Number l30849 - 58 - 0 ) , mirisetron , CHF 2060 ( i. e. , N - Heptylcarbamic acid 2 , 4a , 9 - trimethyl - 2 , 3 , 4 , 4a , 9 , 9a - hexahydro - l , 2 - oxazino [ 6 , 5 - b ] indol - 6 - yl ester - L - tartrate ) , gedocarnil , terbequinil , HOE 065 ( CAS Number l23060 - 44 - 6 ) , SL 650102 , GR 253035 , ALE 260l5 , SB 271046 ( i. e. , 5 - Chloro - N - ( 4 - methoxy - 3 - piperazin - 1 - yl - phenyl ) - 3 - methyl - 2 - benzothiophenesulfonamide ) , iAbeta5 , SCH 2ll803 ( i . e. , Piperidine , l - [ 1 - ( 3 - methyl - 2 - aminophenyl ) carbonylpiperidin - 4 - yl ] - 4 - [ ( 3 - chlorophenyl ) sulphonylphenyl - 4 ] methyl - ) , EVT 30l , alpha - Linolenic acid / linoleic acid , Kamikihi - To , siagoside , FG 7l42 ( CAS Number 78538 - 74 - 6 ) , RU 47067 ( CAS Number lll7l 1 - 92 - 3 ) , RU 35963 ( CAS Number l39886 - 03 - 6 ) , FG 7080 ( CAS Number lO0332 - l8 - l ) , E 2030 ( CAS Number 142007 - 70 - 3 ) , transforming grthh factor beta - 1 , A 72055 ( i. e. , 2 ' , 1 - Dimethylspiro [ piperidine - 4 , 5 oxazolidine ] - 3 ' - carboxaldehyde ) , NS 626 , dimiracetam , GT 300l , GT 250l , GT 2342 , GT 20l6 ( CAS Number lS224l - 24 - 2 ) , ORG 2009l ( CAS Number l4l545 - 50 - 8 ) , BCE 001 ( CAS Number 95678 - 81 - 2 ) , CGP 35348 ( CAS Number 123690 - 79 - 9 ) , WAY lO0635 ( CAS Number l467l4 - 97 - 8 ) , E 4804 ( CAS Number l62559 - 34 - 4 ) , LlGA 20 ( CAS Number l26586 - 85 - 4 ) , NG l2l ( i. e. , 2 - [ 4 , 8 - Dimethyl - 3 ( E ) , 7 ( E ) - nonadienyl ] - 3 , 5 - dihydroxy - 2 - methyl - 3 , 4 , 7 , 9 - tetrahydro - 2H - furo [ 3 , 4 - h ] - 1 - benzopyran - 7 - one ) , MF 247 ( i. e. , N - [ 10 - ( Diethylamino ) decyl ] carbamic acid ( 3aS , 8aR ) - l , 3a , 8 - trimethyl - l , 2 , 3 , 3a , 8 , 8a - hexahydropyrrolo [ 2 , 3 - b ] indol - 5 - yl ester ) , JTP 3399 ( i. e. , N - Benzyl - 2 ( S ) - [ 2 ( S ) - ( phenoxyacetyl ) pyrrolidin - l - ylcarbonyl ] pyrrolidine - l - carboxamide ) , KF l7329 , thioperamide , F 3796 ( i. e. , l - [ 2 - ( l - Benzylpiperidin - 4 - yl ) ethyl ] - 3 - [ 3 , 4 - ( methylene - dioxy ) benzoyl ] thiourea ) , GT 400l , GT 4002 , FPL l4995 ( CAS Number l233l9 - 03 - 9 ) , RU 3433.2 ( CAS Number l37l57 - 58 - 5 ) , SR 96777A ( CAS Number 1 15767 - 94 - 7 ) , SlB T1980 , NS 649 ( CAS Number 146828 - 02 - 6 ) , PD 142505 ( CAS Number l49929 - 08 - 8 ) , GYKl 52466 ( CAS Number lO277l - 26 - 6 ) , RO 246l73 ( CAS Number lS9723 - 57 - 6 ) , SCH 509ll ( CAS Number l604l 5 - 07 - 6 ) , Z 4 l 05 ( CAS Number 1 l9737 - 52 - 9 ) , RS 67333 ( CAS Number 168986 - 60 - 5 ) , NS 1546 , ZM 241385 ( CAS Number 139l80 - 30 - 6 ) , RO 249975 ( i. e. , [ 1S , 3S ( 2 ' S ) , 5R ] - 3 - ( l - Benzyl - 5 - oxopyrrolidin - 2 - ylmethyl ) - 5 - . ( l H - imidazol - 5 - ylmethyl ) cyclohexane - l - acetamide ) , AF lS5 ( i. e. , 8 - Methyl - 3 - ( 2 - propynyl ) - l , 3 , 8 - triazaspiro [ 4 , 5 ] decane - 2 , 4 - dione ) , CEP 427 , CX 423 , CX 438 , CX 480 , CDPethanolamine , GT 4003 , GT 401 l , GT 50l1 , MS 430 ( CAS Number 122l13 - 44 - 4 ) , MBF 379 ( i. e. , [ 3 , 3 - Bis ( hydroxymethyl ) - 8 - hydroxy - 3 , 4 - dihydro - 2H - l , 4 - benzoxazin - 5 - yl ] [ 3 ' , 5 ' - dihydroxy - 4 ' - ( 2 - oxo - 2 - phenylethoxy ) phenyl ] methanone ) , NGD l87 ( CAS Number l63565 - 48 - 8 ) , DUP 856 , MR 3066 , MF 8615 ( i. e. , 5 - Amino - 6 - chloro - 4 - hydroxy - 3 , 4 - dihydro - lH - thiopyrano - [ 3 , 4 - b ] quinoline ) , himbacine , ABS 300 , RJR 2403 ( CAS Number 538 - 79 - 4 ) , MF 268 ( CAS Number l7472l - 00 - 7 ) , RO 465934 ( i. e. , N , N - Dimethylcarbamic acid 3 - ( 2 - cyclohexylethyl ) - 2 , 3 , 3a , 4 , 5 , 9b - hexahydro - lH - benz [ e ] indol - 6 - yl ester ) , NS 393 , RGH 2716 ( CAS Number 134069 - 68 - 4 ) , WlN 678702 ( l2 , 12 - Bis ( 3 - furyl ) - 6 , l1 - dihydro - 6 , 1l - ethanobenzo [ b ] quinolizinium chloride ) , RS 66252 ( i. e. , l - Butyl - 2 - [ ( 2 ' - ( 2H - tetrazol - 5 - yl ) - biphenyl - 4 - yl ) methyl ] - lH - indole - 3 - carboxylic acid ) , AlT 034 ( CAS Number l38ll7 - 48 - 3 ) , NG 012 ( CAS Number l3l774 - 53 - 3 ) , PD l420l2 ( CAS Number 5778 - 84 - 7 ) , GT 4054 , GT 4077 , GT. US 20l0 / 0l30537 Al. 4035 , P 26 ( CAS Number lS2l9l - 74 - 7 ) , RGH 5279 ( i. e. , ( — ) - ( 13aR , 13bS ) - 13a - Ethyl - 2 , 3 , 5 , 6 , 13a , 13b - hexahydro - lHindolo [ 3 , 2 , 1 - de ] pyrido [ 3 , 2 , 1 - ij ] [ 1 , 5 ] naphthyridine - 12 - carboxylic acid 2 - acetoxyethyl ester ) , AlT 083 , CeNeS , estradiol ( i. e. , l , 3 , 5 ( l0 ) - Estratriene - 3 , l7beta - diol ) , WAY l32983 ( ( 3 R , 4R ) - 3 - ( 3 - hexylsulfanylpyrazin - 2 - yloxy ) - 1 - azabicyclo [ 2.2.1 ] heptane hydrochloride ) , ABS 205 , ABS 401 , SX 3507 ( i. e. , 3 - ( 3 - Propyl - 1 , 2 , 4 - oxadiazol - 5 - yl ) quinoxaline - 2 ( lH ) - one ) , ARR l7779 ( i. e. , ( — ) - Spiro [ l - azabicyclo [ 2.2.2 ] octane - 3 , 5 - oxazolidine ] - 2 - one ) , XE 99l ( i. e. , lO , l0 - bis ( 4 - Pyridy1 - methyl ) anthracen - 10 ( 9H ) - one ) , phenethylnorcymserine , RO 657199 , RJR 1781 ( i. e. , R ( + ) - 2 - ( 3 - pyridyl ) - l - azabicyclo [ 2. 2.2 ] octane ) , RJR l782 ( i. e. , S ( — ) - 2 - ( 3 - pyridyl ) - l - azabicyclo [ 2.2.2. ] octane ) , gilatide , tolserine , TC 2559 ( i. e. , ( E ) - N - Methyl - 4 - [ 3 - ( 5 - ethoxypyridin ) y1 ] - 3 - buten - l - amine ) , ER 127528 ( i. e. , 1 - ( 3 - Fluorobenzyl ) - 4 - [ ( 2 - fluoro - 5 , 6 - dimethoxy - 1 - indanone - 2 - yl ) methyl ] piperidine hydrochlo - ride ) , thiatolserine , targacept , axonyx , cymserine , thiacymserine , monoc1onal antibody 266 , Apan - CH , DP lO3 , SPl 339 ( i. e. , 4 - [ 3 - ( 4 - Oxo - 4 , 5 , 6 , 7 - tetrahydroindol - l - yl ) propionylamino ] benzoic acid ethyl ester ) , S 37245 ( i. e. , 4 - ( l , 4 - Benzodioxan - 5 - yl ) - l - [ 3 ( S ) - hydroxy - 5 - nitro - indan - 2 - yl ] - piperazine ) , LLG 88 , AZD 2858 , trometamol , AN 240 , NG 0.002 ( i. e. , 5 - Hydroxy - 5 - ( 2 - hydroxy - l - methylethy1 ) - 4 - methoxyfuran - 2 ( 5H ) - one ) , UCB 29427 ( i. e. , 2 - Cyclopropyl - 4 - ( cyclopropylamino ) - 6 - ( morpholino ) - l , 3 , 5 - triazine ) , TRH - SR , RO 40l64l ( CAS Number l22l99 - 02 - 4 ) , MPV l743Alll ( CAS Number lS0586 - 64 - 4 ) , lDRA 2l ( CAS Number 22503 - 72 - 6 ) , CEP 43l , ACPD ( CAS Number 67684 - 64 - 4 ) , CT 3577 ( i. e. , 3 , 7 - Dimethyl - l - [ l l - ( 3 , 4 , 5 - trimethoxybenzylamino ) - ll - oxoundecyl ] xanthine ) , CT 25 83 , and NXD 9062. [ 0121 ] ln other embodiments , the inVention proVides kits comprising a therapeutically effectiVe amount of : at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of cholinesterase inhibitors ; AMPA receptor antagonists ; and NMDA receptor antagonists. [ 0122 ] The inVention proVides pharmaceutical kits comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of cholinesterase inhibitors ; AMPA receptor antagonists ; NMDA receptor antagonists ; pramiracetam ; aniracetam ; acetylcholine releasing stimulants ; calcium channel agonists ; free radical scaVengers ; platelet actiVating factor antagonists ; platelet aggregation antagonists ; insulin sensitizers ; peroxisome proliferator - actiVated receptor agonists ; peroxisome proliferator - actiVated receptor gamma agonists ; monoamine oxidase B inhibitors ; camitine acetyltransferase stimulants ; NSAle ; nerVe grthh factor agonists ; beta - amy1oid inhibitors ; immunomodulators ; and NF - kappa B inhibitors. [ 0123 ] The inVention proVides pharmaceutical kits comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of cholinesterase inhibitors ; AMPA receptor antagonists ; NMDA receptor antagonists ; pramiracetam ; aniracetam ; acetylcholine releasing stimulants ; calcium channel agonists ; free radical scaVengers ; platelet actiVating factor antagonists ; platelet aggregation antagonists ; insulin sensitizers ; peroxisome proliferator - actiVated receptor agonists ; peroxisome proliferator - actiVated receptor gamma agonists ; monoamine oxidase B inhibitors ; camitine acetyltransferase stimulants ; NSAle ; nerVe grthh factor agonists ; beta - amyloid inhibitors ; immu - . May 27 , 2010. nomodulators ; NF - kappa B inhibitors ; thyrotropin releasing hormone agonists ; dopamine D2 receptor antagonists ; serotonin 2 receptor antagonists ; muscarinic M1 receptor agonists ; a1pha 1 adrenoceptor agonists ; serotonin 3 receptor antagonists ; dopamine D2 receptor agonists ; dopamine D2 receptor antagonists ; serotonin 1A receptor agonists ; serotonin 2A receptor antagonists ; glucocorticoid antagonists ; progesterone antagonists ; HMG - CoA reductase inhibitors ; adenosine uptake inhibitors ; phosphodiesterase inhibitors ; acetylcholine receptor agonists ; membrane permeability enhancers ; cannabinoid 1 receptor antagonists ; cannabinoid receptor agonists ; angiogenesis inhibitors ; immunosuppressants ; tubulin antagonists ; thromboxane A2 synthase inhibitors ; antioxidants ; alpha adrenoreceptor antagonists ; estrogen agonists ; 3 - beta hydroxysteroid dehydrogenase inhibitors ; signal transduction pathWay inhibitors ; melatonin receptor agonists ; immunostimulants ; HlV entry inhibitors ; sodium channel antagonists ; microtubule inhibitors ; glycine NMDA agonists ; adeno sine Al receptor antagonists ; ATPase stimulants ; mitochondrial function enhancers ; and grthh hormone releasing factor agonists. [ 0124 ] The inVention proVides pharmaceutical kits comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of donepezil , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one , and memantine. [ 0125 ] The inVention proVides pharmaceutical kits comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of donepezil , huperzine A , tacrine , riVastigmine , galantamine , pramiracetam , aniracetam , neﬁracetam , EGb 76l , rosiglitazone , rasagiline , leVacecarnine , celecoxib , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one , talampanel , becampanel , memantine , neramexane , xaliproden , tarenﬂurbil , tramiprosate , and leuprorelin - D. [ 0126 ] The inVention proVides pharmaceutical kits comprising a therapeutically effectiVe amount of at least one cinnamide compound and one or more second - line actiVe ingredients selected from the group consisting of donepezil , huperzine A , tacrine , riVastigmine , galantamine , pramiracetam , aniracetam , neﬁracetam , EGb 76l , rosiglitazone , rasagiline , leVacecamine , celecoxib , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one , talampanel , becampanel , memantine , xaliproden , tarenﬂurbil , tramiprosate , leuprorelin - D , taltirelin , risperidone , ceVimeline , modaﬁnil , alosetron , aripiprazole , mifepristone , atorVastatin , propentofylline , choline alfoscerate , FPF 1070 ( CAS Number l43 637 - 0l - 8 ) , rimonabant , dronabinol , docosahexaenoic acid , pac1itaxel , triﬂusal , idebenone , nicergoline , conjugated estrogens , trilostane , simVastatin , selegiline , ramelteon , immune globulin , icosapentethyl ester , procaine , CPH 82 , cycloserine , KW 3902 ( CAS Number l3 6199 - 02 - 5 ) , triacetyluridine , estrogen dementia therapeutics ( e. g. , MlGENlX , VancouVer , Canada ) , and tesamorelin. ln other embodiments , the second - line actiVe ingredients can be one or more compounds selected from the group consisting of leuprorelin , prasterone , peptide T ( CAS Number 53 - 43 - 0 ) , besipiridine , lexipafant , stacofylline , SGS 742 ( CAS Number l23690 - 78 - 8 ) , T 588 ( CAS Number l42935 - 03 - 3 ) , nerispiridine , dexanabinol , sabcomeline , GTS 2l ( CAS Number lS6223 - 05 - l ) , CX 516 ( CAS Number lS4235 - 83 - 3 ) , ABT 089 ( CAS Number 161417 - 03 - 4 ) , anapsos , tesofensine , SlB 1553A. US 20l0 / 0l30537 Al. ( i. e. , 4 - [ [ 2 - ( l - methyl - yl - 2 - pyrrolidinyl ) ethyl ] thia ] phenol ) , ladostigil , radequinil , GPl l485 , ispronicline , arundic acid , MEM 1003 ( i. e. , 3 - lsopropyl 5 - ( 2 - methoxyethyl ) 4 - ( 2 - chloro - 3 - cyanophenyl ) - 2 , 6 - dimethylpyridine - 3 , 5 - dicarboxylate ) , V 338l ( i. e. , 2 - ( 2 , 3 - Dihydro - lH - inden - 3 - ylamino ) acetamide hydrochloride ) , farampator , paliroden , prasterone - paladin , urocortin , DP b99 ( i. e. , 2 , 2 ' - ( ethylenedioxy ) bis ( 2 , l - phenylene ) bis [ N - [ 2 - [ 2 - ( octyloxy ) ethoxy ] - 2 - oxoethyl ] imino ] bis ( acetic acid ) ) , capserod , DU 125530 , bapineuzumab , AL 108 ( i. e. , L - Asparaginyl - L - alanyl - L - prolyl - L - Valyl - L - seryl - L - isoleucy1 - L - prolyl - L - glutamine ) , DAS 43l , DEBlO 9902 , DAR 100 , mitoquinone , lPL 455903 ( i. e. , 5 ( S ) - [ 3 - ( Cyclopentyloxy ) - 4 - methoxyphenyl ] - 3 ( S ) - ( 3 - methylbenzyl ) piperidin - 2 - one ) , E2CDS , PYM 50028 , PBT 2 , lecozotan ; SB 742457 , CX 717 , AVE 1625 ( i. e. , l - ( bis ( 4 - chlorophenyl ) methyl ) - 3 - ( ( 3 , 5 - difluorophenyl ) ( methylsulfonyl ) methylene ) azetidine ) , LY 450l39 ( i. e. , N2 - [ 2 ( s ) - Hydroxy - 3 - methylbutyryl ] - Nl - [ 3 - methyl - 2 - oxo - 2 , 3 , 4 , 5 - tetrahydro - 1 H - 3 - benzazepin - l ( S ) - yl ] - L - alaninamide ) , EM l42l ( i. e. , 4 , 4 ' - [ ( 2R , 3S ) - 2 , 3 - Dimethylbutane - l , 4 - diyl ] bis ( l , 2 - dimethoxybenzene ) , SRN 001 , TTP 488 , PRX 03l40 , dimebolin , glycine - proline - g1utamate , Cl05 , AL 208 , MEM 3454 , AC l202 , L 830982 , LY 451395 ( i. e. , ( R ) 7N - [ 2 - [ 4‘ - ( methylsulfonamidomethyl ) biphenyl - 4 - yl ] propyl ] propane - 2 - sulfonamide ) , MK 0249 , LY 2062430 , diethylnorspermine , neboglamine , Sl8986 , SA 4503 ( CAS Number l65377 - 44 - 6 ) , GRl l , S 17092 ( i. e. , ( 2S , 3aS , 7aS ) - 1 { [ ( R , R ) - 2 - phenylcyclopropyl ] carbonyl } - 2 - [ ( thiazolidin - 3 - yl ) carbonyl ] octahydro - 1H - indole ) , SL251l88 , EUKl89 , R1450 , 6 , 6 - dimethyl - 3 - ( 2 - hydroxyethyl ) thio - l - ( thiazol - 2 - yl ) - 6 , 7 - dihydro - 2 - benzothiophen - 4 ( 5H ) - one , CERE 110 , dexefaroxan , CAD lO6 , HF 0220 , HF 0420 , EHT 0202 , VP 025 , MEM 14l4 , BGC 201259 ( i. e. , N , N - dimethylcarbamic acid , 4 - [ 1 ( S ) - ( methylamino ) - 3 - ( 4 - nitrophenoxy ) propyl ] phenyl ester ) , EN lO0 , ABT 834 , ABT 239 ( i. e. , 4 - [ 2 - [ 2 - [ ( 2R ) - 2 - methylpyrrolidinyl ] ethyl ] - benzofuran - 5 - yl - ] benzonitrile ) , SGS 518 , R lS00 , C 9l38 , SSR 18071l , alfatradiol , R lS77 , T 8l7MA ( i. e. , l - [ 3 - [ 2 - ( 1 - benzothien - 5 - yl ) ethoxy ] propyl ] azetidin - 3 - olmaleate ) , CNP lO6l ( i. e. , 4 - methyl - 5 - ( 2 - nitrooxyethyl ) thiazole ) , KTX 010l ( i. e. , sodium beta - hydroxybutyrate ) , GSK l89254 ( i. e. , 6 - [ 3 - cyclobutyl - 2 , 3 , 4 , 5 - tetrahydro - lHbenzo [ d ] azepin - 7 - yloxy ] - N - methylnicotinamide ) , AZD lO80 , ACC 001 , PRX 07034 , midazolam , R - phenserine , AZD lO3 ( CAS Number488 - 59 - 5 ) , SN 522 , NGX 267 ( CAS Number 50343l - 8l - 0 ) , N - PEP - l2 , RN l2l9 , FGLL , AVE 81l2 , EVT lOl , NP 03lll2 , MK 0752 , MK 0952 , LX 6l7l , PAZ 4l7 , AV 965 , PF 30840l4 , SYN ll4 , GSl 953 , SAM 3l5 , SAM 531 , D - serine , leteprinim potassium , BR l6A ( CAS Number 149175 - 77 - 9 ) , RPR 107393 ( CAS Number l90841 - 57 - 7 ) , NXD 2858 , REN l654 , CDD 0102 , NC l900 ( CAS Number l32925 - 74 - 7 ) , ciclosporin , NCX 22l6 ( i. e. , ( E ) - 4 - ( Nitrooxy ) butyl 3 - [ 4 - [ 2 - ( 2 - fluorobiphenyl - 4 - yl ) propanoyloxy ] - 3 - methoxyphenyl ] acrylate ) , NXD 3109 , NXD 119l , ZSET 845 ( i. e. , 3 , 3 - diphenylimidazo [ l , 2 - a ] pyridin - 2 - ( 3H ) - one ) , ET 002 , NT l3 , RO 638695 ( i. e. , [ l , 6 - ( l , 6 - dioxohexyl ) ] dipyrrolidine - ( 2R ) - carboxy1ic acid ) , bisnorcymserine , BA lOl6 , XD 424l , EUK 207 ( i. e. , ( SP - 5 - l3 ) - ( acetato - KO ) [ l3 , l 6 , l 9 , 22 - tetraoxa - 3 , 6 - diazatricyclo [ 21 .3. 18.12 ] octacosa - 1 ( 27 ) , 2 , 6 , 8 , 10 , 12 ( 28 ) , 23 , 25 - octaene - 27 , 28 - diolato ( 2 - ) - KN3 , KN6 , KO27 , KO28 ] manganese ) , LG 6l7 inhibitors , ZSET l446 , PAN 81 l , F l44l3 ( i. e. , 2 - [ 5 - Fluoro - 2 ( S ) - methoxy - 2 , 3 - dihydro - l , 4 - benzodioxin - 2 - yl ] - 4 , 5 - dihydro - l H - imidazole ) , FP 7832 ( i. e. , N - [ 2 - ( 5 - Methoxy - l - nitroso - lH - indol - 3 - yl ) ethyl ] acetamide ) , ARA 014418 ( i. e. , N - ( 4 - . l6. May 27 , 2010. methoxybenzyl ) - N‘ - ( 5 - nitro - l , 3 - thiazol - 2 - yl ) urea ) , AZD 3 lO2 , KP 544 ( i. e. , 2 - amino - 5 - ( 4 - chlorophenylethyny1 ) - 4 - ( 4 - trans - hydroxycyclohexylamino ) pyrimidine ) , DP 155 , 5 - Chloro - N - [ 3 - [ 2 - ( dimethylamino ) ethyl ] - lH - indol - 5 - yl ] naphthalene - 2 - sulfonamide , TAK 070 , huperzine , N - [ 2 - ( 3 , 5 - Dimethyladamant - l - yl ) ethyl ] acetamidine hydrochloride , 6 - [ 4 - [ ( Dimethylamino ) methyl ] - 5 - ethyl - 2 - methoxyphenyl ] pyridin - 2 - amine , 4 , 6 - diphenyl - 3 - ( 4 - ( pyrimidin - 2 - yl ) piperazin - l - yl ) pyridazine , N - [ ( l S , 2R ) - 3 - ( 3 , 5 - Difluorophenyl ) - l - hydroxy - l - [ ( 5 S , 6R ) - 5 - methyl - 6 - ( neopentyloxy ) morpholin - 3 - y1 ] propan - 2 - yl ] acetamide hydroch1oride , N - [ ( l R , 2S ) - 3 - ( 3 , 5 - Difluorophenyl ) - 1 - hydroxy - 1 - [ ( 2R , 4R ) - 4 - phenoxypyrrolidin - 2 - yl ] propan - 2 - yl ] - 3 - [ ( R ) - 2 - ( methoxymethyl ) pyrrolidine - l - carbonyl ] - 5 - methylbenzamide , R 1589 , midafotel , phenserine , coluracetam , physostigmine , cipralisant , nitroﬂurbiprofen , PPl lOl9 ( i. e. , ( 3alpha , 5beta , 7alpha , l2alpha ) - trihydroxycholan - 24 - oyl - L - leucyl - L - Valyl - L - phenylalanyl - L - phenylalanyl - L - alanine ) , dapsone , MDL 100453 ( CAS Number l29938 - 34 - 7 ) , NS 377 , midaxifylline , propofol phosphate , metrifonate , ceronapril , tenilsetam , sufoxazine , seglitide , ebiratide , nebracetam , milacemide , iododoxorubicin , SM lO888 ( CAS Number l29297 - 2l - 8 ) , U 808l6 ( CAS Number l38554 - ll - 7 ) , YM 954 ( CAS Number l3204l - 85 - l ) , SUT 870l ( CAS Number l23577 - 73 - l ) , apoVincamine , FR l21l96 ( CAS Number l33920 - 65 - 7 ) , LY 2746l4 ( CAS Number l36l09 - 04 - l ) , CL 275838 ( CAS Number llS93l - 65 - 2 ) , igmesine , K 7259 ( CAS Number l33667 - 88 - 6 ) , Vinconate , itasetron , CL 287663 ( CAS Number 125109 - 98 - 0 ) , WAY lO0289 ( CAS Number l360l3 - 69 - 9 ) , SR 46559A ( CAS Number l37733 - 33 - 6 ) , GYKl 46903 ( CAS Number l42999 - 59 - 5 ) , L 670548 ( CAS Number l2l564 - 89 - 4 ) , Y 29794 ( CAS Number l29l84 - 48 - l ) , AF lZ5 ( CAS Number 763l - 86 - 9 ) , KFM l9 ( CAS Number l33058 - 72 - 7 ) , ST 796 ( i . e. , ( S ) - 3 [ 3 - ( triﬂuoromethyl ) benzoyl ) amino ] hexahydroazepin - 2 - one ) , RU 33965 ( CAS Number l2232l - 05 - 5 ) , SDZ 2 lO086 ( i. e. , ( — ) - l ' , 2 ( S ) - Dimethylspiro [ l , 3 - dioxolan - 4 , 4 ' - piperidine ] ) , L 689660 ( CAS Number 144860 - 79 - 7 ) , L 689560 ( CAS Number l3905l - 78 - 8 ) , ST 618 ( i. e. , 1 - ( 6 , 7 - Dimethoxy - l , 2 , 3 , 4 - tetrahydro - 2 - naphthyl ) - 4 - hydroxy pyrrolidin - 2 - one ) , U 74500A ( CAS Number llOl0l - 65 - 0 ) , GEA 857 ( CAS Number l20493 - 42 - 7 ) , BlBN 99 ( CAS Number l4530l - 48 - 0 ) , DX 9366 , ONO l603 ( CAS Number ll4668 - 76 - 7 ) , MDL lO2234 ( CAS Number l37766 - 8l - 5 ) , P 9939 ( CAS Number lS7971 - 37 - 4 ) , PD l40532 ( CAS Number lS797l - 39 - 6 ) , azetirelin , MR l6728 ( CAS Number l476l4 - 2l - 9 ) , dabelotine , MDL lO2503 ( i. e. , 8 - [ l ( R ) - methyl - 2 - phenylethyl ] - 1 , 3 - dipropyl - 7H - xanthine ) , PD 14l606 ( i . e. , ( : ) - ( Z ) - 3 - ( 3 - Phenyl - 2 - propynyloxyimino ) - l - azabicyclo [ 2.2. l ] heptane ) , SNK 882 ( CAS Number lS222l - l2 - 0 ) , L 696986 ( CAS Number l4l553 - 45 - 9 ) , tazomeline , LY 235959 ( CAS Number l37433 - 06 - 8 ) , 2 - ( 2 - thiooxopyrrolidin - 1 - yl ) acetamide , AK 30 NGF , ABT 4l8 ( CAS Number l47402 - 53 - 7 ) , itameline , HUP l3 , sibopirdine , KST 5452 ( CAS Number lS7998 - 88 - 4 ) , TJ 54 , U 92798 ( i. e. , 7 - [ 4 - [ Bis ( 4 - fluorophenyl ) methyl ] perhydro - l , 4 - diazepin - l - ylmethyl ] - 4 - isopropyl - 2 - methoxy - 2 , 4 , 6 - cycloheptatrien - l - one ) , U 92032 ( CAS Number l42223 - 92 - 5 ) , 3 - ( sulfamoyloxy ) estra - 1 , 3 , 5 ( 10 ) - trien - 17 - one , P llO12 ( CAS Number 164723 - 36 - 8 ) , A 82695 ( CAS Number l47388 - 86 - l ) , FR 76659 ( CAS Number ll6904 - 25 - 7 ) , apaxifylline , CX 4l7 , 7 MEOTA ( CAS Number 5778 - 80 - 3 ) , BU 45l4N ( CAS Number 15l013 - 39 - 7 ) , pregnenolone , mexidol , ST 857 ( CAS Number lS4755 - 63 - 2 ) , RU 4904l ( CAS Number l23828 - 80 - . US 20l0 / 0l30537 Al. 8 ) , RU 35929 ( CAS Number lll7l l - 47 - 8 ) , P 878l84 , P lZ8 ( CAS Number lS77l 6 - 52 - 4 ) , eurystatin A , eurystatin B , LK l2 , NBl lO8 , NBl lO7 , NBl 117 , L 705106 , bacoside A + B , clausenamide , SM 21 ( CAS Number lS5l 56 - 22 - 2 ) , alaptide , RS l70l7 ( i. e. , l - ( 4 - Amino - 5 - chloro - 2 - methoxyphenyl ) - 5 - ( 1 - piperidinyl ) - 1 - pentanone hydrochloride ) , AF lS0 ( S ) ( i. e. , ( S ) - [ l - Methyl - piperidine - 4 - spiro - ( 2 ' - methylthiazoline ) ] ) , RO lS3505 ( CAS Number 7877l - l3 - 8 ) , PV ll3 ( i. e. , l , 2 , 3 , 4 - Tetrahydropyrrolo - [ 1 , 2 - a ] - pyrazine ) , arisugacin , A 98284 ( i. e. , 2 ( R ) - ( 3 - Methylisoxazol - 5 - yl ) quinuclidine ) , AP 5 ( CAS Number l3694l - 85 - 0 ) , BD lO54 , SDZ NDD 094 ( i. e. , bis - ( 2 - ( 2 - methylimidazol - 1 - yl ] methyl ) - pyri dine - tris ( hydro genfumarate ) , AZ 36041 ( CAS Number l73324 - 76 - 0 ) , quilostigmine , A 84543 ( i. e. , 3 - [ l - Methylpyrrolidin - 2 - ( S ) - ylmethoxy ] pyridine fumarate ) , BTG 4247 ( i. e. , ( 2 - [ 2 - Chloroethoxy [ 4 - ( dimethylamino ) phenyl ] phosphoryl ] - acetohydrazide ) , CGP 50068 ( CAS Number lS8647 - 49 - 5 ) , cerebrocrast , desferri - nordanoxamine , isolichenan , MHP l33 ( i. e. , 3 - ( N , N - dimethylcarbamoyloxy ) - 1 - methyl - 2 - ( 4 - phenyl - semicarbazonomethyl ) pyridinium chloride ) , FR lS2558 ( CAS Number lSl098 - 08 - 7 ) , GVS lll ( CAS Number lS7ll5 - 85 - 0 ) , P lll49 ( CAS Number l64724 - 79 - 2 ) , PDC 008004 , KST 28l8 ( CAS Number lS8623 - 26 - 8 ) , KST 54l0 ( CAS Number lS8623 - 27 - 9 ) , RU 52583 ( CAS Number l23829 - 33 - 4 ) , PD lSl832 ( CAS Number l49929 - 39 - 5 ) , UCL ll99 ( i. e. , 4 - [ 2 - [ ( 5 - nitropyridin - 2 - ylsulfanyl ) ethyl ] - lH - imidazole ) , isoVanihuperzine A , SlB l765F ( CAS Number l79120 - 52 - 6 ) , JWS USC 75 lX ( i. e. , 3 - [ [ [ 2 - [ [ ( 5 - dimethylaminomethyl ) - 2 - furanyl ] methyl ] thio ] ethyl ] amino ] - 4 - nitropyridazine ) , GR l75737 ( i. e. , 3 - ( 4 - Chlorobenzyl ) - 5 - [ 2 - ( lH - imidazol - 4 - yl ) ethyl ] - l , 2 , 4 - oxadiazole ) , KS 505A ( CAS Number l3l774 - 53 - 3 ) , ZTTA l ( i. e. , N - benzyloxycarbonylthioprolyl - thioprolynal - dimethylaceta 1 ) , AGN 190837 ( CAS Number 136527 - 40 - 7 ) , P 10358 ( 188240 - 59 - 7 ) , WAY l3l256 ( CAS Number l7400l - 7l - 9 ) , DBO 83 ( i. e. , 3 - ( 6 - chloropyridazin - 3 - yl ) - diazabicyclo [ 3 .2. l ] octane dihydrochloride monohydrate ) , FUB l8l ( CAS Number lS2029 - 80 - 6 ) , RJR 2557 , WSU 2088 , LVV - haemorphin - 7 , M 40 ( i. e. , galanin [ l - l2 ] - Pro3 - ( Ala - Leu ) - 2 - Ala - NH2 ) , SlB l757 , SKF 74652 ( i. e. , [ 5 - chloro - 2 - ( 4 - methoxy phenyl ) - 3 - benzofuranyl ] [ 4 - [ 3 - ( diethylamino ) - propoxy ] phenyl ] methanone ) , CGP 7l982 , SCH 57790 ( i. e. , 4 - cyclohexyl - alpha - [ 4 - [ [ 4 - methoxyphenyl ] sulﬁnyl ] phenyl ] - 1 - piperazineacetonitrile ) , Putrescine - D - YiAbetall , DU 14 ( i. e. , p - O - ( sulfamoyl ) - N - tetradecanoyl tyramine ) , CLZ 4 , SL 340026 , PPRT 424 , ciproxifan , UR lS27 ( i. e. , 2 - ( l - benzylpiperidin - 4 - yl ) - l - [ 4 - ( 5 - methylpyrimidin - 4 - ylamino ) phenyl ] - l - ethanone ) , caproctamine , TGS 20 ( i. e. , L - pyroglutamil - D - alanine amide ) , PG 9 ( i. e. , alpha - tropanyl 2 - [ ( 4 - bromo ) phenyl ] propionate ) , TEl 3356 ( i. e. , ( l6S ) - l5 - Deoxy - l6 - hydroxy - l6 - methyl - 9 - ( O ) - methano - DELTA6 ( 9alpha ) - pro staglandin ll ) , LY 392098 ( i. e. , Thiophene , 3 - [ ( 2 - methylethyl - 2 ) sulphonylaminopropyl - 2 ] phenyl - 4 - yl - ) , PG 1000 , DM 232 , NEPP 11 ( i. e. , 12 - iso - 1 5 - Deoxy - 18 - ( 4 - methyl ) phenyl - l3 , l4 - dihydrodelta7 - prostaglandinAl methyl ester ) , VA lO0 ( i. e. , ( 2 , 3 - Dihydro - 2 - [ [ ( 4 - ﬂuorobenzoyl ) amino ] ethyl ] - l - methyl - 5 - phenyl - lH - l , 4 - benzodiazepine ) , VA lOl ( i. e. , ( 2 , 3 - dihydro - 2 - [ [ ( 2 - thienylcarbonyl ) amino ] ethyl ] - 1 - methyl - 5 - phenyl - 1H - l , 4 - benzodiazepine ) , NC 111585 ( i. e. , ( 3S ) - 1 , 3 - Bis - [ 3 - [ ( 3 - azabicylo [ 2 .2.2 ] octanyl ) - l , 2 , 5 - thiadiazol - 4 - yloxy ] - l - propyn - l - yl ] benzene , 2L - ( + ) - tartate ) , lN 20l , imoproxifan , kanokodiol , picroside l , picroside ll , DM 235 ( i. e. , l - ( 4 - Benzoylpiperazin - 1 - yl ) propan - 1 - one ) , monoclonal antibody lOD5 , JLK2 , JLK 6 , JLK 7 , DAPT ( i. e. , N— [ N - ( 3 , 5 - difluo - . May 27 , 2010. rophenacetyl ) - L - alanyl ] - S - phenylglycine t - butyl ester ) , huperine X , SGS lll ( i. e. , ( S ) - ethyl 2 - [ l - ( 2 - phenylacety1 ) pyrrolidine - 2 - carboxamido ] acetate ) , NP 7557 , C 9l36 , C 76 l 7 , R l485 , rofecoxib , Velnacrine , montirelin , lazabemide , ORG 2766 ( CAS Number 509l3 - 82 - l ) , sabeluzole , adafenoxate , CAS Number 9061 - 6l - 4 , ipidacrine , bemesetron , idazoxan , linopirdine , selfotel , suritozole , milameline , xanomeline , TJ 960 , fasoracetam , eptastigmine , ensaculin , zanapezil , posatirelin , zacopride , RS 86 ( CAS Number 3576 - 73 - 6 ) , ORG 5667 ( CAS Number 37552 - 33 - 3 ) , RX 77368 ( CAS Number 76820 - 40 - l ) , BMS l8ll68 ( CAS Number l23259 - 9l - 6 ) , BY l949 ( CAS Number 90l58 - 59 - l ) , AWD 5239 ( CAS Number lO9002 - 93 - 9 ) , YM 796 ( l71252 - 79 - 2 ) , aloracetam , Cl - 933 ( CAS Number 9l829 - 95 - 7 ) , ST 793 ( CAS Number 99306 - 37 - 3 ) , cebaracetam , zifrosilone , talsaclidine , alVameline , JTP 2942 ( l48l52 - 77 - 6 ) , OPC l4l l7 ( CAS Number lO3233 - 65 - 4 ) , e1ziVerine , AP 521 ( i. e. , N - ( 1 , 3 - Benzodioxol - 5 - ylmethyl ) - 1 , 2 , 3 , 4 - tetrahydro [ 1 ] benzothieno [ 2 , 3 - c ] pyridine - 3 ( R ) - carboxamide hydrochloride ) , S 8510 ( CAS Number lSl466 - 23 - 8 ) , JTP 48l9 ( CAS Number 162203 - 65 - 8 ) , icopezil , SC llO , FK 960 ( CAS Number l33920 - 70 - 4 ) , DMP 543 ( CAS Number l60588 - 45 - 4 ) , ganstigmine , Cl 1017 ( i. e. , ( R ) - ( — ) - ( Z ) - 1 - Azabicyclo [ 2.2. l ] heptan - 3 - one , 0 - ( 3 - ( 3 ' - methoxyphenyl ) - 2 - propynyl ) - oxime maleate ) , T 82 ( i. e. , 2 - [ 2 - ( l - Benzylpiperidin - 4 - yl ) ethyl ] - 2 , 3 - dihydro - 9 - methoxy - l H - pyrrolo [ 3 , 4 - b ] quinolin - l - one hemifumarate ) , NGD 971 , Vaccine of Aspartyl - alanylglutamyl - phenylalanyl - arginyl - histidyl - aspartyl - serylglycyl - tyrosyl - glutamyl - Valyl - histidyl - histidyl - glutaminyllysyl - leucyl - Valyl - phenylalanyl - phenylalanyl - alanylglutamyl - aspartyl - Valyl - glycyl - seryl - asparaginyl - lysylglycyl - alanyl - isoleucyl - isoleucyl - glycyl - leucyl - methionylValyl - glycyl - glycyl - Valyl - Valyl - isoleucyl - alanine , PBT 1 ( CAS Number l30 - 26 - 7 ) , TCH 346 , FK 962 ( i. e. , N - ( l - acetylpiperidin - 4 - yl ) - 4 - ﬂuorobenzamide ) , Voxergolide , KW 6055 ( CAS Number 63233 - 46 - 5 ) , thiopilocarpine , ZK 93426 ( CAS Number 89592 - 45 - 0 ) , SDZ NVl 085 ( CAS Number lO4l95 - l7 - 7 ) , Cl lO02 ( CAS Number l49028 - 28 - 4 ) , Z 32l ( CAS Number l30849 - 58 - 0 ) , mirisetron , CHF 2060 ( i. e. , N - Heptylcarbamic acid 2 , 4a , 9 - trimethyl - 2 , 3 , 4 , 4a , 9 , 9a - hexahydro - l , 2 - oxazino [ 6 , 5 - b ] indol - 6 - yl ester - L - tartrate ) , gedocarnil , terbequinil , HOE 065 ( CAS Number l23060 - 44 - 6 ) , SL 650l02 , GR 253035 , ALE 260l5 , SB 27l046 ( i. e. , 5 - Chloro - N - ( 4 - methoxy - 3 - piperazin - 1 - yl - phenyl ) - 3 - methyl - 2 - benzothiophenesulfonamide ) , iAbeta5 , SCH 2ll803 ( i . e. , Piperidine , l - [ l - ( 3 - methyl - 2 - aminophenyl ) carbonylpiperidin - 4 - yl ] - 4 - [ ( 3 - chlorophenypsulphonylphenyl - 4 ] methyl - ) , EVT 30l , alpha - Linolenic acid / linoleic acid , Kamikihi - To , siagoside , FG 7l42 ( CAS Number 78538 - 74 - 6 ) , RU 47067 ( CAS Number lll7l 1 - 92 - 3 ) , RU 35963 ( CAS Number l39886 - 03 - 6 ) , FG 7080 ( CAS Number lO0332 - l8 - l ) , E 2030 ( CAS Number l42007 - 70 - 3 ) , transforming grthh factor beta - 1 , A 72055 ( i. e. , 2 ' , 1 - Dimethylspiro [ piperidine - 4 , 5 ' oxazolidine ] - 3 ' - carboxaldehyde ) , NS 626 , dimiracetam , GT 300l , GT 250l , GT 2342 , GT 20l6 ( CAS Number lS224l - 24 - 2 ) , ORG 2009l ( CAS Number l4l545 - 50 - 8 ) , BCE 001 ( CAS Number 95678 - 8l - 2 ) , CGP 35348 ( CAS Number l23690 - 79 - 9 ) , WAY lO0635 ( CAS Number l467l4 - 97 - 8 ) , E 4804 ( CAS Number l62559 - 34 - 4 ) , LlGA 20 ( CAS Number l26586 - 85 - 4 ) , NG l2l ( i. e. , 2 - [ 4 , 8 - Dimethyl - 3 ( E ) , 7 ( E ) - nonadienyl ] - 3 , 5 - dihydroxy - 2 - methyl - 3 , 4 , 7 , 9 - tetrahydro - 2H - furo [ 3 , 4 - h ] - l - benzopyran - 7 - one ) , MF 247 ( i. e. , N - [ 10 - ( Diethylamino ) decyl ] carbamic acid ( 3aS , 8aR ) - l , 3a , 8 - trimethyl - l , 2 , 3 , 3a , 8 , 8a - hexahydropyrrolo [ 2 , 3 - b ] in - . US 20l0 / 0l30537 Al. dol - 5 - yl ester ) , JTP 3399 ( i. e. , N - Benzyl - 2 ( S ) - [ 2 ( S ) - ( phenoxyacetyl ) pyrrolidin - l - y1carbonyl ] pyrro1idine - l - carboxamide ) , KF 17329 , thioperamide , F 3796 ( i. e. , 1 - [ 2 - ( l - Benzylpiperidin - 4 - yl ) ethyl ] - 3 - [ 3 , 4 - ( methylene - dioxy ) benzoyl ] thiourea ) , GT 400l , GT 4002 , FPL l4995 ( CAS Number l233 1 9 - 03 - 9 ) , RU 34332 ( CAS Number 137157 - 58 - 5 ) , SR 96777A ( CAS Number llS767 - 94 - 7 ) , SlB Tl 980 , NS 649 ( CAS Number l46828 - 02 - 6 ) , PD l42505 ( CAS Number l49929 - 08 - 8 ) , GYKl 52466 ( CAS Number 102771 - 26 - 6 ) , RO 246l73 ( CAS Number lS9723 - 57 - 6 ) , SCH 509l1 ( CAS Number l604l5 - 07 - 6 ) , Z 4l05 ( CAS Number 1 l9737 - 52 - 9 ) , RS 67333 ( CAS Number 168986 - 60 - 5 ) , NS 1546 , ZM 24l385 ( CAS Number l39l80 - 30 - 6 ) , RO 249975 ( i. e. , [ lS , 3 S ( 2 ' S ) , 5R ] - 3 - ( l - Benzyl - 5 - oxopyrrolidin - 2 - y1methyl ) - 5 - ( 1H - imidazol - 5 - ylmethyl ) cyclohexane - 1 - acetamide ) , AF l85 ( i. e. , 8 - Methyl - 3 - ( 2 - propynyl ) - l , 3 , 8 - triazaspiro [ 4 , 5 ] decane - 2 , 4 - dione ) , CEP 427 , CX 423 , CX 438 , CX 480 , CDPethanolamine , GT 4003 , GT 4011 , GT 50l l , MS 430 ( CAS Number l22l l3 - 44 - 4 ) , MBF 379 ( i. e. , [ 3 , 3 - Bis ( hydroxymethy1 ) - 8 - hydroxy - 3 , 4 - dihydro - 2H - l , 4 - benzoxazin - 5 - yl ] [ 3 ' , 5 ' - dihydroxy - 4 ' - ( 2 - oxo - 2 - phenylethoxy ) phenyl ] methanone ) , NGD l87 ( CAS Number l63565 - 48 - 8 ) , DUP 856 , MR 3066 , MF 86l5 ( i. e. , 5 - Amino - 6 - chloro - 4 - hydroxy - 3 , 4 - dihydro - 1H - thiopyrano - [ 3 , 4 - b ] quinoline ) , himbacine , ABS 300 , RJR 2403 ( CAS Number 538 - 79 - 4 ) , MF 268 ( CAS Number l7472l - 00 - 7 ) , RO 465934 ( i. e. , N , N - Dimethylcarbamic acid 3 - ( 2 - cyclohexylethyl ) - 2 , 3 , 3a , 4 , 5 , 9b - hexahydro - lH - benz [ e ] indol - 6 - yl ester ) , NS 393 , RGH 2716 ( CAS Number l34069 - 68 - 4 ) , WlN 678702 ( l2 , l2 - Bis ( 3 - furyl ) - 6 , 1l - dihydro - 6 , l1 - ethanobenzo [ b ] quinolizinium chloride ) , RS 66252 ( i. e. , l - Butyl - 2 - [ ( 2 ' - ( 2H - tetrazol - 5 - yl ) - biphenyl - 4 - yl ) methyl ] - lH - indole - 3 - carboxylic acid ) , AlT 034 ( CAS Number l38117 - 48 - 3 ) , NG 012 ( CAS Number l31774 - 53 - 3 ) , PD l42012 ( CAS Number 5778 - 84 - 7 ) , GT 4054 , GT 4077 , GT 4035 , P 26 ( CAS Number lS2l9l - 74 - 7 ) , RGH 5279 ( i. e. , ( — ) - ( l3aR , l3bS ) - l3a - Ethyl - 2 , 3 , 5 , 6 , l3a , l3b - hexahydro - lHindolo [ 3 , 2 , 1 - de ] pyrido [ 3 , 2 , 1 - ij ] [ 1 , 5 ] naphthyridine - 1 2 - carboxylic acid 2 - acetoxyethyl ester ) , AlT 083 , CeNeS , estradiol ( i. e. , l , 3 , 5 ( l0 ) - Estratriene - 3 , l7beta - diol ) , WAY l32983 ( ( 3 R , 4R ) - 3 - ( 3 - hexylsulfanylpyrazin - 2 - yloxy ) - l - azabicyclo [ 2.2. l ] heptane hydrochloride ) , ABS 205 , ABS 40l , SX 3507 ( i. e. , 3 - ( 3 - Propyl - 1 , 2 , 4 - oxadiazol - 5 - yl ) quinoxaline - 2 ( lH ) - one ) , ARR 17779 ( i. e. , ( — ) - Spiro [ 1 - azabicyclo [ 2.2.2 ] octane - 3 , 5 - oxazolidine ] - 2 - one ) , XE 99l ( i. e. , lO , l0 - bis ( 4 - Pyridylmethyl ) anthracen - l0 ( 9H ) - one ) , phenethylnorcymserine , RO 657l99 , RJR l78l ( i. e. , R ( + ) - 2 - ( 3 - pyridyl ) - l - azabicyclo [ 2. 2.2. ] octane ) , RJR 1782 ( i. e. , S ( + 2 - ( 3 - pyridyl ) - l - azabicyclo [ 2.2.2. ] octane ) , gilatide , tolserine , TC 2559 ( i. e. , ( E ) - N - Methyl - 4 - [ 3 - ( 5 - ethoxypyridin ) yl ] - 3 - buten - l - amine ) , ER l27528 ( i. e. , l - ( 3 - Fluorobenzyl ) - 4 - [ ( 2 - ﬂuoro - 5 , 6 - dimethoxy - l - indanone - 2 - yl ) methyl ] piperidine hydrochlo - ride ) , thiatolserine , targacept , axonyx , cymserine , thiacymserine , monoclonal antibody 266 , Apan - CH , DP 103 , SPl 339 ( i. e. , 4 - [ 3 - ( 4 - Oxo - 4 , 5 , 6 , 7 - tetrahydroindol - l - yl ) propionylamino ] benzoic acid ethyl ester ) , S 37245 ( i. e. , 4 - ( l , 4 - Benzodioxan - 5 - yl ) - l - [ 3 ( S ) - hydroxy - 5 - nitro - indan - 2 - yl ] - piperazine ) , LLG 88 , AZD 2858 , trometamol , AN 240 , NG 002 ( i. e. , 5 - Hydroxy - 5 - ( 2 - hydroxy - 1 - methylethyl ) - 4 - methoxyfuran - 2 ( 5H ) - one ) , UCB 29427 ( i. e. , 2 - Cyclopropyl - 4 - ( cyclopropylamino ) - 6 - ( morpholino ) - l , 3 , 5 - triazine ) , TRH - SR , RO 40l64l ( CAS Number l22l99 - 02 - 4 ) , MPV l743Alll ( CAS Number lS0586 - 64 - 4 ) , lDRA 2l ( CAS Number 22503 - 72 - 6 ) , CEP 431 , ACPD ( CAS Number 67684 - 64 - 4 ) , CT 3577. May 27 , 2010. ( i . e. , 3 , 7 - Dimethyl - l - [ l l - ( 3 , 4 , 5 - trimethoxybenzylamino ) - ll - oxoundecyl ] xanthine ) , CT 2583 , and NXD 9062. [ 0127 ] The cinnamide compounds , all of Which are actiVe ingredients , may be any knoWn in the art. ln one embodiment , the cinnamide compounds are the compounds described in US Publication No. 2006 / 0004013 , and the corresponding PCT Publication No. WO 2005 / l lS990. ln one embodiment , the cinnamide compound is a compound of Formula ( l ) or a pharmaceutically acceptable sa1t thereof : . Where R1 is : [ 0128 ] ( l ) —Xl—Arl. [ 0129 ] Wherein X1 is a Cl - 6 alkylene group optionally substituted With a C1_6 alkyl group ; . [ 0130 ] and Arl is a phenyl group optionally substituted With 1 to 3 substituents selected from the group consisting of ( i ) a halogen atom and ( ii ) a C1_6 alkyl group Which may optionally be substituted With one to ﬁVe C1 - 5 alkyl groups ; . [ 0131 ] ( 2 ) an indenyl group optionally substituted With 1 to 3 halogen atoms ; . [ 0132 ] ( 3 ) a tetrahydronaphthyl group optionally substituted With 1 to 3 halogen atoms ; or. [ 0133 ] ( 4 ) a chromanyl group optionally substituted With 1 to 3 halogen atoms. [ 0134 ] “Halogen atom” refers to a ﬂuorine atom , a chlorine atom , a bromine atom , and an iodine atom. ln one embodiment , the halogen atom is a ﬂuorine atom , a chlorine atom , or a bromine atom. [ 0135 ] “C1_6 alkyl group” refers to a linear or branched alkyl group haVing 1 to 6 carbon atoms. Exemplary C1 - 5 alkyl groups include methyl , ethyl , n - propyl , iso - propyl , n - butyl , iso - butyl , tert - butyl , n - pentyl , iso - pentyl , neopentyl , n - hexyl , l - methylpropyl , l , 2 - dimethylpropyl , l - ethylpropyl , l - methyl - 2 - ethylpropyl , l - ethyl - 2 - methylpropyl , l , l , 2 - trimethylpropyl , l - methylbutyl , 2 - methylbutyl , l , l - dimethylbutyl , 2 , 2 - dimethylbutyl , 2 - ethylbutyl , l , 3 - dimethylbutyl , 2 - methylpentyl , 3 - methylpentyl group , and the like. [ 013 6 ] ln other embodiments , the compound of Formula ( l ) is ( E ) - l - ( 3 , 4 - diﬂuorobenzyl ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lH - imidazol - l - yl ) benzy1idene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - l - indan - 2 - yl - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - l - [ ( 4R ) - chroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lHimidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - l - [ ( 4S ) - chroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - l - [ ( l S ) - l - ( 4 - ﬂuorophenyl ) ethyl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lH - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - l - ( 4 - tert - butylbenzyl ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable. US 20l0 / 0l30537 Al. salt thereof ; ( E ) - l - [ ( 2S ) - 5 - ﬂuoroindan - 2 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - l - [ ( 2R ) - 5 - ﬂuoroindan - 2 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lH - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutica1ly acceptable salt thereof ; ( E ) - 1 - [ ( 4R ) - 7 - ﬂuorochroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1 H - imidazol - 1 - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - l - [ ( 4S ) - 7 - ﬂuorochroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 ( 4 - methy1 - lH - imidazol - l - y1 ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] - 1 - [ ( 2R ) - l , 2 , 3 , 4 - tetrahydronaphthalen - 2 - yl ] piperidin - 2 - one or a pharmaceutical1y acceptable sa1t thereof ; ( E ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1 H - imidazol - l - yl ) benzylidene ] - l - [ ( 2S ) - 1 , 2 , 3 , 4 - tetrahydronaphthalen - 2 - yl ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - 1 - [ ( lR ) - 1 - ( 2 , 4 - diﬂuorophenyl ) ethyl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - l H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - l - [ ( lS ) - l - ( 2 , 4 - diﬂuorophenyl ) ethyl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - l H - imidazol - 1 - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof. [ 0137 ] Methods for administering , dosing , and preparing. cinnamide compounds are described in US Publication No. 2006 / 0004013 , and PCT Publication No. WO 2005 / l lS990. [ 0138 ] The cholinesterase inhibitor , an actiVe ingredient , used in the methods and pharmaceutical compositions of the inVention can be any in the art. Exemplary cholinesterase inhibitors include donepezil , phenserine , to1serine , phenethylnorcymserine , ganstigmine , epastigmine , tacrine , physostigmine , pyridostigmine , neostigmine , riVastigmine , galantamine , citicoline , Velnacrine , huperzine ( e. g. , huperzine A ) , metrifonate , heptastigmine , edrophonium , TAK - l47 ( i. e. , 3 - [ l - ( phenylmethyl ) - 4 - piperidinyl ] - l - ( 2 , 3 , 4 , 5 - tetrahydro - 1H - l - benzazepin - 8 - yl ) - 1 - propanone fumarate or other salts thereof ) , T - 82 , upreazine , and the like. [ 0139 ] ln one embodiment , the cholinesterase inhibitor is a compound of Formula ( ll ) or a pharmaceutically acceptable salt thereof : . / _\. ] : B=T Q—K. ( CH2 ) a. Wherein J is. [ 0140 ] ( a ) a substituted or unsubstituted group selected from the group consisting of ( l ) phenyl , ( 2 ) pyridyl , ( 3 ) pyrazyl , ( 4 ) quinolyl , ( 5 ) cyclohexyl , ( 6 ) quinoxaly1 , and ( 7 ) ﬁ1ry1 ; . [ 0141 ] ( b ) a monoValent or diValent group , in Which the phenyl can haVe one or more substituents selected from ( l ) indanyl , ( 2 ) indanonyl , ( 3 ) indenyl , ( 4 ) indenonyl , ( 5 ) indanediony1 , ( 6 ) tetralonyl , ( 7 ) benzosuberonyl , ( 8 ) indanolyl , and ( 9 ) C6H5—CO—CH ( CH3 ) — ; . [ 0142 ] ( c ) a monoValent group deriVed from a cyclic amide compound ; . [ 0143 ] ( d ) a loWer alkyl group ; or [ 0144 ] ( e ) a group of R217CH : CH7 , in Which R21 is hydrogen or a loWer alkoxycarbonyl group ; . May 27 , 2010. [ 0145 ] B is — ( CHR22 ) , — , —CO— ( CHR22 ) , .— , —NR4— ( CHR22 ) — , —CO—NR5— ( CHR22 ) , — , —CH : CH— ( CHR22 ) , — , —OCOO— ( CHR22 ) , — , —OOC—NH— ( CHR22 ) , — , —NH—OO— ( CHR22 ) , — , —CH , —Co— NH— ( CHR22 ) , — , — ( CH , ) , —NH— ( CHR22 ) , — , —CH ( OH ) — ( CHR22 ) , — , : ( CH—CH : CH ) , , — , : CH— ( CH2 ) , — , : ( CH—CH ) , , : , —CO—CH : CH—CH2— , —CO— CH2—CH ( OH ) —CH2— , —CH ( CH3 ) —CO—NHCHr , %H : CH : CO7NH7 ( CH , ) 27 , 7NH7 , —O— , —S— , a dialkylaminoalkyl - carbonyl or a 10Wer alkoxycarbonyl ; . [ 0146 ] Wherein R4 is hydrogen , loWer alkyl , acy1 , 10Wer alkylsulfonyl , phenyl , substituted phenyl , benzyl , or substituted benzyl ; R5 is hydrogen , loWer alkyl or phenyl ; r is zero or an integer of about 1 to about lO ; R22 is hydrogen or methyl so that one alkylene group can haVe no methy1 branch or one or more methyl branches ; b is an integer of about 1 to about 3 ; c is zero or an integer of about 1 to about 9 ; d is zero or an integer of about 1 to about 5 ; . [ 0147 ] T is nitrogen or carbon ; [ 0148 ] Q is nitrogen , carbon or. \. N—" ' O ; . / . [ 0149 ] q is an integer of about 1 to about 3 ; . [ 0150 ] K is hydrogen , phenyl , substituted phenyl , arylalkyl in Which the phenyl can haVe a sub stituent , cinnamyl , a loWer alkyl , pyridylmethyl , cycloalkylalkyl , adamantanemethyl , furylmethyl , cycloalkyl , loWer alkoxycarbonyl or an acyl ; and. [ 0151 ] — is a single bond or a double bond. [ 0152 ] ln the compound of Formula ( ll ) , J is preferably ( a ) or ( b ) , more preferably ( b ) . ln the deﬂnition of ( b ) , a monoValent group ( 2 ) , ( 3 ) and ( 5 ) and a diValent group ( 2 ) are preferred. The group ( b ) preferably includes , for example , the groups haVing the formulae shoWn beloW : . O. . . \ _ \ ( s ) .—“ [ ( S1 —©3ji / / indanyl tetralonyl O O \ _ \ ( S ) .— [ [ [ I / / / indan0nyl ( Sh benzosuberonyl O OH \ = \ _ <s ) .— [ ( s ) .— [ / / . . . indanonylidenyl indanolyl. US 20l0 / 0l30537 Al. - continued. ( S ) — ' \ |— a ll / [ . indenyl. ©7CO—CH ( CH3 ) — ' / A O. ( S ) — ( \ ( S ) — ( \ ) k|— 1 I / \O I I. . ( S ) a. . . . . . . / . indanedionyl indenonyl. Wherein t is an integer of about 1 to about 4 ; and each S is independently hydrogen or a sub stituent , such as a loWer alkyl haVing l to 6 carbon atoms or a loWer alkoxy haVing l to 6 carbon atoms. Among the substituents , methoxy is most preferred. The phenyl is most preferred to haVe 1 to 3 methoxy groups thereon. ( S ) , can form methylene dioxy groups or ethylene dioxy groups on tWo adjacent carbon atoms of the phenyl group. Of the aboVe groups , indanonyl , indanedionyl and indenyl , optionally haVing sub stituents on the phenyl , are the mo st preferred. [ 0153 ] ln the deﬂnition of B , — ( CHR22 ) , — , —CO— ( CH—CH : CH ) b— , : CH— ( CH2 ) , , — and : ( CH—CH ) a : are preferable. The group of — ( CHR22 ) , — in Which R22 is hydrogen and r is an integer of l to 3 , and the group of : CH7 ( CH2 ) C7 are most preferable. The preferable groups of B can be connected With ( b ) of J , in particular ( b ) ( 2 ) . [ 0154 ] The ring containing T and Q in Formula ( ll ) can be 5 - , 6 - or 7 - membered. lt is preferred that Q is nitrogen , T is carbon or nitrogen , and q is 2 ; or that Q is nitrogen , T is carbon , and q is 1 or 3 ; or that Q is carbon , T is nitrogen and q is 2. [ 0155 ] lt is preferable that K is a phenyl , arylalkyl , cinnamyl , phenylalkyl or a phenylalkyl haVing a substituent ( s ) on the phenyl. [ 0156 ] ln another embodiment , the cyclic amine compounds of Formula ( ll ) are the piperidine compounds of Formula ( lll ) or a pharmaceutically acceptable salt thereof : . R1 : XCN—R2. Wherein R1 is a ( l ) substituted or unsubstituted phenyl group ; ( 2 ) a substituted or unsubstituted pyridyl group ; ( 3 ) a substituted or unsubstituted pyrazyl group ; ( 4 ) a substituted or unsubstituted quinolyl group ; ( 5 ) a substituted or unsubstituted indanyl group ; ( 6 ) a substituted or unsubstituted cyclohexyl group ; ( 7 ) a substituted or unsubstituted quinoxalyl group ; ( 8 ) a substituted or unsubstituted furyl group ; ( 9 ) a monoValent or diValent group deriVed from an indanone haVing a substituted or unsubstituted phenyl ring ; ( l 0 ) a monoValent group deriVed from a cyclic amide compound ; ( 11 ) a. ( lll ) . 20. May 27 , 2010. loWer alkyl group ; or ( l2 ) a group of the formula R37CH : C7 , Where R3 is a hydrogen atom or a loWer alkoxycarbonyl group ; . [ 0157 ] X is — ( CH2 ) — , —C ( O ) — ( CH2 ) , , — , —N ( R4 ) —. ( CH2 ) , , — , —C ( O ) —N ( R5 ) — ( CH2 ) , , — , —CH : CH— ( CHa ) ..—a —O%3 ( O ) —0— ( CHa ) a— , —0—C ( O ) — NH7 ( CH2 ) , , 7 , %H : CH%3H : CO7 , 7NH% : . ( 0 ) — ( CHa ) .—. 4HH : ( 0 ) —NH— ( CHa ) .—. — ( CHa ) a—C<0 ) —NH— ( CHa ) ..—. A : H ( 0H ) —<CHa ) .—. —C ( O ) —CH : CH—CH2— , —C ( O ) —CH2—CH ( OH ) — CH27 , %H ( CH3 ) % ( O ) 7NH7CH27 , %H : CH7 C ( O ) 7NH7 ( CH2 ) 27 , a dialkylaminoalkylcarbonyl group , a loWer alkoxycarbonyl group ; . [ 0158 ] Where n is an integer of 0 to 6 ; R4 is a hydrogen atom , a loWer alkyl group , an acy1 group , a loWer a1kylsu1fonyl group , a substituted or unsubstituted phenyl group , or a substituted or unsubstituted benzyl group ; and R5 is a hydrogen atom a loWer alkyl group or a phenyl group ; . [ 0159 ] R2 is a substituted or unsubstituted phenyl group ; a substituted or unsubstituted arylalky1 group ; a cinnamyl group ; a loWer alkyl group ; a pyridylmethyl group ; a cycloalkylalkyl group ; an adamantanemethyl group ; or a furylmethyl group ; and. [ 0160 ] — is a single bond or a double bond. [ 0161 ] The term “loWer alkyl group” as used herein means a straight or branched alkyl group haVing l to 6 carbon atoms. Exemplary “loWer alkyl groups” include methyl , ethyl , propyl , isopropyl , butyl , isobutyl , sec - butyl , tert - butyl , pentyl ( amyl ) , isopentyl , neopentyl , tert - pentyl , l - methylbutyl , 2 - methylbutyl , l , 2 - dimethylpropyl , hexyl , isohexyl , l - methylpentyl , 2 - methyl - pentyl , 3 - methylpentyl , l , l - dimethylbutyl , 1 , 2 - dimethylbutyl , 2 , 2 - dimethylbutyl , 1 , 3 - dimethyl - butyl , 2 , 3 - dimethylbutyl , 3 , 3 - dimethylbutyl , l - ethylbutyl , 2 - ethylbutyl , l , l , 2 - trimethylpropyl , l , 2 , 2 - trimethylpropyl , l - ethyl - l - methylpropyl , l - ethyl - 2 - methylpropyl , and the like. The loWer alkyl group is preferably methyl , ethyl , propyl or isopropyl ; more preferably methyl. [ 0162 ] Speciﬂc examples of the substituents for the substituted or unsubstituted phenyl , pyridyl , pyrazyl , quinolyl , indanyl , cyclohexyl , quinoxalyl and furyl groups in the deﬁ - nition of R1 include loWer alkyl groups haVing l to 6 carbon atoms , such as methyl , ethyl , n - propyl , isopropyl , n - butyl , isobutyl , and tert - butyl groups ; loWer alkoxy groups corresponding to the aboVe - described loWer alkyl groups , such as methoxy and ethoxy groups ; a nitro group ; halogen atoms , such as chlorine , ﬂuorine and bromine ; a carboxyl group ; loWer alkoxycarbonyl groups corresponding to the aboVedescribed loWer alkoxy groups , such as methoxycarbonyl , ethoxycarbonyl , isopropoxycarbonyl , n - propoxycarbonyl , and n - butyloxycarbonyl groups ; an amino group ; a loWer monoalkylamino group ; a loWer dialky1amino group ; a carbamoyl group ; acylamino groups deriVed from aliphatic saturated monocarboxylic acids haVing l to 6 carbon atoms , such as acetylamino , propionylamino , butyrylamino , isobutyrylamino , Valerylamino , and inaloylamino groups ; cycloalkyloxycarbony1 groups , such as a cyclohexyloxycarbonyl group ; loWer alkylaminocarbonyl groups , such as methylaminocarbonyl and ethylaminocarbonyl groups ; loWer alkylcarbonyloxy groups corresponding to the aboVe - deﬁned loWer alkyl groups , such as methylcarbonyloxy , ethylcarbonyloxy , and n - propy1carbonyloxy groups ; halogenated loWer alkyl groups , such as a triﬂuoromethyl group ; a hydroxyl group ; a formyl group ; and loWer alkoxy loWer alkyl groups , such as ethoxymethyl , methoxymethyl and methoxyethyl groups. US 20l0 / 0l30537 Al. The “loWer alkyl groups” and “loWer alkoxyl groups” in the aboVe description of the substituent include all the groups deriVed from the aboVe - mentioned groups. The substituent can be one to three of them , Which can be the same or different. [ 0163 ] When the sub stituent is a phenyl group , the folloWing group is Within the scope of the substituted phenyl group : . Wherein G is —C ( O ) — , —O—C ( O ) — , —O— , —CH2— NH7C ( O ) 7 , %H2% ) 7 , %H27SO27 , %H ( OH ) 7 , or %H27S ( + - O ) 7 ; E is a carbon or nitrogen atom ; and D is a substituent. [ 0164 ] Preferred examples of the substituents ( i. e. , “D” ) for the phenyl group include loWer alkyl , loWer alkoxy , nitro , halogenated loWer alkyl , loWer alkoxycarbonyl , formyl , hydroxyl , and loWer alkoxy loWer alkyl groups , halogen atoms , and benzoyl and benzylsulfonyl groups. The substituent can be tWo or more of them , Which can be the same or different. [ 01 65 ] Preferred examples of the sub stituent for the pyridyl group include loWer alkyl and amino groups and halogen atoms. [ 0166 ] Preferred examples of the substituent for the pyrazyl group include loWer alkoxycarbonyl , carboxyl , acylamino , carbamoyl , and cycloalkyloxycarbonyl groups. [ 0167 ] With respect to Rl , the pyridyl group is preferably a 2 - pyridyl , 3 - pyridyl , or 4 - pyridyl group ; the pyrazyl group is preferably a 2 - pyrazinyl group ; the quinolyl group is preferably a 2 - quinolyl or 3 - quinolyl group ; the quinoxalinyl group is preferably a 2 - quinoxalinyl or 3 - quinoxalinyl group ; and the furyl group is preferably a 2 - furyl group. [ 0168 ] Speciﬂc examples of preferred monoValent or diValent groups deriVed from an indanone haVing an unsubstituted or substituted phenyl ring include those represented by formulas ( A ) and ( B ) : . O. £j55_ ( A ) a— [ / . O. \ = ( A ) a— [ [ / |. Where m is an integer of from 1 to 4 , and each A is independently a hydrogen atom , a loWer alkyl group , a loWer alkoxy group , a nitro group , a halogen atom , a carboxyl group , a loWer alkoxycarbonyl group , an amino group , a loWer monoalkylamino group , a loWer dialkylamino group , a carbamoyl group , an acylamino group deriVed from aliphatic. . . May 27 , 2010. saturated monocarboxylic acids haVing l to 6 carbon atoms , a cycloalkyloxycarbonyl group , a loWer alkylaminocarbonyl group , a loWer alkylcarbonyloxy group , a halogenated loWer alkyl group , a hydroxyl group , a formyl group , or a loWer alkoxy loWer alkyl group ; preferably a hydrogen atom , a loWer alkyl group or a loWer a1koxy group ; most preferably the indanone group is unsubstituted or substituted With 1 to 3 methoxy groups. [ 0169 ] Examples of the monoValent group deriVed from a cyclic amide compound include quinazolone , tetrahydroisoquinolinone , tetrahydrobenzodiazepinone , and hexahydrobenzazocinone. HoWeVer , the monoValent group can be any one haVing a cyclic amide group in the structural formula thereof , and is not limited to the aboVe - described speciﬂc examples. The cyclic amide group can be one deriVed from a monocyclic or condensed heterocyc1ic ring. The condensed heterocyclic ring is preferably one formed by condensation With a phenyl ring. ln this case , the phenyl ring can be substituted With a loWer alkyl group haVing l to 6 carbon atoms , preferably a methyl group , or a loWer alkoxy group haVing l to 6 carbon atoms , preferably a methoxy group. [ 0170 ] Preferred examples of the monoValent group include the folloWing : . US 20l0 / 0l30537 Al. - continued. [ 0171 ] ln the aboVe formulae , Y is a hydrogen atom or a loWer alkyl group ; V and U are each a hydrogen atom or a loWer alkoxy group ( preferably dimethoxy ) ; W1 and W2 are each a hydrogen atom , a loWer alkyl group , or a loWer alkoxy group ; and W3 is a hydrogen atom or a loWer alkyl group. The. May 27 , 2010. right hand ring in formulae ( j ) and ( l ) is a 7 - membered ring , While the right hand ring in formula ( k ) is an 8 - membered rmg. [ 0172 ] The most preferred examples of the aboVe - deﬂned Rl inc1ude a monoValent group deriVed from an indanone haVing an unsubstituted or substituted phenyl group and a monoValent group deriVed from a cyclic amide compound. [ 0173 ] The most preferred examples of the aboVe - deﬂned X include — ( CH2 ) , , — , an amide group , or groups represented by the aboVe formulae Where n is 2. Thus , it is most preferred that any portion of a group represented by the formula Rl — X7 haVe a carbonyl or amide group. [ 0174 ] The sub stituents inVolVed in the expressions “a substituted or unsubstituted phenyl group” and “a substituted or unsubstituted arylalkyl group” in the aboVe deﬂnition of R2 are the same substituents as those described for the aboVe deﬂnitions of a phenyl group , a pyridyl group , a pyrazyl group , a quinolyl group , an indanyl group , a cyclohexyl group , a quinoxalyl group or a furyl group in the deﬁnition of Rl. [ 0175 ] The term “arylalkyl group” is intended to mean an unsubstituted benzyl or phenethyl group or the like. [ 0176 ] Speciﬂc examples of the pyridylmethyl group include 2 - pyridylmethyl , 3 - pyridylmethyl , and 4 - pyridylmethyl groups. [ 0177 ] Preferred examples of R2 include benzyl and phenethyl groups. The symbol — means a double or single bond. The bond is a double bond only When R1 is the diValent group ( B ) deriVed from an indanone haVing an unsubstituted or substituted phenyl ring , While it is a single bond in other cases. [ 0178 ] ln another embodiment , the compound of formula ll is a compound of Formula ( lV ) or a pharmaceutically acceptable salt thereof : . 0 ( 1V ) . I \ — ( CHR22 ) , —C / —\N—K ( S ) 1—| / Kmm ) . Wherein r is an integer of about 1 to about lO ; each R22 is independently hydrogen or methyl ; K is a phenalkyl or a phenalkyl haVing a substituent on the phenyl ring ; each S is independently a hydrogen , a loWer alkyl group haVing l to 6 carbon atoms or a loWer alkoxy group haVing l to 6 carbon atoms ; t is an integer of l to 4 ; q is an integer of about 1 to about 3 ; With the proViso that ( S ) , can be a methylenedioxy group or an ethylenedioxy group joined to tWo adjacent carbon atoms of the phenyl ring. [ 0179 ] ln other embodiments , the cholinesterase inhibitor is l - benzyl - 4 - ( ( 5 , 6 - dimethoxy - l - indanon ) - 2 - yl ) methylpiperidine ; l - benzyl - 4 - ( ( 5 , 6 - dimethoxy - l - indanon ) - 2 - ylindenyl ) methylpiperidine ; l - benzyl - 4 - ( ( 5 - methoxy - l - indanon ) - 2 - yl ) methylpiperidine ; l - benzyl - 4 - ( ( 5 , 6 - diethoxy - l - indanon ) - 2 - yl ) methylpiperidine ; l - benzyl - 4 - ( ( 5 , 6 - methylenedioxy - l - indanon ) - 2 - yl ) methylpiperidine ; 1 - ( m - nitrobenzyl ) - 4 - ( ( 5 , 6 - dimethoxy - l - indanon ) - 2 - yl ) methylpiperidine ; l - cyclohexylmethyl - 4 - ( ( 5 , 6 - dimethoxy - l - indanon ) - 2 - yl ) methylpiperidine ; l - ( m - ﬂuorobenzyl ) - 4 - ( ( 5 , 6 - dimethoxy - l - indanon ) - 2 - yl ) methylpiperidine ; . l - benzyl - 4 - ( ( 5 , 6 - dimethoxy - l - indanon ) - 2 - yl ) propylpiperi - . . US 20l0 / 0l30537 Al. dine ; l - benzyl - 4 - ( ( 5 - isopropoxy - 6 - methoxy - l - indanon ) - 2 - yl ) methylpiperidine ; l - benzyl - 44 ( 5 , 6 - dimethoxy - l - oxoindanon ) - 2 - yl ) propenylpiperidine ; or a stereoisomer and / or a pharmaceutically acceptable salt thereof. [ 0180 ] ln still other embodiments , the cholinesterase inhibitor is donepezil ( i. e. , l - benzyl - 4 - ( ( 5 , 6 - dimethoxy - 1 - indanon ) - 2 - yl ) methylpiperidine ) or a pharmaceutica1ly acceptable sa1t thereof ( e. g. , hydrochloride ) . Donepezil hydrochloride is commercially aVailable as ARlCEPT® ( Eisai lnc. , Teaneck , N. J. ) . [ 0181 ] ln one embodiment , the AMPA receptor antagonist used in the methods and compositions described herein may be any knoWn in the art. Exemplary AMPA receptor antagonists , all of Which are actiVe ingredients , include 1 , 2 - dihydropyridine compounds , quinoxalinedione aminoalkylphosphonates , and the like. [ 0182 ] ln one embodiment , the AMPA receptor antagonist is a l , 2 - dihydropyridine compound. The l , 2 - dihydropyridine compound used in the methods and compositions described herein may be any knoWn in the art. “l , 2 - dihydropyridine compound” includes l , 2 - dihydropyridine compounds , pharmaceutically acceptable salts of l , 2 - dihydropyridine compounds , stereoisomers of l , 2 - dihydropyridine compounds , pharmaceutically acceptable salts of stereoisomers of l , 2 - dihydropyridine compounds , hydrates of l , 2 - dihydropyridine compounds , hydrates of pharmaceutically acceptable salts of l , 2 - dihydropyridine compounds , stereoisomers of hydrates of l , 2 - dihydropyridine compounds , and stereoisomer of hydrates of pharmaceutically acceptable salts of 1 , 2 - dihydropyridine compounds. [ 0183 ] The l , 2 - dihydropyridine compound used in the methods and compositions described herein may be a compound of Formula ( V ) : . Wherein Q is NH , O or S ; X1 , X2 and X3 are each independently a single bond , an optionally substituted C1_6 alkylene , an optionally substituted C2_6 alkenylene , an optionally substituted C2_6 alkynylene , —O— , —S— , —CO— , —SO— , —so , — , —N ( R6 ) — , —N ( R7 ) —CO— , —CO—N ( R8 ) — , . 7N ( R9 ) %3H , _7 , A : H27N ( R10 ) 7 , %H2%3O7 , —CO—CH2— , —N ( R” ) —S ( O ) , , , , — , —S ( O ) , , , —N ( R12 ) — , —CH , —s ( o ) , , — , —s ( o ) , , —CH , — , —CH , —o— , . —O—CH2— , —N ( R13 ) —CO—N ( Rl4 ) — or —N ( R15 ) — CS—N ( Rl6 ) ; R6 , R7 , R8 , R9 , RlO , R11 , R12 , Rl3 , R14 , Rl5 and R16 are each independently hydrogen , C1 - 5 alkyl , or C1_6 alkoxy ; m , n , p and q are each independently an integer of 0 , l or 2 ; Al , A2 and A3 are each independently an optionally substituted C3_8 cycloalkyl , an optionally substituted C_ , _8 cycloalkenyl , an optionally substituted 5 - to l4 - membered non - aromatic heterocyclic ring , an optionally substituted C6_l4 aromatic hydrocarbocyclic ring , or an optionally sub - . May 27 , 2010. stituted 5 to l4 - membered aromatic heterocyclic ring ; and Rl7 and R18 are each independently hydrogen , halogen , or. ( : , _6 alkyl. [ 0184 ] The inVention proVides the compound of Formula ( V ) Wherein Xl , X2 and X3 are each independently a single bond , an optionally substituted Cl - 6 alky1ene , an optionally substituted C2_6 alkenylene , or an optionally substituted C2_6 alkynylene. The substituents may be one or more of % ) 7 , isi , 7CO7 , isoi , isof , 7N ( R6 ) 7 , 7N ( R7 ) 7. CO— , —CO—N ( R8 ) — , —N ( R9 ) —CH2— , —CH , —N ( Rl0 ) — , —CH2—CO— , —CO—CH2— , —N ( R“ ) —S ( O ) m—a —S ( 0 ) —N ( Rl2 ) —a —CH2—S ( 0 ) , a—a —S ( 0 ) a—. CH27 , 7CH27O7 , %%H27 , 7N ( Rl3 ) 7CO7N ( Rl4 ) 7 and 7N ( Rl5 ) 7CS7N ( Rl6 ) 7 ; R6 , R7 , R8 , R9 , R10 , Rll , Rl2 , R13 , Rl4 , R15 and Rl6 are each independently hydrogen , Cl - 6 alkyl , or Cl - 6 alkoxy ; m , n , p and q are each independently an integer of 0 , l or 2 ; Al , A2 and A3 are each independently an optionally substituted C3 , _8 cycloalkyl , an optionally substituted C3_8 cycloalkenyl , an optionally substituted 5 - to l4 - membered non - aromatic heterocyclic ring , an optional1y substituted C6_ 14 aromatic hydrocarbocyclic ring , or an optionally substituted 5 - to l4 - membered aromatic heterocyclic ring. [ 0185 ] The substituents for the 1 , 2 - dihydropyridine compounds of the inVention may be one or more of hydroxy ; halogen ; nitrile ; nitro ; Cl_6 alkyl ; C2_6 alkenyl ; C2_6 alkynyl [ Wherein the alkyl , alkenyl , and alkynyl can independently and optionally be substituted With one or more groups selected from hydroxy , nitrile , halogen , C1 - 5 alkylamino , di ( C1_6 alkyl ) amino , C2_6 alkenylamino , di ( C2_6 alkenylamino , C2_6 alkynylamino , di ( C2_6 alkynyl ) amino , N—Cl_6 alkyl - N—C2_6 alkenylamino , N—C1_6 alkyl - N—C2_6 alkynylamino , N%I2_6 alkenyl - N%I2_6alkynylamino , aralkyloxy , TBDMS oxy , C1_6 alkylsulfonylamino , C1_6 alkylcarbonyloxy , C2_6 alkenylcarbonyloxy , C2_6 alkynylcarbonyloxy , N—Cl_6 alkylcarbamoyl , N—C2_6 alkenylcarbamoyl , and N—Cl - 6 alkynylcarbamoyl ] ; Cl - 6 alkoxy ; C2_6 alkenyloxy ; C2_6 alkynyloxy [ Wherein the alkoxy , alkenyloxy , and alkynyloxy may independently and optionally be substituted With one or more groups selected from Cl - 6 alkylamino , aralkyloxy , and hydroxy ] ; Cl - 6 alkylthio ; C2_6 alkenylthio ; C2_6 alkynylthio [ Wherein the alkylthio , alkenylthio , and alkynylthio may independently and optionally be substituted With one or more groups selected from hydroxy , nitrile , halogen , C M alkylamino , aralkyloxy , TBDMS oxy , Cl - 6 alkylsulfonylamino , Cl_6 alkylcarbony1oxy , and Cl - 6 alkylcarbamoyl ] ; optionally substituted carbonyl [ Which may be substituted With C1 - 5 alkoxy , amino , C1 - 5 alkylamino , di ( Cl_6 alkyl ) amino , C2_6 alkenylamino , di ( C2_6 alkenyl ) amino , C2_6 alkynylamino , di ( C2_6 alkynyl ) amino , alkenylamino , N—Cl_6 alky1 - N—C2_6 alkynylamino and N—C2_6 alkenyl - N—C2_6 alkynylamino ] ; an optionally substituted amino [ Which may be substituted With one or tWo groups selected from Cl - 6 alkyl , C2_6 alkenyl , C2_6 alkynyl , C1_6 alkylsulfonyl , C2_6 alkenylsulfonyl , C2_6 alkynylsulfonyl , C1 - 6 alkylcarbonyl , C2_6 a1kenylcarbonyl and C2_6 alkynylcarbonyl ] ; Cl - 6 a1kylsulfonyl ; C2_6 alkenylsulfonyl ; C2_6 alkynylsulfonyl ; Cl - 6 alkylsulfonyl ; C2 - 5 alkenylsulﬂnyl ; C2 - 5 alkynylsulﬂnyl ; formyl ; optionally substituted C3_8 cycloalkyl ; an optionally substituted C3_8 cycloalkenyl [ Where the cycloalkyl group and / or the cycloalkenyl group may independently and optionally be substituted With one or more groups selected from hydroxy , halogen , nitrile , C1_6 alkyl , C1_6 alkyloxy , C1_6 alkyloxy C1_6 alkyl , and aralkyl ] ; a 5 - to l4 - membered non - aromatic het - . US 20l0 / 0l30537 Al. erocyclic ring [ Which may optionally be substituted With one or more groups selected from hydroxy , halogen , nitrile , C1_6 alkyl , C1_6 alkyloxy , C1_6 alkyloxy C1_6 alkyl , and aralkyl ] ; C6_l4 aromatic hydrocarbocyclic ring [ Which may optionally be substituted With one or more groups selected from hydroxy , halogen , nitrile , C1_6 alkyl , C m alkyloxy , C1 - 6 alkyloxy C1_6 alkyl , and aralkyl ] ; and a 5 - to 14 - membered aromatic heterocyclic ring [ Which may optionally be substituted With one or more groups selected from hydroxy , halogen , nitri1e , C1_6 alkyl , C M alkyloxy , C M alkyloxy C H alkyl , and aralkyl ] . [ 0186 ] ln another embodiment , the inVention proVides compounds of Formula ( V ) Wherein Al , A2 and A3 are each independently an optional1y substituted C3_8 cycloa1kyl , an optional1y substituted C3_8 cycloalkenyl or an optional1y substituted 5 - to 14 - membered non - aromatic hetero ring. ln another embodiment , the inVention proVides the compound of Formula W ) WhereinA1 , A2 and A3 are each independently an optional1y substituted C6_ 14 aromatic hydrocarbon ring or an optional1y substituted 5 - to l4 - membered aromatic hetero ring. ln another embodiment , the inVention proVides the compound of Formula ( V ) Wherein A1 , A2 and A3 are each independently phenyl , pyrrolyl , pyridyl , pyridazinyl , pyrimidinyl , pyraziny1 , thienyl , thiazoly1 , furyl , naphthyl , quino1yl , isoquinolyl , indolyl , benzimidazolyl , benzothiazolyl , benzoxazolyl , imidazopyridyl , carbazolyl , cyclopentyl , cyclohexyl , cyclohexenyl , dioxinyl , adamantyl , pyrrolidinyl , piperidinyl , piperazinyl or morpholyl ; any of Which may optionally haVe substituents. ln another embodiment , the inVention proVides the compound of Formula ( V ) WhereinAl , A2 andA3 are each. independently selected from : , —H ( 1\ij : L?N I , I. 0. each of Which may optionally be substituted. ln another embodiment , the inVention proVides the compound of Formula ( V ) Wherein A1 , A2 and A3 are each independently substituted With hydroxyl , halogen , amino , or nitri1e. ln another embodiment , the inVention proVides the compound of Formula ( V ) Wherein Al , A2 and A3 are each independently hydroxyl , halogen , amino , nitrile , or nitro. ln another embodiment , the inVention proVides the compound of Formula ( V ) Wherein Q is oxygen. [ 0187 ] ln another embodiment , the inVention proVides the compounds of Formula ( V ) Wherein Xl , X2 and X3 are each independently a sing1e bond , —CH2— , —CH ( OH ) — , —CH2—CH2— , —CH : CH— , —CEC— , —O— or 7CO7. ln another embodiment , the inVention proVides the compounds of Formula ( V ) WhereinXl , X2 and X3 are each a. May 27 , 2010. single bond. ln another embodiment , the inVention proVides the compounds of Formula ( V ) Wherein Rl7 and R1 8 are each independently hydrogen , ﬂuorine , chlorine , bromine , iodine , methyl , ethyl , n - propyl , or iso - propyl. ln another embodiment , the inVention proVides the compounds of Formula ( V ) Wherein Rl7 and Rl8 are each hydrogen. [ 0188 ] “Halogen atom” indicates ﬂuorine , chlorine , bromine , iodine and the like , and the preferable halogen atoms include ﬂuorine , chlorine and bromine. [ 0189 ] carbons , and examples include linear chain or branched chain alkyl groups such as methyl , ethyl , n - propyl , iso - propyl , n - buty1 , iso - butyl , sec - butyl ( l - methylpropyl ) , tert - butyl , isopentyl , n - pentyl , tert - pentyl ( 1 , 1 - dimethylpropyl ) , 1 , 2 - dimethylpropyl , 2 , 2 - dimethylpropyl ( neopentyl ) , l - ethylpropyl , 2 - methylbutyl , n - hexyl , iso - hexyl , l , 2 - dimethylbutyl , l - ethyl - 1 - methylpropyl , l - ethyl - 2 - methylpropyl , l , l , 2 - trim - . “C1_6 alkyl” refers to an alkyl group haVing l to 6. ethylpropyl , l , 2 , 2 - trimethylpropyl , l - ethylbutyl , 1 - methylbutyl , l , l - dimethylbutyl , 2 , 2 - dimethylbutyl , l , 3 - dimethylbutyl , 2 , 3 - dimethylbutyl , 3 , 3 - dimethylbutyl , 2 - ethylbutyl , l - methylpentyl , 2 - methylpentyl , 3 - methylpentyl , and the like. [ 0190 ] “C2_6 alkenyl” refers to an alkenyl group haVing 2 to 6 carbons , and examples include Vinyl , l - ethylethenyl ( l - buten - 2 - yl ) , allyl ( 2 - propenyl ) , l - propenyl , iso - propenyl , 2 - methyl - l - propenyl , l - methyl - l - propenyl ( 2 - buten - 2 - yl ) , 2 - methyl - 2 - propenyl , 1 - methyl - 2 - propenyl , l - butenyl ( l - buten - l - yl ) , 2 - butenyl ( 2 - buten - 1 - yl ) , 3 - butenyl , 1 - pentenyl , 1 - hexenyl , 1 , 3 - hexadienyl , 1 , 6 - hexadienyl , and the like. [ 0191 ] “C2_6 alkynyl” refers to an alkynyl group haVing 2 to 6 carbons , and examples include ethynyl , l - propynyl , 2 - propynyl , l - butynyl , 2 - butynyl , 3 - butynyl , l - ethyl - l - propynyl , l - ethynyl - 2 - propynyl , 2 - methyl - 3 - butenyl , 1 - pentynyl , l - hexynyl , l , 3 - hexadiynyl , 1 , 6 - hexadiynyl , and the like. [ 0192 ] “C m alkoxy” refers to an alkoxy group haVing 1 to 6 carbons , and examples include methoxy , ethoxy , n - propoxy , iso - propoxy , n - butoxy , iso - butoxy , sec - butoxy , tert - butoxy , n - pentyloxy , iso - pentyloxy , tert - pentyloxy , l , 2 - dimethylpropoxy , neopentyloxy , 1 - ethylpropoxy , 1 - methylbutoxy , 2 - methylbutyoxy , n - hexyloxy , iso - hexyloxy , 1 - ethyl - l - methylpropoxy , l - ethyl - 2 - methylpropoxy , 1 , l , 2 - trimethylpropoxy , l , 2 , 2 - trimethylpropoxy , l , l - dimethylbutoxy , 2 , 2 - dimethylbutoxy , 2 , 3 - dimethylbutoxy , 3 , 3 - dimethylbutoxy , 2 - ethylbutoxy , l , 3 - dimethylbutoxy , 1 - ethylbutoxy , 1 - methylbutoxy , 1 - methylpentyloxy , 2 - methylpentyloxy , 3 - methylpentyloxy , and the like. [ 0193 ] “C2_6 alkynyloxy” refers to an alkynyloxy group haVing 2 to 6 carbon atoms , and examples include ethynyloxy , l - propynyloxy , 2 - propynyloxy , l - butynyloxy , 2 - butynyloxy , 3 - butynyloxy , l - methyl - 2 - propynyloxy , l - ethyl - 2 - propynyloxy , l - ethynyl - 2 - propynyloxy , l - pentynyloxy , l - hexynyloxy , l , 3 - hexadiynyloxy , l , 6 - hexadiynyloxy , and the like. [ 0194 ] “C2_6 alkenyloxy” refers to an alkenyloxy group haVing 2 to 6 carbons , and examples include Vinyloxy , l - ethylethenyloxy ( l - buten - 2 - yloxy ) , allyloxy ( 2 - propenyloxy ) , l - propenyloxy , iso - propenyloxy , 2 - methyl - 1 - propenyloxy , l - methyl - l - propenyloxy ( 2 - buten - 2 - yloxy ) , 2 - methyl - 2 - propenyloxy , l - methyl - 2 - propenyloxy ( l - buten - 3 - yloxy ) , l - butenyloxy ( l - buten - l - yloxy ) , 2 - butenyloxy ( 2 - buten - l - yloxy ) , 3 - butenyloxy , 1 - pentenyloxy , l - hexenyloxy , l , 3 - hexadienyloxy , 1 , 6 - hexadienyloxy , and the like. US 20l0 / 0l30537 Al. [ 0195 ] “C3_8 cycloalkyl” refers to a cycloalkyl group composed of 3 to 8 carbon atoms , and examples include cyclopropyl , cyclobutyl , cyclopentyl , cyclohexyl , cycloheptyl , cyclooctyl , and the like. [ 0196 ] “C3_8 cycloalkenyl” refers to a cycloalkenyl group composed of 3 to 8 carbon atoms , and examples include cyclopropen - l - yl , 2 - cyclopropen - l - yl , cyclobuten - l - yl , 2 - cyclobuten - l - yl , l , 3 - cyc1obutadien - l - yl , cyclopenten - l - yl , 2 - cyclopenten - 1 - yl , 3 - cyclopenten - 1 - yl , l , 3 - cyclopentadien - l - yl , l , 4 - cyclopentadien - l - yl , 2 , 4 - cyclopentadien - 1 - yl , cyclohexen - l - yl , 2 - cyclohexen - 1 - yl , 3 - cyclohexen - l - yl , 1 , 3 - cyclohexadien - l - yl , l , 4 - cyclohexadien - l - yl , l , 5 - cyclohexadien - l - yl , 2 , 4 - cyclohexadien - l - yl , 2 , 5 - cyclohexadien - l - yl , cyclohepten - 1 - yl , 2 - cyclohepten - l - yl , 3 - cyclohepten - l - yl , 4 - cyclohepten - 1 - yl , l , 3 - cyclopentadien - 1 - yl , l , 4 - cyclopentadien - l - yl , l , 5 - cycloheptadien - l - yl , l , 6 - cycloheptadien - l - yl , 2 , 4 - cycloheptadien - l - yl , 2 , 5 - cycloheptadien - l - yl , 2 , 6 - cycloheptadien - l - y1 , 3 , 5 - cycloheptadien - l - yl , l , 3 , 5 - cycloheptatrien - l - yl , 1 , 3 , 6 - cycloheptatrien - l - yl , 1 , 4 , 6 - cycloheptatrien - l - yl , 2 , 4 , 6 - cycloheptatrien - 1 - yl , cycloocten - l - yl , 2 - cycloocten - l - yl , 3 - cycloocten - l - yl , 4 - cycloocten - l - yl , l , 3 - cyclooctadien - l - yl , l , 4 - cyclooctadien - l - yl , l , 5 - cyclooctadien - 1 - yl , 1 , 6 - cyclooctadien - 1 - yl , 1 , 7 - cyclooctadien - 1 - yl , cyclooctadien - 1 - yl , cyclooctadien - l - yl , cyclooctadien - l - yl , cyclooctatrien - 1 - yl , . 2 , 4 - cyclooctadien - 1 - yl , 2 , 5 - . 2 , 6 - cyclooctadien - 1 - yl , 2 , 7 - . 3 , 5 - cyclooctadien - l - yl , 3 , 6 - l , 3 , 5 - cyclooctatrien - l - yl , l , 3 , 6 - 1 , 3 , 7 - cyclooctatrien - l - yl , 1 , 4 , 6 - cyclooctatrien - 1 - yl , 1 , 4 , 7 - cyclooctatrien - l - yl , 1 , 5 , 7 - cyclooctatrien - l - yl , 2 , 4 , 6 - cyclooctatrien - l - yl , 2 , 4 , 7 - cyclooctatrien - l - yl group , and the like. [ 0197 ] “5 - to 14 - membered non - aromatic heterocyclic ring” refers to a mono - cyclic , di - cyclic , or tri - cyclic 5 - to l4 - membered non - aromatic heterocyclic ring Which contains one or more hetero atoms selected from nitrogen , sulfur , and oxygen. Speciﬂc examples include pyrrolidinyl , pyrrolinyl , piperidyl , piperazinyl , pyrazolidinyl , imidazolidinyl , morpholinyl , tetrahydrofuryl , tetrahydropyranyl , dihydrofuryl , dihydropyranyl , imidazolinyl , oxazolinyl , and the like. Further , a group deriVed from a pyridone ring and a non - aromatic condensed ring ( for example , a group deriVed from a phthalimide ring , a succinimide ring , and the like ) are also included in the non - aromatic heterocyclic ring. [ 0198 ] “C6_l4 aromatic hydrocarbocyclic ring and the aryl” refers to an aromatic hydrocarbocyclic ring Which is composed of 6 to l4 carbon atoms , a mono - cyclic ring , and a condensed di - cyclic , tri - cyclic and the like. Speciﬂc examples include phenyl , indenyl , l - naphthyl , 2 - naphthyl , azulenyl , heptalenyl , biphenyl , indathenyl , acenaphthyl , ﬂuorenyl , phenalenyl , phenanthrenyl , anthracenyl , cyclopentacyclooctenyl , benzocyclooctenyl and the like. [ 0199 ] “5 - to l4 - membered aromatic heterocyclic ring and the heteroaryl ring” refers to mono - cyclic , di - cyclic , or tricyclic 5 - to 14 - membered aromatic heterocyclic ring Which contain one or more hetero atoms selected from nitrogen , sulfur , and oxygen. Speciﬂc examples include ( l ) aromatic heterocyclic rings containing nitrogen such as pyrrolyl , pyridyl , pyridazinyl , pyrimidinyl , pyrazinyl , triazolyl , tetrazolyl , benzotriazolyl , pyrazolyl , imidazolyl , benzimidazolyl , indolyl , iso - indolyl , indolizinyl , prenyl , indazolyl , quinolyl , iso - quinolyl , quinoliziyl , phthalazyl , naphthylidinyl , quinoxalyl , quinazolinyl , cynnolinyl , pteridinyl , imidazotriazinyl , pyrazinopyridazinyl , acridinyl , phenanthridinyl , carbazolyl , carbazolinyl , perimidinyl , phenanthrolinyl , phenazinyl , imi - . May 27 , 2010. dazopyridyl , imidazopyrimidinyl , or pyrazolopyridyl ; ( 2 ) aromatic heterocyclic rings containing sulfur such as thienyl or benzothienyl ; ( 3 ) aromatic heterocyclic rings containing oxygen such as furyl , pyrany1 , cyc1opentapyranyl , benzofu - ry1 , or iso - benzofuryl ; and ( 4 ) aromatic heterocyclic rings containing 2 or more different hetero atoms such as thiazolyl , iso - thiazolyl , benzothiazolyl , benzothiadiazolyl , phenothiazinyl , isoxazolyl , furazanyl , phenoxazinyl , oxazolyl , isoxazoyl , benzoxazolyl , oxadiazolyl , pyrazoloxadiazolyl , imidazothiazolyl , thienofuranyl , furopyrrolyl or pyridoxadinyl. [ 0200 ] The 1 , 2 - dihydropyridine compound used in the methods and compositions described herein may be a compound of Formula ( V l ) : . ( V1 ) . A3\X3 x1 / A1 / N / R17 \ 0 X2 | A2. Wherein X1 , X2 , X3 , Al , A2 , A3 , Rl7 and RlS haVe the same meanings as deﬂned in the aboVe compound of Formula W ) . [ 0201 ] ln another embodiment , the inVention proVides the compounds of Formula ( Vl ) Wherein Al , A2 and A3 are each independently an optionally substituted C6_l4 aromatic hydrocarbon ring or 5 - to l4 - membered aromatic hetero ring. ln another embodiment , the inVention proVides the compounds of Formula ( V l ) Wherein A1 , A2 and A3 are each independently phenyl , pyrrolyl , pyridyl , pyridazinyl , pyrimidinyl , pyrazinyl , thienyl , thiazolyl , furyl , naphthyl , quinolyl , iso - quinolyl , indolyl , benzimidazolyl , benzothiazolyl , benzoxazolyl , imidazopyridyl , carbazolyl , cyclopentyl , cyclohexyl , cyclohexenyl , dioxinyl , adamantyl , pyrrolidinyl , piperidinyl , piperazinyl , or morpholyl ; Wherein each may optionally be substituted. ln another embodiment , the inVention proVides the compounds of Formula ( V l ) Wherein A1 , A2 and A3 are each independently selected from : . 000 6 l / .| / Nor N / , . each of Which may optionally be substituted. ln another embodiment , the inVention proVides the compounds of Formula ( V l ) Wherein the bonding site of the substituent atA1 , A2 and A3 are in the a - position of the carbon atom bonding to the group X1 , X2 and X3 , respectiVely. ln another embodiment , the inVention proVides the compounds of Formula W l ) Wherein Xl , X2 and X3 are single bonds. ln another embodiment , the inVention proVides the compounds of Formula ( V l ) Wherein R7 and RR are hydrogen. [ 0202 ] The l , 2 - dihydropyridine compound used in the methods and compositions described herein may be Compound C : . . US 20l0 / 0l30537 Al. The lUPAC name for Compound C is 2 - ( 2 - oxo - l - phenyl - 5 - pyridin - 2 - yl - 1 , 2 - dihydropyridin - 3 - yl ) benzonitrile. Compound C may also be referred to as 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one. Compound C is also knoWn as perampanel. [ 0203 ] The terms “Compound C , ” “2 - ( 2 - oxo - l - phenyl - 5 - pyridin - 2 - yl - 1 , 2 - dihydropyridin - 3 - yl ) benzonitrile , ” “3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - phenyl - 1 , 2 - dihydropyridin - 2 - one” and “perampanel” are intended to include pharmaceutically acceptable salts thereof , stereoisomers thereof , pharmaceutically acceptable salts of stereoisomers thereof , hydrates thereof , hydrates of pharmaceutically acceptable salts thereof , stereoisomers of hydrates thereof , and stereoisomer of hydrates of pharmaceutically acceptable salts thereof. ln another embodiment , the terms “Compound C , ” “2 - ( 2 - oxo - l - phenyl - 5 - pyridin - 2 - yl - l , 2 - dihydropyridin - 3 - yl ) benzonitrile , ” “3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one” and “perampanel” are intended to include pharmaceutically acceptable salts thereof , hydrates thereof , and hydrates of pharmaceutically acceptable salts thereof. [ 0204 ] ln other embodiments , the l , 2 - dihydropyridine compounds that are useful in the methods and compositions of the inVention are 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - methylsulfonylaminophenyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - chloro - 3 - pyridyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - ( 3 - nitrophenyl ) - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - aminophenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - methylsulfonylaminophenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - methylaminophenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - dimethylaminophenyl ) - l , 2 - dihydropyridin - 2 - one , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - [ 3 - ( 5 - methoxymethyl - 2 - oxazolidinon - 3 - yl ) - phenyl ] - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - ( 3 - methoxycarbonylphenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - methylaminocarbonylphenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyano - 3 - pyridy1 ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - chlorophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 4 - hydroxyphenyl ) - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - chlorophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 4 - . dimethylamino ethoxyphenyl ) - l , 2 - dihydropyridin - 2 - one ; . 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - formy1phenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - hydroxymethylphenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - ( 3 - cyanomethylphenyl ) - l , 2 - . May 27 , 2010. dihydropyridine - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - acetylaminomethylphenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - methylsulfonylaminomethylphenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - acetoxymethylphenyl ) - l , 2 - dihydro - pyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 4 - methylthiophenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 4 - methy1sulfony1pheny - l ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - formylthiophen - 3 - yl ) - 1 - phenyl - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - diethylaminomethylthiophen - 3 - yl ) - l - phenyl - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - hydroxymethylthiophen - 3 - yl ) - 1 - phenyl - 1 , 2 - dihydropyridine - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - benzyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - pyridy1 ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - phenyl - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one , 3 - ( 2 - cyanophenyl ) - 1 , 5 - diphenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - methoxyphenyl ) - 1 - phenyl - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 3 , 4 - dimethoxyphenyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( thiophen - 3 - yl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - ﬂuorophenyl ) - l - phenyl - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( thiophen - 2 - yl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one , 3 - ( 2 - cyanophenyl ) - 5 - ( 3 - furfuryl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - furfuryl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - chlorophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - methoxycarbonylphenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - phenyl - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - ﬂuorophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - chlorophenyl ) - 5 - ( 2 - pyridyl ) - 1 - ( 3 - methoxyphenyl ) - 1 , 2 - dihydropyridin - 2 - one ; . 3 - ( 2 - ﬂuoro - 3 - pyridyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 4 - methoxy - 3 - pyridyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - ﬂuoro - 3 - pyridyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - methoxyphenyl ) - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - ﬂuoro - 3 - pyridyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - ﬂuorophenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 4 - ﬂuorophenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - ﬂuorophenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 4 - methoxyphenyl ) - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - methoxy - phenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - phenyl - 5 - ( 2 - pyridyl ) - l - ( 3 - ﬂuorophenyl - ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - chlorophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 4 - ﬂuorophenyl ) - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 4 - formylphenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 2 - formy1phenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - chlorophenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - tolyl ) - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - triﬂuoromethylphenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanopheny1 ) - 5 - ( 2 - pyridyl ) - l - ( thiophen - 3 - yl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - furfuryl ) - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 4 - tolyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridy1 ) - l - ( 4 - triﬂuoromethy1phenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 2 - methoxypyridin - 5 - yl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( pyrimidin - 5 - yl ) - 1 , 2 - . US 20l0 / 0l30537 Al. dihydrop - yridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - . ( 3 - benzyloxymethylpyridin - 5 - yl ) - l , 2 - dihydropyridin - 2 - . one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 2 - ethylthiopyridin - 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl - ) - l - ( 4 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - ( 3 - methoxypyridin - 5 - yl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 2 - chloropyridin - 5 - yl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - . 5 - yl ) - l , 2 - dihydropyridin - 2 - one ; . cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - ( 2 - ﬂuoropyridin - 5 - yl ) - 1 , 2 - . dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - ( 2 - methoxyphenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - phenyl - 5 - ( 2 - pyridyl ) - l - ( 3 - pyridyl ) - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - . chlorophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - pyridyl ) - 1 , 2 - . dihydropyridin - 2 - one ; 3 - ( thiophen - 3 - yl ) - 5 - ( 2 - pyridyl ) - 1 - ( 3 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 , 6 - dimethylphenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - . cyanothiophen - 3 - y1 ) - 5 - ( 2 - pyridyl ) - l - ( 3 - pyridyl ) - l , 2 - . dihydropyridin - 2 - one ; 3 - ( 2 - ﬂuoro - 3 - pyridyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - pyridyl ) - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - . chlorophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 3 - hydroxyphenyl ) - l - , 2 - . dihydropyridin - 2 - one ; 3 - ( 2 - chlorophenyl ) - 5 - ( 2 - pyridyl ) - l - . ( 3 - dimethylaminoethoxyphenyl ) - l , 2 - dihydropyridin - 2 - one ; 342 - chlorophenyl ) - 5 - ( 2 - pyridyl ) - 1 - ( 3 - dimethylaminopro - . poxyphenyl ) - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - . 5 - ( 2 - pyridyl ) - l - ( 2 - hydroxymethylphenyl ) - l , 2 - dihydropyridin - 2 - one ; . cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - ( 2 - cyanomethylphenyl ) - l , 2 - dihydropyridin - 2 - one ; diethylaminomethyl - 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; . hydroxypyridin - 6 - yl ) - l - phenyl - 5 - ( 2 - pyridyl ) - 1 , 2 - . dihydropyridin - 2 - one ; l - ( 2 - aminobenzothiazol - 6 - yl ) - 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - . cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( l - benzyl - l , 2 , 3 , 6 - . tetrahydropyridin - 5 - yl ) - l , 2 - dihydropyridin - 2 - one ; 3 - [ 2 - ( 5 - . methyl - 1 , 2 , 4 - oxadiazol - 3 - yl ) phenyl ] - 1 - phenyl - 5 - ( 2 - . pyridyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 6 - . methylpyridin - 2 - yl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 5 - methylpyridin - 2 - yl ) - l - phenyl - l , 2 - . dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 3 - hydroxypy - 3 - ( 2 - cy - . ridin - 2 - yl ) - l - phenyl - 1 , 2 - dihydropyridin - 2 - one ; anophenyl ) - 1 - phenyl - 5 - ( 2 - thiazolyl ) - l , 2 - dihydropyridin - 2 - . one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - methoxypyridin - 6 - yl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; l - ( 4 - aminophenyl ) - 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; l - ( 3 - . aminophenyl ) - 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyrimidinyl ) - 1 , 2 - . dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 - 2 - dihydropyridin - 2 - one ; 3 - ( 2 - . ( 2 - aminotoluen - 4 - yl ) - l - , cyanophenyl ) - l - [ 3 - ( dimethy1aminoethoxy ) phenyl ] - 5 - ( 2 - . pyridyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - l - [ 3 - . ( piperidinoethoxy ) phenyl ] - 5 - ( 2 - pyridyl ) - 1 , 2 - dihydropyridin - 2 - one ; ( pyrrolidinoethoxy ) phenyl ] - 5 - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; ( diisopropylaminoethoxy ) phenyl ] - 5 - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; piperidinobutyl - l - oxy ) phenyl ] - 5 - ( 2 - pyridyl ) - 1 , 2 - dihydropyridin - 2 - one ; nitrophenyl ) - 5 - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; . l - phenyl - 5 - ( 2 - pyridyl ) - 3 - ( 2 - thiazolyl ) - l , 2 - dihydropyridin - . 2 - one ; 3 - ( 2 - cyanophenyl ) - l - ( 3 - pyridyl ) - 5 - ( 2 - pyrimidinyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - ﬂuoropyridin - 3 - yl ) - l - phe - . 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 4 - cyanomethylphenyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - . 3 - ( 2 - cyanophenyl ) - 5 - ( 6 - . 3 - ( 2 - cyanophenyl ) - l - phenyl - 5 - ( 2 - pyrimidinyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - . 3 - ( 2 - cyanophenyl ) - 1 - [ 3 - 3 - ( 2 - cyanophenyl ) - l - [ 3 - 3 - ( 2 - cyanophenyl ) - 1 - [ 3 - ( 4 - . 3 - ( 2 - cyanophenyl ) - l - ( 4 - . May 27 , 2010. nyl - 5 - ( 2 - pyrimidinyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanopyridin - 3 - yl ) - l - phenyl - 5 - ( 2 - pyrimidinyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - l - ( 3 - nitrophenyl ) - 5 - ( 2 - pyrimidinyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - nitrophenyl ) - l - phenyl - 5 - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - formylthiophen - 3 - yl ) - 5 - ( 2 - pyridyl ) - 1 - phenyl - l , 2 - dihydropyrid - in - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 2 - naphthy1 ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 1 - naphthyl ) - 1 , 2 - dihydropyridin - 2 - one ; 5 - ( 2 - aminopyridin - 6 - yl ) - 3 - ( 2 - cyanophenyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 5 - ( 2 - bromopyridin - 6 - y1 ) - 3 - ( 2 - cyanophenyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - morphorinopyridin - 6 - yl ) - l - phenyl - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - l - ( 3 - hydroxyphenyl ) - 5 - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanopheny1 ) - l - [ 3 - ( 4 - piperidy1oxy ) ] phenyl - 5 - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; l - [ 3 - ( N - acetylpiperidin - 4 - yl - oxy ) phenyl ] - 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - l - { 3 - [ l - ( methanesulfonyl ) piperidin - 4 - yloxy ] phenyl } - 5 - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; l - [ 3 - ( N - methylpiperidin - 4 - yl - oxy ) pheny - l ] - 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 6 - chloro - 1H - benzimidazol - 2 - yl ) - 5 - ( 2 - pyridyl ) - 1 - phenyl - 1 , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - ( 2 - nitrotoluen - 4 - y1 ) - l , 2 - dihydropyridin - 2 - one ; 3 - ( 2 - cyanothiophen - 3 - yl ) - 5 - ( 2 - pyridyl ) - l - phenyl - 1 , 2 - dihydropyridin - 2 - one ; 3 - [ 2 - ( 5 - oxazolyl ) phenyl ] - 1 - phenyl - 5 - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; 3 - [ 2 - ( 5 - oxazolyl ) thiophen - 3 - yl ] - l - phenyl - 5 - ( 2 - pyridyl ) - l , 2 - dihydropyridin - 2 - one ; and 3 - ( 2 - ethoxycarbonylVinylthiophen - 3 - y1 ) - 5 - ( 2 - pyridyl ) - 1 - phenyl - 1 , 2 - dihydropyridin - 2 - one. [ 0205 ] The 1 , 2 - dihydropyridine compounds and methods for making the 1 , 2 - dihydropyridine compounds are described in U. S. Pat. No. 6 , 949 , 57l , US Publication No. 2004 / 0023973 , and PCT Publication Nos. WO 03 / 047577 , WO 04 / 009553 , WO 06 / 004l00 , WO 06 / 004l07 , WO 07 / 072 , 868 , and WO 07 / 072 , 869 , the disclosures of each of Which are incorporated by reference herein in their entirety. [ 0206 ] Methods for administering , dosing , and making other AMPA receptor antagonists such as quinoxalinedione aminoalkylphosphonates are described , for example , in WO 2005 / 094797 and WO 98 / l7672. ln one embodiment , the AMPA receptor antagonist is a compound of Formula ( V ll ) : . ( Vll ) . Wherein R1 is hydroxy , an aliphatic group , an aryl aliphatic group , or an aromatic group ; R2 is hydrogen , an aliphatic group , or an aryl aliphatic group ; R3 , R4 and R5 are each independently hydrogen , halogen , cyano , nitro , triﬂuoromethyl , or a C1_7 alkyl group ; and X is an aliphatic group , a. US 20l0 / 0l30537 Al. cycloaliphatic group , an aryl aliphatic group , a heteroaryl aliphatic group , or an aromatic group. [ 0207 ] ln other embodiments , the AMPA receptor antagonist may be becampanel , EGlS 8332 ( 7 - acetyl - 5 - ( 4 - aminophenyl ) - 8 , 9 - dihydro - 8 - methyl - 7H - l , 3 - dioxolo [ 4 , 5 - h ] [ 2 , 3 ] benzodiazepine - 8 - carbonitrile ) ; GYKl 4726l ( 4 - ( 7 - chloro - 2 - methyl - 4H - 3 , lO , lOa - triaza - benzo [ f ] azulen - 9 - yl ) phenylamine ) ) ; irampanel ( N , N - dimethyl - 2 - [ 2 - ( 3 - pheny1 - l , 2 , 4 - oxadiazol - 5 - yl ) phenoxy ] ethanamine ) ; KRP 199 ( ( 7 - [ 4 - [ [ [ [ 4 - carboxyphenyl ) - amino ] carbony1 ] oxy ] methy1 ] - l H - imidazol - l - yl ] - 3 , 4 - dihydro - 3 - oxo - 6 - ( triﬂuoromethyl ) - 2 - quinoxalinecarboxylic acid ) ; NS l209 ( 2 - [ [ [ 5 - [ 4 - [ ( dimethylamino ) - sulfony1 ] phenyl ] - l , 2 , 6 , 7 , 8 , 9 - hexahydro - 8 - methyl - 2 - oxo - 3H - pyrrolo [ 3 , 2 - h ] isoquinolin - 3 - ylidene ] amino ] oxy ] - 4 - hydroxybutanoic acid monosodium salt ; topiramate ( TOPAMAX® ) ; talampanel ( LY - 300l64 , ( R ) - 7 - acetyl - 5 - ( 4 - aminophenyl ) - 8 , 9 - dihydro - 8 methyl - 7H - l , 3 - dioxolo [ 4 , 5 - h ] [ 2 , 3 ] benzo - diazepine ; YM9OK ( 6 - imidazol - 1 - yl - 7 - nitro - 1 , 4 - dihydro - quinoxaline - 2 , 3 - dione ) ; S - 34730 ( 7 - chloro - 6 - sulfamoyl - 2 - ( 1H ) - quinolinone - 3 - phosphonic acid ) ; Zonampanel ( Y M - 872 ; ( 7 - imidazol - l - yl - 6 - nitro - 2 , 3 - dioxo - 3 , 4 - dihydro - 2H - quinoxalin - l - yl ) - acetic acid ) ; GYKl 52466 ( 4 - ( 8 - methyl - 9H - l , 3 - dioxa - 6 , 7 - diaza - cyclohepta [ f ] inden - 5 - yl ) - phenylamine ) ; ZK 200775 ( MPQX , ( 7 - morpholin - 4 - yl - 2 , 3 - dioxo - 6 - triﬂuoromethyl - 3 , 4 - dihydro - 2H - quinoxalin - l - ylmethyl ) - phosphonic acid ) ; CP - 465022 ( 3 - ( 2 - chlorophenyl ) - 2 - [ 2 - ( 6 - diethylaminomethyl - pyridin - 2 - y1 ) - Vinyl ] - 6 - ﬂuoro - 3H - quinazolin - 4 - one ) ; SYM - 2189 ( 4 - ( 4 - amino - phenyl ) - 6 - methoxy - l - methyl - 1 H - phthalazine - 2 - carboxylic acid propylamide ) ; SYM - 2206 ( 8 - ( 4 - aminophenyl ) - 5 - methyl - 5H - [ l , 3 ] dioxolo [ 4 , 5 - g ] phthalazine - 6 - carboxylic acid propylamide ) ; RPR - ll7824 ( ( 4 - oxo - 2 - phosphono - 5 , 10 - dihydro - 4H - imidazo [ 1 , 2 - a ] indeno [ 1 , 2 - e ] pyrazin - 9 - yl ) - acetic acid ) ; or LY - 293558 ( 6 - [ 2 - ( 1H - tetrazol - 5 - yl ) - ethyl ] - decahydro - isoquinoline - 3 - carboxylic acid ) . [ 0208 ] The NMDA receptor antagonist , Which is an actiVe ingredient , may be any knoWn in the art. ln one embodiment , the NMDA receptor antagonist is represented by Formula ( Vlll ) , a pharmaceutically acceptable salt thereof , a stereoisomer thereof , or a pharmaceutically acceptable salt of a stereoisomer thereof : . ( Vlll ) R1\N / R2. Wherein R 1 and R2 are each independently hydrogen or a straight or branched chain C H alkyl group , or R1 and R2 in conjunction With the nitrogen atom form a C5_6 heterocyclic group ; R3 and R4 are each independently hydrogen , a straight or branched chain C1_6 alkyl group , a C5_6 cycloalkyl group , or phenyl ; and R5 is hydrogen or a straight or branched chain C H alkyl group. ln one embodiment , Rl , R2 , R3 , R4 and R5 are not simultaneously hydrogen atoms. ln one embodiment , the pharmaceutically acceptable salt is a pharmaceutically acceptable acid addition salt. Exemplary branched or straight. May 27 , 2010. chain Cl - 6 alkyl groups include methyl , ethyl , iso - propyl , n - propyl , n - butyl , iso - butyl , t - butyl , n - pentyl , n - hexyl , and isomers thereof. [ 0209 ] ln one embodiment , the compound of Formula ( V lll ) is Compound ( D ) , a pharmaceutically acceptable salt thereof , a stereoisomer thereof , or a pharmaceutically acceptable salt of a stereoisomer thereof : . NH2. CH3. ( : H3. [ 0210 ] ln another embodiment , the compound of Formula ( V lll ) is Compound ( Dl ) or a pharmaceutically acceptable salt thereof : . ( D1 ) NH2. IIIIIIC H3. CH3. [ 0211 ] Compound ( Dl ) is also knoWn as memantine and can be in the form of any pharmaceutically acceptable salt knoWn in the art. ln one embodiment , memantine is in the form of a hydrochloride salt. Compounds ( D ) and ( Dl ) are also knoWn as l - amino - 3 , 5 - dimethyl - adamantane. [ 0212 ] ln other embodiments , the adamantane compound is l - amino adamantine ; l - amino - 3 - phenyl adamantine ; l - amino - methyl - adamantane ; l - amino - 3 , 5 - dimethyl adamantine ; l - amino - 3 - ethyl adamantine ; l - amino - 3 - isopropyl adamantine ; l - amino - 3 - n - butyl adamantine ; l - amino - 3 , 5 - diethyl adamantine ; 1 - amino - 3 , 5 - diisopropyl adamantine ; l - amino - 3 , 5 - di - n - butyl adamantine ; l - amino - 3 - methyl - 5 - ethyl adamantine ; l - N - methylamino - 3 , 5 - dimethyl adamantine ; l - N - ethylamino - 3 , 5 - dimethyl adamantine ; l - N - isopropyl - amino - 3 , 5 - dimethyl adamantine ; 1 - N , N - dimethylamino - 3 , 5 - dimethyl adamantine ; l - N - methyl - N - isopropylamino - 3 - methyl - 5 - ethyl adamantine ; l - amino - 3 - butyl - 5 - phenyl adamantine ; l - amino - 3 - pentyl adamantine ; l - amino - 3 , 5 - dipentyl adamantine ; 1 - amino - 3 - p entyl - 5 - hexyl adamantine ; 1 - amino - 3 - pentyl - 5 - cyclohexyl adamantine ; l - amino - 3 - pentyl - 5 - phenyl adamantine ; l - amino - 3 - hexyl adamantine ; l - amino - 3 , 5 - dihexyl adamantine ; l - amino - 3 - hexyl - 5 - cyclohexyl adamantine ; l - amino - 3 - hexyl - 5 - phenyl adamantine ; l - amino - 3 - cyclohexyl adamantine ; l - amino - 3 , 5 - dicyclohexyl adamantine ; l - amino - 3 - cyclohexyl - 5 - phenyl adamantine ; l - amino - 3 , 5 - diphenyl adamantine ; 1 - amino - 3 , 5 , 7 - trimethyl adamantine ; l - amino - 3 , 5 - dimethyl - 7 - ethyl adamantine ; l - amino - 3 , 5 - diethyl - 7 - methyl adamantine ; l - N - pyrrolidino and l - N - piperidine deriVatiVes ; l - amino - 3 - methyl - 5 - propyl adamantine ; l - amino - 3 - methyl - 5 - butyl adamantine ; l - amino - 3 - methyl - 5 - p entyl adamantine ; . US 20l0 / 0l30537 Al. l - amino - 3 - methyl - 5 - hexyl adamantine ; l - amino - 3 - methyl - 5 - cyclohexyl adamantine ; 1 - amino - 3 - methyl - 5 - phenyl adamantine ; l - amino - 3 - ethyl - 5 - propyl adamantine ; 1 - amino - 3 - ethyl - 5 - butyl adamantine ; l - amino - 3 - ethyl - 5 - pentyl adamantine ; l - amino - 3 - ethyl - 5 - hexyl adamantine ; l - amino - 3 - ethyl - 5 - cyclohexyl adamantine ; 1 - amino - 3 - ethyl - 5 - phenyl adamantine ; l - amino - 3 - propyl - 5 - butyl adamantine ; l - amino - 3 - propyl - 5 - pentyl adamantine ; 1 - amino - 3 - propyl - 5 - hexyl adamantine ; l - amino - 3 - propyl - 5 - cyclohexyl adamantine ; l - amino - 3 - propyl - 5 - phenyl adamantine ; l - amino - 3 - butyl - 5 - pentyl adamantine ; l - amino - 3 - butyl - 5 - hexyl adamantine ; 1 - amino - 3 - butyl - 5 - cyclohexyl adamantine ; their N - methyl , N , N - dimethyl , N - ethyl , N - propyl deriVatiVes. Each of these compounds can be in the form of a pharmaceutically acceptab1e salt thereof , a stereoisomer thereof , or a pharmaceutically acceptable salt of a stereoisomer thereof. [ 0213 ] Methods for preparing Compounds ( Vlll ) , ( D ) and ( Dl ) are described in U. S. Pat. No. 5 , 06l , 703 , the disclosure of Which is incorporated by reference herein in its entirety. Memantine is commercially aVailable as NAMENDA® from Forest Laboratories. [ 0214 ] ln another embodiment , the NMDA receptor antagonist is a compound of Formula ( lX ) , a pharmaceutically acceptable salt thereof , a stereoisomer thereof , or a pharmaceutically acceptable salt of a stereoisomer thereof : . ( 1X ) . . Where X1 and X2 are each independently hydrogen or a C1 - 5 aliphatic group ; R2 through R16 are each independently hydrogen or a chain Cl_5 aliphatic group. R4 and RlO may alternatiVely and independently be halogen or an acyl group. [ 0215 ] ln one embodiment , the compound of Formula ( lX ) is amantadine , a pharmaceutically acceptable salt thereof , a stereoisomer thereof , or a pharmaceutically acceptable salt of a stereoisomer thereof ; Wherein R2 - R16 are all hydrogen atoms. ln another embodiment , the compound of Formula ( lX ) is memantine ; a pharmaceutically acceptable salt thereof , a stereoisomer thereof , or a pharmaceutically acceptable salt of a stereoisomer thereof ; memantine is shoWn aboVe as Compounds ( D ) and ( Dl ) . ln another embodiment , the compound of Formula ( lX ) is rimantadine , a pharmaceutically acceptable salt thereof , a stereoisomer thereof , or a pharmaceutically acceptable salt of a stereoisomer thereof ; Wherein R2 - Rl7 are all hydrogen atoms and R1 is. May 27 , 2010. Wherein X1 is hydrogen and X2 is methyl. [ 0216 ] Methods for preparing Compound ( lX ) are described in U. S. Pat. No. 5 , 614 , 5 60 , the disclosure of Which is incorporated by reference herein in its entirety. [ 0217 ] ln another embodiment , the NMDA receptor antagonist is neramexane ( i . e. , l - amino - l , 3 , 3 , 5 , 5 - pentamethylcyclohexane ) or a pharmaceutically acceptable salt thereof as described in U. S. Pat. No. 6 , 034 , l34 and WO 2004 / 037234 , the disclosures of Which are incorporated by reference herein in their entirety. [ 0218 ] ln other embodiments , exemplary NMDA receptor antagonists that can be used in the compositions , combinations , and methods described herein , include ketamine or a pharmaceutically acceptable salt thereof , eliprodil or a pharmaceutically acceptab1e salt thereof , ifenprodil or a pharmaceutically acceptable salt thereof , dizocilpine or a pharmaceutically acceptable salt thereof , remacemide or a pharmaceutically acceptable salt thereof , iamotrigine or a pharmaceutically acceptable salt thereof , riluzole or a pharmaceutically acceptable salt thereof , aptiganel or a pharmaceutically acceptable salt thereof , phencyclidine or a pharmaceutically acceptable salt thereof , ﬂupirtine or a pharmaceutically acceptable salt thereof , celfotel or a pharmaceutically acceptable salt thereof , felbamate or a pharmaceutically acceptable salt thereof , spermine or a pharmaceutically acceptable salt thereof , spermidine or a pharmaceutically acceptable salt thereof , leVemopamil or a pharmaceutically acceptable salt thereof , dextromethorphan ( ( + ) - 3 - hydroxy - N - methylmorphinan ) or a pharmaceutically acceptable salt thereof , dextrorphan ( ( + ) - 3 - hydroxy - N - methylmorphinan ) or a pharmaceutically acceptable salt thereof , and the like. These NMDA receptor antagonists are knoWn in the art and described , for example , in PCT Publication Nos. WO 2004 / 07l43l and WO 2006 / l2l560 , the disclosures of Which are incorporated by reference herein in their entirety. [ 0219 ] Other NMDA receptor antagonists knoWn in the art can be used in the compositions , combinations and methods described herein , including the NMDA receptor antagonists described in U. S. Pat. Nos. 4 , 346 , l l2 ; 5 , 06l , 703 ; 5 , 334 , 6l8 ; 5 , 382 , 60l ; 6 , 444 , 702 ; 6 , 620 , 845 ; and 6 , 662 , 845 , the disclosures of Which are incorporated by reference herein in their entirety. [ 0220 ] The dosage form of the formulation included in the combination , kit and / or pharmaceutical composition of the inVention is not particularly limited. The combination , kit and / or pharmaceutical composition of the inVention is useful as a combination , kit and / or a pharmaceutical composition for treating dementia and / or mild co gnitiVe impairments ; for the prophy1axis of dementia and / or mild cognitiVe impairments ; and for delaying the onset of dementia and / or mild cognitiVe impairments. [ 0221 ] The combination , kit and / or pharmaceutical composition of the inVention may be used as a drug for treating dementia and / or mild cognitiVe impairments ; for the prophylaxis of dementia and / or mild cognitiVe impairments ; and for delaying the onset of dementia and / or mild co gnitiVe impairments. US 20l0 / 0l30537 Al. [ 0222 ] The combination , kit and / or pharmaceutical composition of the inVention may be administered to a patient. [ 0223 ] The combination , kit and / or pharmaceutica1 composition of the inVention may be used through oral or parental administration. When the combination , kit and / or pharmaceutical composition of the inVention is used , the giVen dose of the compound of the inVention differs depending on the degree of the symptom , age , sex , Weight and sensitiVity difference of the patient , administration mode , administration period , administration interVal , nature , prescription and the type of the pharmaceutical formulation , and the type of the actiVe element. [ 0224 ] The pharmaceutical composition of the inVention may be made into Various forms , for example , into solid oral formulations , inj ectable solution or the like. [ 0225 ] The actiVe ingredients described herein can be administered orally , parenterally , or rectally in dosage unit formulations containing conVentiona1 nontoxic pharmaceutically acceptable excipients as desired. The term parenteral includes subcutaneous , intraVenous , intramuscular , intrathecal , intrastemal injection , or infusion techniques. [ 0226 ] For oral administration , the daily dose of the cinnamide compounds of the inVention may be from 30 ug / day to lO g / day ; from lO0 pg / day to 5 g / day ; or from lO0 [ Lg / day to l g / day. For parenteral administration , the daily dose of the cinnamide compounds may be from 30 [ Lg / day to 3 g / day ; from 100 [ Ig / day to l g / day ; or from 100 [ Ig / day to 500 mg / day. The cinnamide compounds may be administered as a single dose or in multiple doses. [ 0227 ] The daily dose of the cholinesterase inhibitors is usually from 0.0l mg / day to 300 mg / day ; from 0. l mg / day to 50 mg / day ; or from 1 mg / day to 25 mg / day. Donepezil hydrochloride , commercially aVailable as ARlCEPT® ( Eisai lnc. , Teaneck , N. J. ) , can be administered as tablets containing any one of 3 mg donepezil hydrochloride , 5 mg donepezil hydrochloride or lO mg donepezil hydrochloride. The tablets can be administered one to about four times a day. [ 0228 ] The daily dose of the AMPA receptor antagonists , such as the l , 2 - dihydropyridine compounds of the inVention ( e. g. , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one ) is usually 30 [ Ig / day to lO g / day ; from lO0 [ Ig / day to 5 g / day or , from lO0 [ Lg / day to lO0 mg / day in the case of oral administration. For administration by injection , the daily dose is usually 30 [ Lg / day to l g / day ; from lO0 [ Lg / day to 500 mg / day or , from lO0 [ Lg / day to 30 mg / day. The AMPA receptor antagonists are administered once daily or in seVeral portions a day. [ 0229 ] The daily dose of the NMDA receptor antagonists , such as the adamantane compounds of the inVention ( e. g. , memantine ) is usually 0.0l mg / day to lO0 mg / day ; from 0.0l mg / day to lO00 mg / day ; from 0. l mg / day to 500 mg / day ; from 1 mg / day to 100 mg / day ; from 1 mg / day to 50 mg / day ; or from lO mg / day to 30 mg / day. The NMDA receptor antagonists are administered once daily or in seVeral portions a day. [ 0230 ] The other actiVe ingredients described herein are commercially aVailable or can be prepared by processes knoWn in the art and can be administered in dosages knoWn in the art. [ 0231 ] ln one embodiment , the mode of administration is by injection , such as subcutaneous injection , intramuscular injection , intraVenous injection , or intra - arterial injection. lnjectable preparations , for example , sterile injectable aqueous or oleaginous suspensions can be formulated according to. May 27 , 2010. the art using suitable dispersing or Wetting agents , suspending agents ( e. g. , methylcellulose , Polysorbate 80 , hydroxyethylcellulose , acacia , poWdered tragacanth , sodium carboxymethylcellulose , polyoxyethylene sorbitan monolaurate and the like ) , pH modiﬂers , buffers , solubi1izing agents ( e. g. , polyoxyethylene hydrogenated castor oil , Polysorbate 80 , nicotinamide , polyoxyethylene sorbitan monolaurate , Macrogol , an ethyl ester of castor oil fatty acid , and the like ) , stabi1izers ( e. g. , sodium sulﬂte and sodium metasulﬂte ; examples of the preserVatiVe inc1ude methyl parahydroxybenzoate , ethyl parahydroxybenzoate , sorbic acid , phenol , cresol , chlorocresol , and the like ) , tonicity agents and preserVatiVes. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solVent , for examp1e , as a solution in l , 3 - butanediol. Among the acceptable Vehicles and solVents that can be used are Water , Ringers solution , and isotonic sodium chloride solution. ln addition , sterile , ﬂxed oils are conVentiona1ly used as a solVent or suspending medium. For this purpose any bland ﬂxed oil can be used including synthetic mono - or diglycerides , in addition , fatty acids , such as oleic acid , can be used in the preparation of injectables. The preparations can be lyophilized by methods knoWn in the art. [ 0232 ] ln order to prepare a solid oral formulation , an excipient , and if necessary , a binder , disintegrant , lubricant , colorant , a ﬂaVoring agent and the like are added to the principal agent , and then made into a tablet , a coated tablet , granule , ﬂne granule , dispersant , a capsule or the like according to a conVentional method. [ 0233 ] For example , lactose , cornstarch , sucrose , g1ucose , sorbit , crystalline cellulose , silicon dioxide or the like may be used as the excipient ; for example , polyVinyl alcohol , ethyl cellulose , methyl cellulose , gum arabic , hydroxypropyl cellulose , hydroxypropylmethyl cellulose or the like may be used as the binder ; for example , magnesium stearate , talc , silica or the like may be used as the lubricant ; those that are alloWed to be added to drugs may be used as the colorant ; and for example , cocoa poWder , menthol , aromatic acid , peppermint oil , camphor , cinnamon poWder or the like may be used as the ﬂaVoring agent. Of course , if necessary , these tablets and granule may be coated appropriately With sugar coating , gelatin coating or else. [ 0234 ] Solid dosage forms for oral administration can include cheWing gum , capsules , tablets , sublingual tablets , poWders , granules , and gels. ln such solid dosage forms , the actiVe ingredient ( s ) can be admixed With one or more inert diluents such as lactose or starch. As is normal practice , such dosage forms can also comprise other substances including lubricating agents such as magnesium stearate. ln the case of capsules , tablets , and pills , the dosage forms can also comprise buffering agents. The tablets can be prepared With enteric or ﬂlm coatings. [ 0235 ] To make tablets , the actiVe ingredient ( s ) can be admixed With pharmaceutically acceptable carriers knoWn in the art such as Vehicles ( e. g. , lactose , White sugar , mannitol , glucose , starches , calcium carbonate , crystalline cellulose , silicic acid , and the like ) , binders ( e. g. , Water , ethanol , myranol , glucose solution , starch solution , gelatin solution , polyVinylpyrrolidone , and the like ) , disintegrators ( e. g. , dry starch , sodium , alginate , sodium hydrogen carbonate , ca1 - cium carbonate , polyoxyethylene sorbitan fatty acid esters , sodium laurylsulfate , stearic monoglyceride , starches , lactose , and the like ) , absorption promoters ( e. g. , quaternary ammonium base , sodium laurylsulfate , and the like ) , Wetting. US 20l0 / 0l30537 Al. agents ( e. g. glycerin , starches , and the like ) , lubricants ( e. g. , stearates , polyethylene glycol , and the like ) , and ﬂaVoring agents ( e. g. , sWeeteners ) . The tablets can be in the form of a conVentional tablet , a molded tablet , a Wafer and the like. Sublingual administration refers to the administration in the mouth ( e. g. , under the tongue , betWeen the cheek and gum , betWeen the tongue and roof of the mouth ) . The highly Vascular mucosal lining in the mouth is a conVenient location for the actiVe ingredients to be administered into the body. [ 023 6 ] ln other embodiments , the solid dosage form can be packaged as granules or a poWder in a pharmaceutica1ly acceptable carrier , Where the granules or poWder are remoVed from the packaging and sprinkled on food or mixed With a liquid , such as Water or juice , or Where the granules are inserted into capsules. ln this embodiment , the actiVe ingredients described herein can be mixed With ﬂaVoring or sWeetening agents. The packaging materia1 can be p1astic , coated paper , or any material that preVents Water or moisture from reaching the granules and / or poWder. [ 0237 ] Liquid dosage fauns for oral administration can include pharmaceutically acceptable gels , emulsions , solutions , sublingual solutions , suspensions , and syrups containing inert diluents commonly used in the art , such as Water. Such compositions can also comprise adjuVants , such as Wetting agents , emulsifying and suspending agents , and sWeetening , ﬂaVoring , and perfuming agents. To make sublingual solutions , the actiVe ingredients can be admixed With Various carriers , excipients , pH adjusters , and the like ( e. g. , Water , sugar , lactic acid , acetic acid , fructose , glucose , saccharin , polyethylene glycol , propylene glycol , alcohol , bentonite , tragacanth , gelatin , alginates , aspartame , sorbitol , methylparaben , propylparaben , sodium benzoate , artiﬁcial ﬂaVoring and coloring agents ) . [ 023 8 ] Hereinafter , the present inVention Will be illustrated by Way of speciﬁc examples , although the inVention should not be limited thereto. Example. [ 0239 ] A clinical trial in combination With a cinnamide compound of the present inVention and a cholinesterase inhibitor on patients With Alzheimers disease. [ 0240 ] Male and female patients aging from 60 to 85 suffering from mild to moderate Alzheimers disease Who fulﬁll the NlNCDS - ADRDA criteria Will be recruited , and 50 to lO0 patients Will be registered as a cinnamide compound treatment group for the main test. Physicians judge the patients Who Will be applied for the main test based on the NlNCDSADRDA criteria before administration. The physicians also Will diagnose patients clinical signs for dementia and mild cognitiVe impairments , such as disorientation , impaired memory , impaired judgment , impaired intellect , anxiety , depression , agitation and deterioration in actiVity in daily life and Will judge based on all information aVailable at the point of analysis such as report from family members or care attendants , and period of care. Alzheimers disease subjects Will be attended by care attendants Who Will make sure of compliance With dosing regimen , hospital Visit and procedure for this test. Patients suffering from other disease With a medically seVere symptom , patients With any contraindication or patients Who regularly Will use cinnamide compound Will be eliminated. Patients receiVing treatment With a cholinesterase inhibitor ( e. g. , donepezil hydrochloride ) for Alzheimers disease Will. May 27 , 2010. not be eliminated if they Will be administered With a stable dose in a range of about 3 to 20 mg / day for at least seVeral Weeks ( preferably , 4 Weeks ) . [ 0241 ] To Alzheimers disease patients Who Will fulﬁll the NlNCDS - ADRDA criteria , cinnamide compound Will be administered at an amount formulated in a carrier appropriate for the selected dosing regimen. The patients Will start With cinnamide compound treatment protocol. An amount of cinnamide compound in a range of about 10 to 500 mg / day , for example , 100 mg / day Will be prescribed in 1 to 3 doses. During the test period , administration Will be repeated daily. Starting from day 0 , a test for assessment scale Will be conducted regular1y , for example , once a month. [ 0242 ] The cinnamide compound treatment group Will be eValuated for one or seVeral assessment items including , for example , a test for cognitiVe and memory function , A beta present in cerebro spinal cord ﬂuid or plasma , A beta deposition in the brain , brain amyloid plaque , or a Volume of a brain or hippocampus. ln the cinnamide compound treatment group , progression of the disease Will be inhibited or delayed or a symptom of the disease Will be alleViated as compared to the untreated control group. Speciﬁcally , results Will be obtained Where the degree or period of patients disorientation , impaired memory , impaired judgment and impaired intellect Will be reduced , patients anxiety , depression , agitation , frustration or fecklessness Will be reduced , or patients start to feel stable , Will become socially actiVe , or Will become to haVe improVed language ability or comprehension. [ 0243 ] Each of the patents , patent applications , and publications cited herein are incorporated by reference herein in their entirety. [ 0244 ] lt Will be apparent to one skilled in the art that Various modiﬁcations can be made to the inVention Without departing from the spirit or scope of the appended claims. 1. A pharmaceutical composition comprising : . ( A ) a compound of Formula ( l ) or a pharmaceutically acceptable salt thereof : . Wherein R1 is : . ( l ) 7Xl7Ar1 , Wherein X1 is a Cl - 6 alkylene group optionally substituted With a C1_6 alkyl group ; andAr1 is a phenyl group optionally substituted With 1 to 3 substituents selected from the group consisting of ( i ) a halogen atom and ( ii ) a Cl - 6 alkyl group Which may optionally be substituted With one to ﬁVe Cl - 6 alkyl groups ; . ( 2 ) an indenyl group optionally substituted With 1 to 3 halogen atoms ; . ( 3 ) a tetrahydronaphthyl group optionally substituted With 1 to 3 halogen atoms ; or. ( 4 ) a chromanyl group optionally substituted With 1 to 3 halogen atoms ; . US 20l0 / 0l30537 Al. ( B ) a cholinesterase inhibitor ; an AMPA receptor antagonist ; an NMDA receptor antagonist ; or a mixture or combination of tWo or more thereof ; and. ( C ) one or more pharmaceutica1ly acceptable carriers. 2. The pharmaceutical composition of claim 1 , Wherein R1 is —X1—Arl ; Wherein X1 is a C1 - 6 alkylene group optionally substituted With a Cl - 6 alkyl group ; and Arl is a phenyl group optional1y substituted With 1 to 3 substituents selected from the group consisting of ( i ) a halogen atom and ( ii ) a C M alkyl group Which may optionally be substituted With one to ﬁVe C1_6 alkyl groups ; . 3. The pharmaceutical composition of claim 1 , Wherein R1 is an indenyl group optionally substituted With 1 to 3 halogen atoms ; a tetrahydronaphthyl group optional1y substituted With 1 to 3 halogen atoms ; or a chromanyl group optionally substituted With 1 to 3 halogen atoms. 4. The pharmaceutical composition of claim 1 , Wherein ( A ) is at least one compound selected from : ( E ) - l - ( 3 , 4 - diﬂuorobenzyl ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - l H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereat. ( E ) - 1 - indan - 2 - yl - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lH - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - l - [ ( 4R ) - chroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lH - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereat ( E ) - l - [ ( 4S ) - chroman - 4 - y1 ] - 3 - [ 3 - methoxy - 4 - ( 4 - methy1 - lH - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - l - [ ( l S ) - 1 - ( 4 - ﬂuorophenyl ) ethyl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereat. ( E ) - 1 - ( 4 - tert - butylbenzyl ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - 1 - [ ( 2S ) - 5 - ﬂuoroindan - 2 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - 1 - [ ( 2R ) - 5 - ﬂuoroindan - 2 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lHimidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - l - [ ( 4R ) - 7 - ﬂuorochroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1 H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; or ( E ) - 1 - [ ( 4 8 ) - 7 - ﬂuorochroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - l H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutical1y acceptable sa1t thereof ; . ( E ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - l H - imidazol - l - yl ) benzylidene ] - l - [ ( 2R ) - l , 2 , 3 , 4 - tetrahydronaphthalen - 2 - yl ] piperidin - 2 - one or a pharmaceutical1y acceptable salt thereof ; ( E ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - l H - imidazol - 1 - yl ) benzylidene ] - 1 - [ ( 2 S ) - l , 2 , 3 , 4 - tetrahydronaphthalen - 2 - yl ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; and. ( E ) - 1 - [ ( lR ) - 1 - ( 2 , 4 - diﬂuorophenyl ) ethyl ] - 3 - [ 3 - methoxy - . 4 - ( 4 - methyl - l H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutica1ly acceptable salt thereof ; or ( E ) - l - [ ( l S ) - l - ( 2 , 4 - diﬂuorophenyl ) ethy1 ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof. 5. The pharmaceutical composition of claim 1 , Wherein ( B ) . is one or more compounds selected from the group consisting. May 27 , 2010. of donepezil or a pharmaceutically acceptable salt thereof , huperzine A or a pharmaceutically acceptable salt thereof , tacrine or a pharmaceutically acceptable salt thereof , riVastigmine or a pharmaceutica1ly acceptab1e salt thereof , galantamine or a pharmaceutica1ly acceptable sa1t thereof , pramiracetam or a pharmaceutically acceptable salt thereof , aniracetam or a pharmaceutically acceptable salt thereof , neﬁracetam or a pharmaceutically acceptable salt thereof ; EGb 76l or a pharmaceutica1ly acceptable salt thereof ; rosiglitazone or a pharmaceutically acceptable salt thereof , rasagiline or a pharmaceutically acceptable salt thereof ; leVacecamine or a pharmaceutically acceptable salt thereof , celecoxib or a pharmaceutically acceptable salt thereof , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one , a pharmaceutically acceptab1e salt thereof or a hydrate thereof ; talampanel or a pharmaceutically acceptable salt thereof ; becampanel or a pharmaceutically acceptable salt thereof ; memantine or a pharmaceutically acceptable salt thereof , neramexane or a pharmaceutically acceptable sa1t thereof ; xaliproden or a pharmaceutically acceptable sa1t thereof ; tarenﬂurbil or a pharmaceutically acceptable salt thereof ; tramiprosate or a pharmaceutically acceptable salt thereof ; and leuprorelin - D or a pharmaceutically acceptable sa1t thereof. 6. The pharmaceutical composition of claim 1 , Wherein ( B ) is one or more compounds selected from the group consisting of donepezil or a pharmaceutically acceptable salt thereof ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one , a pharmaceutically acceptable sa1t thereof or a hydrate thereof and memantine or a pharmaceutically acceptable salt thereof. 7. The pharmaceutical composition of claim 1 , Wherein ( B ) is donepezil or a pharmaceutically acceptable salt thereof. 8. The pharmaceutical composition of c1aim 1 , Wherein the composition is used for : treating dementia or one or more mild cognitiVe impairments ; the prophylaxis of dementia or one or more mild cognitiVe impairments ; or delaying the onset of dementia or one or more mild cognitiVe impairments. 9. A combination comprising : . ( A ) a compound of Formula ( l ) or a pharmaceutically. acceptable salt thereof : . Wherein R1 is : . ( l ) —Xl—Arl , Wherein X , is a C1_6 alkylene group optional1y substituted With a C H , alkyl group ; andArl is a phenyl group optionally substituted With 1 to 3 substituents selected from the group consisting of ( i ) a halogen atom and ( ii ) a C1_6 alkyl group Which may optionally be substituted With one to ﬁVe C1_6 alkyl groups ; . ( 2 ) an indenyl group optionally substituted With 1 to 3 halogen atoms ; . ( 3 ) a tetrahydronaphthyl group optionally substituted With 1 to 3 halogen atoms ; or. US 20l0 / 0l30537 Al. ( 4 ) a chromanyl group optionally substituted With 1 to 3 halogen atoms ; and. ( B ) a cholinesterase inhibitor ; an AMPA receptor antagonist ; an NMDA receptor antagonist ; or a mixture or combination of tWo or more thereof. 10. The combination of claim 9 , Wherein R1 is —X1—Ar1 ; Wherein X1 is a C1_6 alkylene group optionally substituted With a C1_6 alkyl group ; and Arl is a phenyl group optionally substituted With 1 to 3 substituents selected from the group consisting of ( i ) a halogen atom and ( ii ) a C1_6 alkyl group Which may optionally be substituted With one to ﬁVe C1_6 alkyl groups ; . 11. The combination of claim 9 , Wherein R1 is an indenyl group optionally substituted With 1 to 3 halogen atoms ; a tetrahydronaphthyl group optionally substituted With 1 to 3 halogen atoms ; or a chromanyl group optionally substituted With 1 to 3 halogen atoms. 12. The combination of claim 9 , Wherein ( A ) is at least one compound selected from : ( E ) - 1 - ( 3 , 4 - diﬂuorobenzyl ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - 1 - indan - 2 - yl - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lH - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - l - [ ( 4R ) - chroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lH - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - l - [ ( 4S ) - chroman - 4 - y1 ] - 3 - [ 3 - methoxy - 4 - ( 4 - methy1 - lH - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - l - [ ( l S ) - 1 - ( 4 - ﬂuorophenyl ) ethyl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - 1 - ( 4 - tert - butylbenzyl ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - 1 - [ ( 2S ) - 5 - ﬂuoroindan - 2 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - 1 - [ ( 2R ) - 5 - ﬂuoroindan - 2 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lHimidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - l - [ ( 4R ) - 7 - ﬂuorochroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1 H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; or ( E ) - 1 - [ ( 4S ) - 7 - ﬂuorochroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - l H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutical1y acceptable sa1t thereof ; . ( E ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - l H - imidazol - l - yl ) benzylidene ] - l - [ ( 2R ) - l , 2 , 3 , 4 - tetrahydronaphthalen - 2 - yl ] piperidin - 2 - one or a pharmaceutical1y acceptable salt thereof ; ( E ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - l H - imidazol - 1 - yl ) benzylidene ] - 1 - [ ( 2 S ) - l , 2 , 3 , 4 - tetrahydronaphthalen - 2 - yl ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; and. ( E ) - 1 - [ ( lR ) - 1 - ( 2 , 4 - diﬂuorophenyl ) ethyl ] - 3 - [ 3 - methoxy - . 4 - ( 4 - methyl - l H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutica1ly acceptable salt thereof ; or ( E ) - l - [ ( l S ) - l - ( 2 , 4 - diﬂuorophenyl ) ethy1 ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof. 13. The combination of claim 9 , Wherein ( B ) is one or more compounds selected from the group consisting of donepezil. May 27 , 2010. or a pharmaceutically acceptable salt thereof , huperzineA or a pharmaceutically acceptable salt thereof , tacrine or a pharmaceutically acceptable salt thereof , riVastigmine or a pharmaceutically acceptable salt thereof , galantamine or a pharmaceutically acceptable salt thereof , pramiracetam or a pharmaceutically acceptable salt thereof , aniracetam or a pharmaceutically acceptable salt thereof , neﬁracetam or a pharmaceutically acceptable salt thereof , EGb 76l or a pharmaceutically acceptab1e salt thereof , rosiglitazone or a pharmaceutically acceptable sa1t thereof , rasagiline or a pharmaceutically acceptable salt thereof , leVacecamine or a pharmaceutically acceptable salt thereof , celecoxib or a pharmaceutically acceptable salt thereof , 3 - ( 2 - cyanophenyl ) - 5 ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one , a pharmaceutically acceptable salt thereof or a hydrate thereof , talampanel or a pharmaceutically acceptable salt thereof , becampanel or a pharmaceutically acceptable salt thereof ; memantine or a pharmaceutically acceptable salt thereof , neramexane or a pharmaceutically acceptable salt thereof , xaliproden or a pharmaceutically acceptable salt thereof , tarenﬂurbil or a pharmaceutically acceptable salt thereof , tramiprosate or a pharmaceutically acceptable salt thereof , and leuprorelin - D or a pharmaceutically acceptable salt thereof. 14. The combination of claim 9 , Wherein ( B ) is one or more compounds selected from the group consisting of donepezil or a pharmaceutically acceptable salt thereof , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - 1 , 2 - dihydropyridin - 2 - one , a pharmaceutically acceptable salt thereof or a hydrate thereof and memantine or a pharmaceutically acceptable salt thereof. 15. The combination of claim 9 , Wherein ( B ) is donepezil or a pharmaceutically acceptable salt thereof. 16. The combination of claim 9 , Wherein ( A ) and ( B ) are administered separately to a patient or are administered to a patient in the form of a pharmaceutical composition. 17. The combination of claim 9 , Wherein the combination is used for treating dementia or one or more mild cognitiVe impairments ; for the prophylaxis of dementia or one or more mild co gnitiVe impairments ; or delaying the onset of dementia or one or more mild co gnitiVe impairments. 18. A method for producing a pharmaceutical composition comprising compounds ( A ) and ( B ) in the treatment of dementia or one or more mild co gnitiVe impairments ; for the prophylaxis of dementia or one or more mild cognitiVe impairments ; or delaying the onset of dementia or one or more mild cognitiVe impairments , Wherein ( A ) and ( B ) are : . ( A ) a compound of Formula ( l ) or a pharmaceutically. acceptable salt thereof : . Wherein R1 is : . ( l ) —Xl—Ar1 , Wherein X1 is a Cl - 6 alkylene group optionally substituted With a C m alkyl group ; andArl is a phenyl group optionally substituted With 1 to 3 substituents selected from the group consisting of ( i ) . US 20l0 / 0l30537 Al. a halogen atom and ( ii ) a C m alkyl group Which may optionally be substituted With one to ﬁVe C1_6 alkyl groups ; . ( 2 ) an indenyl group optionally substituted With 1 to 3 halogen atoms ; . ( 3 ) a tetrahydronaphthyl group optionally substituted With 1 to 3 halogen atoms ; or. ( 4 ) a chromanyl group optionally substituted With 1 to 3 halogen atoms ; and. ( B ) a cholinesterase inhibitor ; an AMPA receptor antagonist ; an NMDA receptor antagonist ; or a mixture or combination of Wm or more thereof. 19. The method of claim 18 , Wherein R1 is 7X17Ar1 ; Wherein X1 is a C1_6 alkylene group optionally substituted With a C1_6 alkyl group ; and Arl is a phenyl group optionally substituted With 1 to 3 substituents selected from the group consisting of ( i ) a halogen atom and ( ii ) a Cl - 6 alkyl group Which may optionally be substituted With one to ﬁVe C1_6 alkyl groups ; . 20. The method of claim 18 , Wherein R1 is an indenyl group optionally substituted With 1 to 3 halogen atoms ; a tetrahydronaphthy1 group optionally substituted With 1 to 3 halogen atoms ; or a chromanyl group optionally substituted With 1 to 3 halogen atoms. 21. The method of claim 18 , Wherein ( A ) is at least one compound selected from : ( E ) - 1 - ( 3 , 4 - diﬂuorobenzyl ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - 1 - indan - 2 - yl - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lH - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - l - [ ( 4R ) - chroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lH - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - l - [ ( 4S ) - chroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lH - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - l - [ ( l S ) - l - ( 4 - ﬂuorophenyl ) ethyl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - l - ( 4 - tert - butylbenzyl ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - l - [ ( 2S ) - 5 - ﬂuoroindan - 2 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; ( E ) - 1 - [ ( 2R ) - 5 - ﬂuoroindan - 2 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - lHimidazol - l - y1 ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; . ( E ) - l - [ ( 4R ) - 7 - ﬂuoro chroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1 H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; or ( E ) - 1 - [ ( 4S ) - 7 - ﬂuorochroman - 4 - yl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutical1y acceptable sa1t thereof ; . ( E ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] - l - [ ( 2R ) - l , 2 , 3 , 4 - tetrahydronaphthalen - 2 - yl ] piperidin - 2 - one or a pharmaceutical1y acceptable salt thereof ; ( E ) - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - l H - imidazol - 1 - yl ) benzylidene ] - 1 - [ ( 2 S ) - l , 2 , 3 , 4 - tetrahydronaphthalen - 2 - yl ] piperidin - 2 - one or a pharmaceutically acceptable salt thereof ; and. ( E ) - 1 - [ ( lR ) - 1 - ( 2 , 4 - diﬂuorophenyl ) ethyl ] - 3 - [ 3 - methoxy - . 4 - ( 4 - methyl - 1H - imidazol - 1 - yl ) benzylidene ] piperidin - . May 27 , 2010. 2 - one or a pharmaceutically acceptable salt thereof ; or ( E ) - 1 - [ ( lS ) - 1 - ( 2 , 4 - diﬂuorophenyl ) ethyl ] - 3 - [ 3 - methoxy - 4 - ( 4 - methyl - 1H - imidazol - l - yl ) benzylidene ] piperidin - 2 - one or a pharmaceutically acceptab1e sa1t thereof. 22. The method of claim 18 , Wherein ( B ) is one or more compounds selected from the group consisting of donepezil or a pharmaceutically acceptable salt thereof , huperzineA or a pharmaceutically acceptable salt thereof , tacrine or a pharmaceutically acceptable salt thereof , riVastigmine or a pharmaceutically acceptable salt thereof ; galantamine or a pharmaceutically acceptable salt thereof ; pramiracetam or a pharmaceutically acceptable salt thereof , aniracetam or a pharmaceutically acceptab1e salt thereof ; neﬁracetam or a pharmaceutically acceptable salt thereof ; EGb 76l or a pharmaceutically acceptable salt thereof ; rosiglitazone or a pharmaceutically acceptable salt thereof , rasagiline or a pharmaceutically acceptable salt thereof ; leVacecamine or a pharmaceutically acceptable sa1t thereof ; celecoxib or a pharmaceutically acceptable sa1t thereof , 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one , a pharmaceutically acceptable salt thereof or a hydrate thereof , talampanel or a pharmaceutically acceptable salt thereof , becampanel or a pharmaceutically acceptable sa1t thereof ; memantine or a pharmaceutically acceptable salt thereof , neramexane or a pharmaceutically acceptable salt thereof , xaliproden or a pharmaceutically acceptable salt thereof , tarenﬂurbil or a pharmaceutically acceptable salt thereof ; tramiprosate or a pharmaceutically acceptable salt thereof , and leuprorelin - D or a pharmaceutically acceptable salt thereof. 23. The method of claim 18 , Wherein ( B ) is one or more compounds selected from the group consisting of donepezil or a pharmaceutically acceptable salt thereof ; 3 - ( 2 - cyanophenyl ) - 5 - ( 2 - pyridyl ) - l - phenyl - l , 2 - dihydropyridin - 2 - one , a pharmaceutically acceptable salt thereof or a hydrate thereof and memantine or a pharmaceutically acceptable salt thereof. 24. The method of claim 18 , Wherein ( B ) is donepezil or a pharmaceutically acceptable salt thereof. 25. The method of claim 18 , Wherein ( A ) and ( B ) are to be administered separately to a patient or are administered to a patient in the form of a pharmaceutical composition. 26. A method for the treatment of dementia or one or more mild cognitiVe impairments ; for the prophylaxis of dementia or one or more mild cognitiVe impairments ; or delaying the onset of dementia or one or more mild cognitiVe impairments , by administering compounds ( A ) and ( B ) , Wherein ( A ) and ( B ) are : . ( A ) a compound of Formula ( l ) or a pharmaceutically. acceptable salt thereof : . Wherein R1 is : . ( l ) —Xl—Ar1 , Wherein X1 is a Cl - 6 alkylene group optionally substituted With a C1_6 alkyl group ; andAr1 is a phenyl group optionally substituted With 1 to 3. US 20l0 / 0l30537 Al. substituents selected from the group consisting of ( i ) a halogen atom and ( ii ) a C1_6 alkyl group Which may optionally be substituted With one to ﬁVe C1_6 alkyl groups ; . ( 2 ) an indenyl group optionally substituted With 1 to 3 halogen atoms ; . ( 3 ) a tetrahydronaphthyl group optionally substituted With 1 to 3 halogen atoms ; or. ( 4 ) a chromanyl group optionally substituted With 1 to 3 halogen atoms ; and. ( B ) a cholinesterase inhibitor ; an AMPA receptor antagonist ; an NMDA receptor antagonist ; or a mixture or combination of tWo or more thereof. 27. A kit comprising the pharmaceutical composition of claim 1. May 27 , 2010. 28. A method for treating dementia or one or more mild cognitiVe impairments ; for the prophylaxis of dementia or one or more mild cognitiVe impairments ; or. delaying the onset of dementia or one or more mild cogni - . tiVe impairments comprising administering to a patient in need thereof a therapeutical1y effectiVe amount of the pharmaceutical composition of claim 1. 29. A kit comprising the combination of claim 9. 30. A method for treating dementia or one or more mild cognitiVe impairments ; for the prophylaxis of dementia or one or more mild cognitiVe impairments ; or delaying the onset of dementia or one or more mild co gnitiVe impairments comprising administering to a patient in need thereof a therapeutically effectiVe amount of the combination of claim 9. $ $ $ $ $